fbpx
Wikipedia

HPV vaccine

January 07, 2023

Human papillomavirus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus (HPV).[19] Available HPV vaccines protect against either two, four, or nine types of HPV.[19][20] All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer.[19] It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers.[21][22][23][24] They additionally prevent some genital warts, with the quadrivalent and nonavalent vaccines that protect against HPV types HPV-6 and HPV-11 providing greater protection.[19]

HPV vaccine
Vaccine description
TargetHuman papillomavirus (HPV)
Vaccine typeProtein subunit
Clinical data
Trade namesGardasil, Cervarix, others
AHFS/Drugs.comMonograph
MedlinePlusa615028
License data
  • US DailyMed: Human_papillomavirus_vaccine
Pregnancy
category
Routes of
administration		Intramuscular injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
  • 910046-32-1
ChemSpider
  • none
 NY (what is this?)  (verify)

The World Health Organization (WHO) recommends HPV vaccines as part of routine vaccinations in all countries, along with other prevention measures.[19] The vaccines require two or three doses depending on a person's age and immune status.[19] Vaccinating girls around the ages of nine to thirteen is typically recommended.[19] The vaccines provide protection for at least 5 to 10 years.[19] Cervical cancer screening is still required following vaccination.[19] Vaccinating a large portion of the population may also benefit the unvaccinated.[25]

HPV vaccines are very safe.[19] Pain at the site of injection occurs in about 80% of people.[19] Redness and swelling at the site and fever may also occur.[19] No link to Guillain–Barré syndrome has been found.[19]

The first HPV vaccine became available in 2006.[19][26] As of 2017, 71 countries include it in their routine vaccinations, at least for girls.[19] It is on the World Health Organization's List of Essential Medicines[27][28] and prequalified vaccines.[29] Vaccination may be cost effective in the low and middle-income countries.[30] As of 2017, Gardasil 9 is the only version available in the United States as the older version, Gardasil has been discontinued as the Gardasil 9 offers protection against same four HPV types as Gardasil, as well as an additional five HPV types.[31][32]

Medical uses

 
Gardasil
 
Syringe

HPV vaccines are used to prevent HPV infection and therefore cervical cancer.[19] Good evidence supports that vaccination of large percentage of people within a population decreases rates of HPV infections with part of the benefit from herd immunity.[33] Some types are recommended in the United States for women and men who are 9–26 years of age, and are approved for those who are 27–45 years of age.[34][35]

Since the vaccines only cover some high-risk types of HPV, cervical cancer screening is recommended even after vaccination.[19][36] In the U.S., the recommendation is for women to receive routine Pap smears beginning at age 21.[37] In Australia, the national screening program has changed from the two yearly cytology (pap smears) to being based on tests for HPV DNA,[38] based on work by Karen Canfell and others.[39]

Efficacy

The HPV vaccine has been shown to prevent cervical dysplasia from the high-risk HPV types 16 and 18 and provide some protection against a few closely related high-risk HPV types.[19][40] However, there are other high-risk HPV types that are not affected by the vaccine.[41] The protection against HPV 16 and 18 has lasted at least eight years after vaccination for Gardasil[42] and more than nine years for Cervarix.[42] It is thought that booster vaccines will not be necessary.[43]

Gardasil and Gardasil 9 protect against HPV types 6 and 11 which can cause genital warts.[13][14][19]

Cervarix is just as effective at protecting women against persistent HPV 16 and 18 infection in the anus as it is at protecting them from these infections in the cervix. Overall, about 30 percent of cervical cancers will not be prevented by these vaccines. Also, in the case of Gardasil, ten percent of genital warts will not be prevented by the vaccine. Neither vaccine prevents other sexually transmitted diseases, nor do they treat existing HPV infection or cervical cancer.[44][45]

HPV types 16, 18 and 45 contribute to 94% of cervical adenocarcinoma (cancers originating in the glandular cells of the cervix).[46] While most cervical cancer arises in the squamous cells, adenocarcinomas make up a sizable minority of cancers.[46] Further, Pap smears are not as effective at detecting adenocarcinomas, so where Pap screening programs are in place, a larger proportion of the remaining cancers are adenocarcinomas.[46] Trials suggest that HPV vaccines may also reduce the incidence of adenocarcinoma.[46]

Two doses of the vaccine may work as well as three doses.[47] The Centers for Disease Control and Prevention (CDC) recommends two doses in those less than 15 years and three doses in those over 15 years.[48] A single dose might be effective.[49]

A study with 9vHPV, a 9-valent HPV vaccine that protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, came to the result that the rate of high-grade cervical, vulvar, or vaginal disease was the same as when using a quadrivalent HPV vaccine.[50] A lack of a difference may have been caused by the study design of including women 16 to 26 years of age, who may largely already have been infected with the five additional HPV types that are additionally covered by the 9-valent vaccine.[51]

Males

HPV vaccines are approved for males in several countries and regions, including Switzerland, Portugal, Canada, Australia, Ireland, South Korea, Hong Kong, the United Kingdom, New Zealand, and the United States.[52][53]

In males, Gardasil may reduce their risk of genital warts and precancerous lesions caused by HPV. This reduction in precancerous lesions might be predicted to reduce the rates of penile and anal cancer in men. Gardasil has been shown to also be effective in preventing genital warts in males.[54][55] While Gardasil and the Gardasil 9 vaccines have been approved for males, a third HPV vaccine, Cervarix, has not. Unlike the Gardasil-based vaccines, Cervarix does not protect against genital warts.[56]

Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women.[57]

Gardasil is also used among men who have sex with men, who are at higher risk for genital warts, penile cancer, and anal cancer.[58]

Recommendations by national bodies

Australia introduced HPV vaccination for boys over 12 from 2013 onwards,[59] while UK and Ireland introduced HPV vaccination for boys aged 12 and 13 as part of their National Immunization Plan in 2019.[60][61] Portugal introduced universal HPV vaccination for boys aged 10 years and above as part of its National Immunization Plan in 2020.[62]

On 9 September 2009, an advisory panel recommended that the Food and Drug Administration (FDA) of the USA license Gardasil in the United States for boys and men ages 9–26 for the prevention of genital warts.[63] Soon after that, the vaccine was approved by the FDA for use in males aged 9 to 26 for prevention of genital warts[54][55] and anal cancer.[64][65][66]

In 2011, an advisory panel for the Centers for Disease Control and Prevention (CDC) recommended the vaccine for boys ages 11–12.[35] This was intended to prevent genital warts and anal cancers in males, and possibly prevent head and neck cancer (though the vaccine's effectiveness against head and neck cancers has not yet been proven).[67] The committee also made the vaccination recommendation for males 13 to 21 years who have not been vaccinated previously or who have not completed the three-dose series.[54][68] For those under the age of 27 who have not been fully vaccinated the CDC recommends vaccination.[35]

Harald zur Hausen's support for vaccinating boys (so that they will be protected, and thereby so will women) was joined by professors Harald Moi and Ole-Erik Iversen in 2011.[69]

Older age

When Gardasil was first introduced, it was recommended as a prevention for cervical cancer for women that were 25 years old or younger.[35] Evidence suggests that HPV vaccines are effective in preventing cervical cancer for women up to 45 years of age.[34] In 2018, the Food and Drug Administration released a summary basis for regulatory action and approval for expansion of usage and indication for the 9-valent HPV vaccine to include men and women 27 to 45 years of age.[70]

Public health

The National Cancer Institute states "Widespread vaccination has the potential to reduce cervical cancer deaths around the world by as much as two-thirds if all women were to take the vaccine and if protection turns out to be long-term. In addition, the vaccines can reduce the need for medical care, biopsies, and invasive procedures associated with the follow-up from abnormal Pap tests, thus helping to reduce health care costs and anxieties related to abnormal Pap tests and follow-up procedures."[36]

As of 2004 preventive vaccines protect against the two HPV types (16 and 18) that cause about 70% of cervical cancers worldwide.[71] Because of the distribution of HPV types associated with cervical cancer, the vaccines are likely to be most effective in Asia, Europe, and North America.[71] Some other high-risk types cause a larger percentage of cancers in other parts of the world.[71] Vaccines that protect against more of the types common in cancers would prevent more cancers, and be less subject to regional variation.[71] For instance, a vaccine against the seven types most common in cervical cancers (16, 18, 45, 31, 33, 52, 58) would prevent an estimated 87% of cervical cancers worldwide.[71]

Only 41% of women with cervical cancer in the developing world get medical treatment.[72] Therefore, prevention of HPV by vaccination may be a more effective way of lowering the disease burden in developing countries than cervical screening. The European Society of Gynecological Oncology sees the developing world as most likely to benefit from HPV vaccination.[73] However, individuals in many resource-limited nations, Kenya for example, are unable to afford the vaccine.[74]

In more developed countries, populations that do not receive adequate medical care, such as poor or minorities in the United States or parts of Europe also have less access to cervical screening and appropriate treatment, and are similarly more likely to benefit.[46] In 2009, Dr. Diane Harper, a researcher for the HPV vaccines, questioned whether the benefits of the vaccine outweigh its risks in countries where Pap smear screening is common.[75] She has also encouraged women to continue pap screening after they are vaccinated and to be aware of potential adverse effects.[76]

According to the CDC, in 2012, use of the HPV vaccine had cut rates of infection with HPV-6, -11, -16 and -18 in half in American teenagers (from 11.5% to 4.3%) and by one third in American women in their early twenties (from 18.5% to 12.1%).[77]

Side effects

The HPV vaccine is generally safe with no increased risk of serious adverse effects.[40] HPV vaccines are approved for use in over 100 countries, with more than 100 million doses distributed worldwide. Extensive clinical trial and post-marketing safety surveillance data indicate that both Gardasil and Cervarix are well tolerated and safe.[40][78] When comparing the HPV vaccine to a placebo (control) vaccine taken by women, there is no difference in the risk of severe adverse events.[40]

Gardasil is a three-dose (injection) vaccine. As of 8 September 2013, there were more than 57 million doses distributed in the United States, though it is unknown how many were administered.[79] There have been 22,000 Vaccine Adverse Event Reporting System (VAERS) reports following the vaccination.[80] 92% were reports of events considered to be non-serious (e.g., fainting, pain and swelling at the injection site (arm), headache, nausea and fever), and the rest were considered to be serious (death, permanent disability, life-threatening illness and hospitalization). However, VAERS reports include any reported effects whether coincidental or causal. In response to concerns regarding the rates of adverse events associated with the vaccine, the CDC stated: "When evaluating data from VAERS, it is important to note that for any reported event, no cause-and-effect relationship has been established. VAERS receives reports on all potential associations between vaccines and adverse events."[80]

As of 1 September 2009, in the US there were 44 reports of death in females after receiving the vaccine.[80] None of the 27 confirmed deaths of women and girls who had taken the vaccine were linked to the vaccine.[80] There is no evidence suggesting that Gardasil causes or raises the risk of Guillain–Barré syndrome. Additionally, there have been rare reports of blood clots forming in the heart, lungs, and legs.[80] A 2015 review conducted by the European Medicines Agency's Pharmacovigilance Risk Assessment Committee concluded that evidence does not support the idea that HPV vaccination causes complex regional pain syndrome or postural orthostatic tachycardia syndrome.[81]

As of 8 September 2013, the CDC continued to recommend Gardasil vaccination for the prevention of four types of HPV.[80] The manufacturer of Gardasil has committed to ongoing research assessing the vaccine's safety.[82]

According to the Centers for Disease Control and Prevention (CDC) and the FDA, the rate of adverse side effects related to Gardasil immunization in the safety review was consistent with what has been seen in the safety studies carried out before the vaccine was approved and were similar to those seen with other vaccines. However, a higher proportion of syncope (fainting) was seen with Gardasil than is usually seen with other vaccines. The FDA and CDC have reminded health care providers that, to prevent falls and injuries, all vaccine recipients should remain seated or lying down and be closely observed for 15 minutes after vaccination.[45] The HPV vaccination does not appear to reduce the willingness of women to undergo pap tests.[83]

Contraindications

While the use of HPV vaccines can help reduce cervical cancer deaths by two-thirds around the world,[84] not everyone is eligible for vaccination. There are some factors that exclude people from receiving HPV vaccines. These factors include:[85]

  • People with history of immediate hypersensitivity to vaccine components. Patients with a hypersensitivity to yeast should not receive Gardasil since yeast is used in its production.
  • People with moderate or severe acute illnesses. This does not completely exclude patients from vaccination, but postpones the time of vaccination until the illness has improved.[86]

Pregnancy

In the Gardasil clinical trials, 1,115 pregnant women received the HPV vaccine. Overall, the proportions of pregnancies with an adverse outcome were comparable in subjects who received Gardasil and subjects who received placebo.[87][88] However, the clinical trials had a relatively small sample size. As of 2018, the vaccine is not recommended for pregnant women.[40][87][89][90]

The FDA has classified the HPV vaccine as a pregnancy Category B, meaning there is no apparent harm to the fetus in animal studies. HPV vaccines have not been causally related with adverse pregnancy outcomes or adverse effects on the fetus. However, data on vaccination during pregnancy is very limited and vaccination during the pregnancy term should be delayed until more information is available. If a woman is found to be pregnant during the three-dose series of vaccination, the series should be postponed until pregnancy has been completed. While there is no indication for intervention for vaccine dosages administered during pregnancy, patients and healthcare providers are encouraged to report exposure to vaccines to the appropriate HPV vaccine pregnancy registry.[85][86][91]

Mechanism of action

The HPV vaccines are based on hollow virus-like particles (VLPs) assembled from recombinant HPV coat proteins. The natural virus capsid is composed of two proteins, L1 and L2, but vaccines only contain L1.

Gardasil contains inactive L1 proteins from four different HPV strains: 6, 11, 16, and 18, synthesized in the yeast Saccharomyces cerevisiae. Each vaccine dose contains 225 µg of aluminum, 9.56 mg of sodium chloride, 0.78 mg of L-histidine, 50 µg of polysorbate 80, 35 µg of sodium borate, and water. The combination of ingredients totals 0.5 mL.[92] HPV types 16 and 18 cause about 70% of all cervical cancer.[71] Gardasil also targets HPV types 6 and 11, which together cause about 90 percent of all cases of genital warts.[93]

Gardasil and Cervarix are designed to elicit virus-neutralizing antibody responses that prevent initial infection with the HPV types represented in the vaccine. The vaccines have been shown to offer 100 percent protection against the development of cervical pre-cancers and genital warts caused by the HPV types in the vaccine, with few or no side effects. The protective effects of the vaccine are expected to last a minimum of 4.5 years after the initial vaccination.[41]

While the study period was not long enough for cervical cancer to develop, the prevention of these cervical precancerous lesions (or dysplasias) is believed highly likely to result in the prevention of those cancers.[94]

History

The vaccine was first developed by the University of Queensland in Australia and the final form was made by researchers at the University of Queensland, Georgetown University Medical Center, University of Rochester, and the U.S. National Cancer Institute.[95] Researchers Ian Frazer and Jian Zhou at the University of Queensland have been accorded priority under U.S. patent law for the invention of the HPV vaccine's basis, the VLPs.[96] In 2006, the FDA approved the first preventive HPV vaccine, marketed by Merck & Co. under the trade name Gardasil. According to a Merck press release,[97] by the second quarter of 2007 it had been approved in 80 countries, many under fast-track or expedited review. Early in 2007, GlaxoSmithKline filed for approval in the United States for a similar preventive HPV vaccine, known as Cervarix. In June 2007, this vaccine was licensed in Australia, and it was approved in the European Union in September 2007.[98] Cervarix was approved for use in the U.S. in October 2009.[99]

Harald zur Hausen, a German researcher who suspected, and later helped to prove that genital HPV infection can lead to cervical cancer, was awarded half of the $1.4 million Nobel Prize in Medicine in 2008 for his work. Verification that cervical cancer is caused by an infectious agent led several other groups to develop vaccines against HPV strains that cause most cases of cervical cancer. The other half of the award went to Françoise Barré-Sinoussi and Luc Montagnier, two French virologists, for their part in the discovery of HIV.[100]

Harald zur Hausen was skeptical of the prevailing dogma and postulated that oncogenic human papilloma virus (HPV) caused cervical cancer.[45] He realized that HPV-DNA could exist in an inactive state in the tumours, and should be detectable by specific searches for viral DNA.[100] He and workers at the Pasteur Institute found HPV to be a heterogeneous family of viruses. Only some HPV types cause cancer.[45]

Harald zur Hausen pursued his research for over ten years searching for different HPV types.[100] This research was difficult because only parts of the viral DNA were integrated into the host genome. He found novel HPV-DNA in cervix cancer biopsies, and thus discovered the new, tumourigenic HPV16 type in 1983. In 1984, he cloned HPV16 and 18 from patients with cervical cancer.[100] The HPV types 16 and 18 were consistently found in about 70% of cervical cancer biopsies throughout the world.[45]

His observation of HPV oncogenic potential in human malignancy provided impetus within the research community to characterize the natural history of HPV infection, and to develop a better understanding of mechanisms of HPV-induced carcinogenesis.[45]

In December 2014, the US Food and Drug Administration (FDA) approved a vaccine called Gardasil 9 to protect females between the ages of 9 and 26 and males between the ages of 9 and 15 against nine strains of HPV.[101] Gardasil 9 protects against infection from the strains covered by the first generation of Gardasil (HPV-6, HPV-11, HPV-16, and HPV-18) and protects against five other HPV strains responsible for 20% of cervical cancers (HPV-31, HPV-33, HPV-45, HPV-52, and HPV-58).[101]

Society and culture

Cost

As of 2013, vaccinating girls and young women was estimated to be cost-effective in the low and middle-income countries, especially in places without organized programs for screening cervical cancer.[30] When the cost of the vaccine itself, or the cost of administering it to individuals, were higher, or if cervical cancer screening were readily available, then vaccination was less likely to be cost-effective.

From a public health point of view, vaccinating men as well as women decreases the virus pool within the population, but is only cost-effective to vaccinate men when the uptake in the female population is extremely low.[102] In the United States, the cost per quality-adjusted life year is greater than US$100,000 for vaccinating the male population, compared to the less than US$50,000 for vaccinating the female population.[102] This assumes a 75% vaccination rate.

In 2013, the two companies who sell the most common vaccines announced a price cut to less than US$5 per dose to poor countries, as opposed to US$130 per dose in the U.S.[103]

Vaccine implementation

Main article: Vaccination policy

In developed countries, the widespread use of cervical "Pap smear" screening programs has reduced the incidence of invasive cervical cancer by 50% or more. Preventive vaccines reduce but do not eliminate the chance of getting cervical cancer. Therefore, experts recommend that women combine the benefits of both programs by seeking regular Pap smear screening, even after vaccination.[104] School-entry vaccination requirements were found to increase the use of the HPV vaccine.[105][106]

Due to the COVID-19 pandemic (2019–2021), HPV vaccination programs have been significantly affected in the United States, low-income and lower-middle income countries.[107][108][109][110] On 30 August 2021, fifteen leading academic and freestanding cancer centers with membership in the Association of American Cancer Institutes (AACI), all National Cancer Institute (NCI)-designated cancer centers, the American Cancer Society, the American Society of Clinical Oncology, the American Association for Cancer Research, and the St. Jude Children's Research Hospital have issued a joint statement urging the U.S. health care systems, physicians, parents, children and young adults to get HPV vaccination and other recommended vaccinations back on track during the National Immunization Awareness Month.[109][110]

Africa

With support from the GAVI Alliance, a number of low-income African countries have begun rollout of the HPV vaccine, with others to follow. In 2013 Ghana, Kenya, Madagascar, Malawi, Niger, Sierra Leone, and the United Republic of Tanzania begin implementation of the vaccine. In 2014, Rwanda will begin nationwide rollout, and demonstration programs will take place in Mozambique and Zimbabwe.[111]

Australia

In April 2007, Australia became the second country—after Austria—to introduce a government-funded National Human Papillomavirus (HPV) Vaccination Program to protect young women against HPV infections that can lead to cancers and disease.[112] The National HPV Vaccination Program is listed on the National Immunisation Program (NIP) Schedule and funded under the Immunise Australia Program.[113] The Immunise Australia Program is a joint Federal, State, and Territory Government initiative to increase immunisation rates for vaccine-preventable diseases.

The National HPV Vaccination Program for females was made up of two components: an ongoing school-based program for 12- and 13-year-old girls; and a time-limited catch-up program (females aged 14–26 years) delivered through schools, general practices, and community immunization services, which ceased on 31 December 2009.

During 2007–2009, an estimated 83% of females aged 12–17 years received at least one dose of HPV vaccine and 70% completed the 3-dose HPV vaccination course.[112] By 2017, HPV coverage data on the Immunise Australia website show that by 15 years of age, over 82% of Australian females had received all three doses.[114]

Since the National HPV Vaccination Program commenced in 2007, there has been a reduction in HPV-related infections in young women. A study published in The Journal of Infectious Diseases in October 2012 found the prevalence of vaccine-preventable HPV types (6, 11, 16 and 18) in Papanicolaou test results of women aged 18–24 years has significantly decreased from 28.7% to 6.7% four years after the introduction of the National HPV Vaccination Program.[112] A 2011 report published found the diagnosis of genital warts (caused by HPV types 6 and 11) had also decreased in young women and men.[115]

In October 2010, the Australian regulatory agency, the Therapeutic Goods Administration, extended the registration of the quadrivalent vaccine (Gardasil) to include use in males aged 9 through 26 years of age, for the prevention of external genital lesions and infection with HPV types 6, 11, 16 and 18.

In November 2011, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended the extension of the National HPV Vaccination Program to include males. The PBAC made its recommendation on the preventive health benefits that can be achieved, such as a reduction in the incidence of anal and penile cancers and other HPV-related diseases. In addition to the direct benefit to males, it was estimated that routine HPV vaccination of adolescent males would contribute to the reduction of vaccine HPV-type infection and associated disease in women through herd immunity.[116]

In 2012, the Australian Government announced it would be extending the National HPV Vaccination Program to include males, through the National Immunisation Program Schedule.[117]

Updated results were reported in 2014.[118]

From February 2013, free HPV vaccine is being provided through school-based programs for:

  • males and females aged 12–13 years (ongoing program); and
  • males aged between 14 and 15 years – until the end of the school year in 2014 (catch up program).

Canada

In July 2006, human papillomavirus vaccine against four types of HPV was authorized in Canada for females 9 to 26 years.[119] In February 2010, use in males 9 to 26 years of age for prevention of genital warts was authorized.[120]

Canada has approved use of Gardasil.[121] Initiating and funding free vaccination programs has been left to individual Province/Territory Governments. All Provincial/Territorial governments offer free vaccination for school-aged children, irrespective of gender, at grade 4 (Quebec[122]), grade 6 (British Columbia,[123] Alberta,[124] Saskatchewan,[125] Manitoba,[126] Newfoundland and Labrador,[127] Prince Edward Island,[128] Yukon,[129] Northwest Territories [130] and Nunavut [131]) or grade 7 (Ontario,[132] Nova Scotia[133] and New Brunswick[134]) level.

China

GlaxoSmithKline China announced in 2016, that Cervarix (HPV vaccine 16 and 18) had been approved by the China Food and Drug Administration (CFDA).[135] Cervarix is registered in China for girls aged 9 to 45, adopting 3-dose program within 6 months.[136] Cervarix was launched in China in 2017, and it was the first approved HPV vaccine in China.[137]

Colombia

The vaccine was introduced in 2012, approved for girls aged 9.[138][139] The HPV vaccine was initially offered to girls aged 9 and older, and attending the fourth grade of school. Since 2013 the age of coverage was extended to girls in school from grade four (who have reached the age of 9) to grade eleven (independent of age); and no schooling from age 9–17 years 11 months and 29 days old.[140]

Costa Rica

Since June 2019, the vaccine is administered compulsorily by the state, free of charge to girls at ten years of age.[141][142]

Europe

Country Date of introduction Gender(s) Target age group Financed by Policy
Austria 2006 M/F 10–12 Fully financed by national health authorities[143]
Belgium 2007 F 10–13 Fully financed by national health authorities Mandatory; part of the national immunization schedule
Croatia 20 May 2016 M/F 12 Fully financed by national health authorities Voluntary immunization for women not yet sexually active
Denmark[144] 1 January 2009 M/F 12 Fully financed by national health authorities Part of the Danish Childhood Vaccination program
Finland[145] 21 November 2013 for female, 20 May 2020 for male[146] M/F 11–12 Fully financed by national health authorities Part of the Finnish National Vaccination program
France[147] 11 July 2007 F 14–23 Financed 65% by national health authorities Voluntary immunization for women not yet sexually active
Germany[148][149] 26 March 2007 M/F 9–14 Fully financed by mandatory health insurance Voluntary immunization
Greece[150][151] 12 February 2007 F 12–26 Fully financed by national health authorities Mandatory for all girls entering 7th grade
Hungary[152] 2014 F 12 Fully financed by national health authorities. In addition subsidised by local councils for 13- and 14-year-olds.
Iceland 2011 12 Fully financed by national health authorities
Ireland[153] 2009 M/F 12–13 Fully financed by national health authorities Offered to males and female in first year of secondary school. Non-mandatory. HPV vaccination introduced to national immunisation scheme for males in 2019.
Italy[148] 26 March 2007 M/F 12 Fully financed by national health authorities initially for girls only. Offered to boys from 2017.
Latvia 2009 12 Fully financed by national health authorities
Luxembourg 2008 12 Fully financed by national health authorities
Netherlands 2009 F 12–13 Fully financed by national health authorities
North Macedonia 2009 F 12 Fully financed by national health authorities Mandatory; part of the national immunization schedule
Norway 2009 F 12–13 Part of the national immunization program
Portugal 2007 F 13 Fully financed by national health authorities Part of the national immunization program for both boys and girls
Romania November 2008 F 10-18 Fully financed by national health authorities Part of the national immunization program, but not mandatory for 10–14 years old girls until August 2021, up to 18 years old as of 3 September 2021
Slovenia 2009 11–12 Fully financed by national health authorities
Spain 2007 11–14 Fully financed by national health authorities
Sweden[154] 2012[155] M/F 10–11 The school-based vaccination program is fully financed by national health authorities, initially for girls only. Offered to all children in fifth grade from August 2020 (boys born 2009 are included). [156] All vaccinations within the national vaccination programme for children are voluntary.
Switzerland 2008 11–14 Fully financed by national health authorities
UK September 2008 M/F M: 9–45

F: 9–45

Fully financed by national health authorities initially for girls only. Offered to boys aged 12 and 13 years from September 2019.[157] The HPV vaccine is available for free on the NHS up until a person's 25th birthday if they were eligible and missed the HPV vaccine offered in Year 8 at school,:[158]
  • girls born after 1 September 1991
  • boys born after 1 September 2006

Also fully financed by national health authorities since 2018 for men aged up to and including 45 years of age who have sex with other men (MSM) when they visit sexual health clinics and HIV clinics in England. Trans women (people who were assigned male at birth) are eligible in the same way as MSM if their risk of getting HPV is similar to the risk of MSM who are eligible for the HPV vaccine. Trans men (people who were assigned female at birth) are eligible if they have sex with other men and are aged 45 or under.[158]

 Offered to males and female in second year of secondary school, as well as at sexual health and HIV clinics in England. Non-mandatory.

Hong Kong

HPV vaccines are approved for use in Hong Kong. As part of the Hong Kong Childhood Immunisation Programme, HPV vaccines became mandatory for students in the 2019/2020 school year, exclusively for females at primary 5 and 6 levels.[159]

India

HPV vaccination has been recommended by the National Technical Advisory Group on Immunization, but has not been implemented in India as of 2018.[160]

Ireland

The HPV vaccination programme in Ireland is part of the national strategy to protect females from cervical cancer. Since 2009, the Health Service Executive has offered the HPV vaccine, free of charge, to all girls from first year onwards (ages 12–13). Secondary schools began implementing the vaccine program on an annual basis from September 2010 onwards.[161] The programme was expanded to include males in 2019.[162] Two HPV vaccines are licensed for use in Ireland: Cervarix and Gardasil. To ensure high uptake, the vaccine is administered to teenagers aged 12–13 in their first year of secondary school, with the first dose administered between September–October and the final dose in April of the following year.[162][163] Males and females aged 12–13 who are outside of the traditional school setting (home school, etc.) are invited to Health service Executive clinics for their vaccines. HPV vaccination in Ireland in not mandatory and consent is obtained prior to vaccination.[153][162] For males and females aged 16 and under, consent is granted by a parent or guardian, unless it is explicitly refused by the child. Any male or female aged 16 and over may provide their own consent if they want to be vaccinated.[162] HIQA has stated the vaccine will provide further protection, particularly to men who have sex with men. The vaccine has been extended following evidence that 25% of HPV cancers occur in men.[164] Additionally, HIQA is aiming to replace the current vaccination, which covers 4 major HPV strains, with an updated vaccine providing protection from 9 strains. The over cost with the "gender-neutral nine-talent" vaccine is estimated to be nearly €11.66 million over the next five years.[153]

Israel

Introduced in 2012. Target age group 13–14. Fully financed by national health authorities only for this age group. For the year 2013–2014, girls in the eighth grade may get the vaccine free of charge only in school, and not in Ministry of Health offices or clinics. Girls in the ninth grade may receive the vaccine free of charge only at Ministry of Health offices, and not in schools or clinics.[165] Religious and conservative groups are expected to refuse the vaccination.[166]

Japan

Introduced in 2010, widely available only since April 2013. Fully financed by national health authorities to females aged 11 to 16 years. In June 2013, however, Japan's Vaccine Adverse Reactions Review Committee (VARRC) suspended recommendation of the vaccine due to fears of adverse events. This directive has been criticized by researchers at the University of Tokyo as a failure of governance since the decision was taken without presentation of adequate scientific evidence.[167] At the time, Ministry spokespeople emphasized that "The decision does not mean that the vaccine itself is problematic from the viewpoint of safety," but that they wanted time to conduct analyses on possible adverse effects, "to offer information that can make the people feel more at ease."[168] However, the suspension of the Ministry's endorsement was still in place as of February 2019, by which time the HPV vaccination rate among younger women fell from approximately 70% in 2013 to 1% or less.[169] Over an overlapping time period (2009–2019), the age-adjusted mortality rate from cervical cancer increased by 9.6%.[169] Japan to Resume Active Promotion of HPV Vaccinations in April 2022.[170][171] In December 2021, the Ministry of Health, Labour and Welfare has decided to allow free vaccines to women born between fiscal year 1997 and 2005 after eight-year hiatus.[172] A panel of Japan's Ministry of Health, Labour and Welfare agreed to give women (born between fiscal 1997 and fiscal 2005), free vaccinations, if they missed the country's free vaccination program.[173]

Kenya

Both Cervarix and Gardasil are approved for use within Kenya by the Pharmacy and Poisons Board. However, at a cost of 20,000 Kenyan shillings, which is more than the average annual income for a family, the director of health promotion in the Ministry of Health, Nicholas Muraguri, states that many Kenyans are unable to afford the vaccine.[74]

Laos

In 2013, Laos began implementation of the HPV vaccine, with the assistance of the Gavi Alliance.[111]

Mexico

The vaccine was introduced in 2008 to 5% of the population. This percentage of the population had the lowest development index which correlates with the highest incidence of cervical cancer.[174] The HPV vaccine is delivered to girls 12 – 16 years old following the 0-2-6 dosing schedule. By 2009 Mexico had expanded the vaccine use to girls, 9–12 years of age, the dosing schedule in this group was different, the time elapsed between the first and second dose was six months and the third dose 60 months later.[175] In 2011 Mexico approved a nationwide use of HPV vaccination program to include vaccination of all 9-year-old girls.[175]

New Zealand

Immunization as of 2017 is free for males and females aged 9 to 26 years.[176]

The public funding began on 1 September 2008. The vaccine was initially offered only to girls, usually through a school-based program in Year 8 (approximately age 12), but also through general practices and some family planning clinics. Over 200,000 New Zealand girls and young women have received HPV immunization.[176]

Panama

The vaccine was added to the national immunization program in 2008, to target 10-year-old girls.[174]

South Africa

Cervical cancer represents the most common cause of cancer-related deaths—more than 3,000 deaths per year—among women in South Africa because of high HIV prevalence, making introduction of the vaccine highly desirable.[177] A Papanicolaou test program was established in 2000 to help screen for cervical cancer, but since this program has not been implemented widely, vaccination would offer more efficient form of prevention.[178] In May 2013 the Minister of Health of South Africa, Aaron Motsoaledi, announced the government would provide free HPV vaccines for girls aged 9 and 10 in the poorest 80% of schools starting in February 2014 and the fifth quintile later on.[179] South Africa will be the first African country with an immunisation schedule that includes vaccines to protect people from HPV infection, but because the effectiveness of the vaccines in women who later become infected with HIV is not yet fully understood, it is difficult to assess how cost-effective the vaccine will be. Negotiations are currently[when?] underway for more affordable HPV vaccines since they are up to 10 times more expensive than others already included in the immunization schedule.[177][179]

South Korea

On 27 July 2007, South Korean government approved Gardasil for use in girls and women aged 9 to 26 and boys aged 9 to 15.[180] Approval for use in boys was based on safety and immunogenicity but not efficacy.

Since 2016, HPV vaccination has been part of the National Immunization Program, offered free of charge to all children under 12 in South Korea, with costs fully covered by the Korean government.[181]

For 2016 only, Korean girls born between 1 January 2003 and 31 December 2004 were also eligible to receive the free vaccinations as a limited time offer. From 2017, the free vaccines are available to those under 12 only.[182]

Trinidad and Tobago

Introduced in 2013. Target Group 9–26. Fully financed by national health authorities. But was suspended later on that year owing to objections and concerns raised by the Catholic Board, but fully available in local health centers.[183]

United Arab Emirates

The World Health Organization ranks cervical cancer as the fourth most frequent cancer among women in UAE, at 7.4 per 100,000 women,[184] and according to Abu Dhabi Health Authority, the cancer is also the seventh highest cause of death of women in the U.A.E.[185]

In 2007, the HPV vaccine was approved for girls and young women, 15 to 26 years of age, and offered optionally at hospitals and clinics.[186][187] Moreover, starting 1 June 2013, the vaccine was offered free of charge for women between the ages of 18 and 26, in Abu Dhabi.[188] However, on 14 September 2018, the U.A.E's Ministry of Health and Community Protection announced that HPV vaccine became a mandatory part of the routine vaccinations for all girls in the U.A.E.[189] The vaccine is to be administers to all school girls in the 8th grade girls, aged 13.[190]

United Kingdom

In the UK the vaccine is licensed for females aged 9–26, for males aged 9–15, and for men who have sex with men aged 18–45.[191]

HPV vaccination was introduced into the national immunisation programme in September 2008, for girls aged 12–13 across the UK. A two-year catch-up campaign started in Autumn 2009 to vaccinate all girls up to 18 years of age. Catch up vaccination was offered to girls aged between 16 and 18 from autumn 2009, and girls aged between 15 and 17 from autumn 2010. It will be many years before the vaccination programme has an effect on cervical cancer incidence so women are advised to continue accepting their invitations for cervical screening.[192] Men who have sex with men up to and including the age of 45 became eligible for free HPV vaccination on the NHS in April 2018. They get the vaccine by visiting sexual health clinics and HIV clinics in England.[193] A meta-analysis of vaccinations for men who have sex with men showed that this strategy is most effective when combined with gender-neutral vaccination of all boys, regardeless of their sexual orientation.[194]

From the 2019/2020 school year, it is expected that 12- to 13-year-old boys will also become eligible for the HPV vaccine as part of the national immunisation programme. This follows a statement by the Joint Committee on Vaccination and Immunisation.[195] The first dose of the HPV vaccine will be offered routinely to boys aged 12 and 13 in school year 8, in the same way that it is currently (May 2018) offered to girls.[193] Boots UK had opened a private HPV vaccination service to boys and men aged 12–44 years in April 2017 at a cost of £150 per vaccination. In children aged 12–14 years two doses are recommended, while those aged 15–44 years a course of three is recommended.[196]

Cervarix was the HPV vaccine offered from introduction in September 2008, to August 2012, with Gardasil being offered from September 2012.[193][197] The change was motivated by Gardasil's added protection against genital warts.[198]

United States

Adoption

As of late 2007, about one quarter of U.S. females age 13–17 years had received at least one of the three HPV shots.[199] By 2014, the proportion of such females receiving an HPV vaccination had risen to 38%.[200] The government began recommending vaccination for boys in 2011; by 2014, the vaccination rate among boys (at least one dose) had reached 35%.[200]

According to the U.S. Centers for Disease Control and Prevention (CDC), getting as many girls vaccinated as early and as quickly as possible will reduce the cases of cervical cancer among middle-aged women in 30 to 40 years and reduce the transmission of this highly communicable infection. Barriers include the limited understanding by many people that HPV causes cervical cancer, the difficulty of getting pre-teens and teens into the doctor's office to get a shot, and the high cost of the vaccine ($120/dose, $360 total for the three required doses, plus the cost of doctor visits).[44][201] Community-based interventions can increase the uptake of HPV vaccination among adolescents.[202]

A survey was conducted in 2009 to gather information about knowledge and adoption of the HPV vaccine. Thirty percent of 13- to 17-year-olds and 9% of 18- to 26-year-olds out of the total 1,011 young women surveyed reported receipt of at least one HPV injection. Knowledge about HPV varied; however, 5% or fewer subjects believed that the HPV vaccine precluded the need for regular cervical cancer screening or safe-sex practices. Few girls and young women overestimate the protection provided by the vaccine. Despite moderate uptake, many females at risk of acquiring HPV have not yet received the vaccine.[203] For example, young black women are less likely to receive HPV vaccines compared to young white women. Additionally, young women of all races and ethnicities without health insurance are less likely to get vaccinated.[204]

Since the approval of Gardasil in 2006 and despite low vaccine uptake, prevalence of HPV among teenagers aged 14–19 has been cut in half with an 88% reduction among vaccinated women. No decline in prevalence was observed in other age groups, indicating the vaccine to have been responsible for the sharp decline in cases. The drop in number of infections is expected to in turn lead to a decline in cervical and other HPV-related cancers in the future.[205][206]

Legislation

Shortly after the first HPV vaccine was approved, bills to make the vaccine mandatory for school attendance were introduced in many states.[207] Only two such bills passed (in Virginia and Washington DC) during the first four years after vaccine introduction.[207] Mandates have been effective at increasing uptake of other vaccines, such as mumps, measles, rubella, and hepatitis B (which is also sexually transmitted).[201] However most such efforts developed for five or more years after vaccine release, while financing and supply were arranged, further safety data was gathered, and education efforts increased understanding, before mandates were considered.[207] Most public policies including school mandates have not been effective in promoting HPV vaccination while receiving a recommendation from a physician increased the probability of vaccination.[208] The FDA approved Gardasil 9 for women and men ages 27 to 45 in October 2018.[32]

State-by-state

The National Conference of State Legislatures periodically issues summaries of HPV vaccine related legislation.[209]

All school immunization laws grant exemptions to children for medical reasons, with other "opt-out" policies varying by state.[210]

In July 2015, Rhode Island added an HPV vaccine requirement for admittance into public school. This mandate requires all students entering the seventh grade to receive at least one dose of the HPV vaccine starting in August 2015, all students entering the eighth grade to receive at least two doses of the HPV vaccine starting in August 2016, and all students entering the ninth grade to receive at least three doses of the HPV vaccine starting in August 2017.[211][212][213] No legislative action is required for the Rhode Island Department of Health to add new vaccine mandates. Rhode Island is the only state that requires the vaccine for both male and female 7th graders.[106][209][214]

Other states are also preparing bills regarding the HPV vaccine.[209]

State Proposal Status
Alabama HB 42 would allow parents the option of immunizing female students entering the sixth grade, and requires the Department of Health and Senior Services to directly mail age appropriate information to parents or guardians to those students regarding the connection between HPV and cervical cancer and the availability of the immunization. Passed
Alaska Voluntary vaccination program Passed
District of Columbia Required vaccination program starting with 2014/2015 school year for sixth grade. Passed. D.C. Municipal Regulations 22-B §146
Florida SB 1116 Would require the Department of Health to adopt a rule adding HPV/cervical cancer to the list of communicable diseases for which immunizations are recommended; requires that schools provide the parents or guardians of certain public school students information regarding the disease and the availability of a vaccine; requires the department to prescribe the required information. Not passed
Georgia HB 736 Would require public Schools to provide parents or guardians of sixth grade female students information concerning the infection and the immunization against the human papillomavirus.
Hawaii Mandatory vaccination program starting with 2020/2021 school year for seventh grade. Passed.[215] Hawaii Administrative Rule 11-157.
Iowa SSB 3097 Would create a study bill for a HPV public awareness program and make appropriations for the public awareness program, provision of vaccinations, and cervical cancer screenings. In committee
Kansas HR 6019 Resolution would urge the FDA to use caution in approving new vaccines such as Gardasil which has had a number of health problems including some deaths associated with the use of this vaccine. In committee
Kentucky HR 80 Would urge females ages 9 to 26 and males ages 11 to 26 to obtain the Human papillomavirus (HPV) vaccination and all citizens to become more knowledgeable about the benefits of HPV vaccination. Passed
Maryland HB 411 Would require the Statewide Advisory Commission on Immunizations to study the safety of the human papillomavirus (HPV) vaccine; requires the commission to include specified components in the study, make recommendations, and report the results of its study. Passed
Minnesota HF 1758 Would require the commissioner of health to prepare informational materials on vaccines including the HPV vaccines and encourages public and private schools with students in grades 6–12 to provide this information to parents in a cost-effective and programmatically effective manner. (Introduced 3/16/09)
Michigan SB 1062 and SB 1063 Each would require health insurers to provide coverage for human papillomavirus screenings for cervical cancer. In committee
Mississippi HB 1512 Would require health benefit plans to cover HPV screenings. Not Passed
Missouri HB 1935 Would require health insurers to provide coverage for human papillomavirus screenings for cervical cancer. In committee
New Jersey S 1163 Would require health insurers and State Health Benefits Program and SEHBP to provide coverage for screening for cervical cancer, including testing for HPV. (Sent to Committee 1/23/12)

A 2185 Would require insurers and State health care coverage programs to cover cost of HPV vaccine.

In committee
New York SB 98 (same as AB 2360) Would encourage voluntary, informed vaccination against human papillomavirus (HPV). (Amended in Senate Committee on Health 1/5/12)

AB 699 Would require immunization against HPV for children born after 1 January 1996. (Sent to Assembly Committee on Health 1/5/11) AB 1946 Would require insurance companies to provide coverage for the vaccine against human papilloma virus. (Sent to committee 1/12/11) AB 2360 Would encourage voluntary, informed vaccination against human papillomavirus (HPV) for school-aged children and their parents or guardians. (Sent to committee 1/18/11) SB 4708 Would require insurance companies to cover HPV vaccine.

In committee
Oregon HB 2794 Would require health benefit plans to provide coverage of human papillomavirus vaccine for female beneficiaries who are 11 years of age or older. Passed
Pennsylvania HB 524 Would require health insurance policies to provide coverage for vaccinations for human papilloma virus. In committee
Puerto Rico Required starting with 2018/2019 school year. Passed. Law 25
South Carolina HB 4497 Would enact the Cervical Cancer Prevention Act and allow the Department of Health and Environmental Control to offer the option of an HPV vaccine series to female students entering the seventh grade at the request of their parent or guardian pending state and federal funding. In committee
Texas HB 2220 Would allow the Executive Commissioner of the Health and Human Services Commission to require immunization against human papillomavirus or other immunizations for a person's admission to elementary or secondary school. In committee
Virginia Three doses of properly spaced HPV vaccines are required for females before entering the sixth grade.[216]

HB 1419 would repeal the HPV vaccination requirement for female children. (Passed House 1/21/11, Indefinitely passed by the Senate Committee 2/17/11) HB 65 would repeal the requirement for children to receive the HPV vaccination for school attendance. (Left in committee 2/14/12) HB 824 would require that the Commonwealth shall assume liability for any injury resulting from administration of the human papillomavirus vaccine. HB 1112 would eliminate the requirement for vaccination against human papillomavirus for female children.

Passed House and sent to Senate
Source: National Conference of State Legislatures[209]
Immigrants

Between July 2008 and December 2009, proof of the first of three doses of HPV Gardasil vaccine was required for women ages 11–26 intending to legally enter the United States. This requirement stirred controversy because of the cost of the vaccine, and because all the other vaccines so required prevent diseases which are spread by respiratory route and considered highly contagious.[217] The Centers for Disease Control and Prevention repealed all HPV vaccination directives for immigrants effective 14 December 2009.[218] Uptake in the United States appears to vary by ethnicity and whether someone was born outside the United States.[219][220]

Coverage

Measures have been considered including requiring insurers to cover HPV vaccination, and funding HPV vaccines for those without insurance. The cost of the HPV vaccines for females under 18 who are uninsured is covered under the federal Vaccines for Children Program.[221] As of 23 September 2010, vaccines are required to be covered by insurers under the Patient Protection and Affordable Care Act. HPV vaccines specifically are to be covered at no charge for women, including those who are pregnant or nursing.[222]

Medicaid covers HPV vaccination in accordance with the ACIP recommendations, and immunizations are a mandatory service under Medicaid for eligible individuals under age 21.[223] In addition, Medicaid includes the Vaccines for Children Program.[224] This program provides immunization services for children 18 and under who are Medicaid eligible, uninsured, underinsured, receiving immunizations through a Federally Qualified Health Center or Rural Health Clinic, or are Native American or Alaska Native.[224]

The vaccine manufacturers also offer help for people who cannot afford HPV vaccination. GlaxoSmithKline's Vaccines Access Program[225] provides Cervarix[226] free of charge 1-877-VACC-911[227] to low income women, ages 19 to 25, who do not have insurance.[228] Merck's Vaccine Patient Assistance Program 1-800-293-3881[229] provides Gardasil free to low income women and men, ages 19 to 26, who do not have insurance, including immigrants who are legal residents.[230]

Opposition in the United States
See also: Vaccine controversy

The idea that the HPV vaccine is linked to increased sexual behavior is not supported by scientific evidence. A review of nearly 1,400 adolescent girls found no difference in teen pregnancy, incidence of sexually transmitted infection, or contraceptive counseling regardless of whether they received the HPV vaccine.[231] Thousands of Americans die each year from cancers preventable by the vaccine.[231]

Insurance companies

There has been significant opposition from health insurance companies to covering the cost of the vaccine ($360).[232][233][234]

Religious and conservative groups

Opposition due to the safety of the vaccine has been addressed through studies, leaving opposition focused on the sexual implications of the vaccine to remain. Conservative[235][who?] groups in the U.S. have opposed the concept of making HPV vaccination mandatory for pre-adolescent girls, claiming that making the vaccine mandatory is a violation of parental rights and that it will give a false sense of immunity to sexually transmitted disease, leading to early sexual activity. (See Peltzman effect) Both the Family Research Council and the group Focus on the Family support widespread (universal) availability of HPV vaccines but oppose mandatory HPV vaccinations for entry to public school.[236][237][238][239] Parents also express confusion over recent mandates for entry to public school, pointing out that HPV is transmitted through sexual contact, not through attending school with other children.[240]

Conservative groups are concerned children will see the vaccine as a safeguard against STDs and will have sex sooner than they would without the vaccine while failing to use contraceptives.[240] However, the American Academy of Pediatrics disagreed with the argument that the vaccine increases sexual activity among teens.[241] Christine Peterson, director of the University of Virginia's Gynecology Clinic, said "The presence of seat belts in cars doesn't cause people to drive less safely. The presence of a vaccine in a person's body doesn't cause them to engage in risk-taking behavior they would not otherwise engage in."[242][243] A 2018 study of college-aged students found that HPV vaccination did not increase sexual activity.[244][unreliable medical source]

Parental opposition

Many parents opposed to providing the HPV vaccine to their pre-teens agree the vaccine is safe and effective, but find talking to their children about sex uncomfortable. Elizabeth Lange, of Waterman Pediatrics in Providence, RI, addresses this concern by emphasizing what the vaccine is doing for the child. Lange suggests parents should focus on the cancer prevention aspect without being distracted by words like 'sexually transmitted'. Everyone wants cancer prevention, yet here parents are denying their children a form of protection due to the nature of the cancer—Lange suggests that this much controversy would not surround a breast cancer or colon cancer vaccine. The HPV vaccine is suggested for 11-year-olds because it should be administered before possible exposure to HPV, but also because the immune system has the highest response for creating antibodies around this age. Lange also emphasized the studies showing that the HPV vaccine does not cause children to be more promiscuous than they would be without the vaccine.[240]

Controversy over the HPV vaccine remains present in the media. Parents in Rhode Island have created a Facebook group called "Rhode Islanders Against Mandated HPV Vaccinations" in response to Rhode Island's mandate that males and females entering the 7th grade, as of September 2015, be vaccinated for HPV before attending public school.[106][240]

Physician impact

The effectiveness of a physician's recommendation for the HPV vaccine also contributes to low vaccination rates and controversy surrounding the vaccine. A 2015 study of national physician communication and support for the HPV vaccine found physicians routinely recommend HPV vaccines less strongly than they recommend Tdap or meningitis vaccines, find the discussion about HPV to be long and burdensome, and discuss the HPV vaccine last, after all other vaccines. Researchers suggest these factors discourage patients and parents from setting up timely HPV vaccines. In order to increase vaccination rates, this issue must be addressed and physicians should be better trained to handle discussing the importance of the HPV vaccine with patients and their families.[245]

Ethics

Some researchers have compared the need for adolescent HPV vaccination to that of other childhood diseases such as chicken pox, measles, and mumps. This is because vaccination before infection decreases the risk of a number of forms of cancer.[246][247]

There has been some controversy around the HPV vaccine's rollout and distribution. Countries have taken different routes based on economics and social climate leading to issues of forced vaccination and marginalization of segments of the population in some cases.[248]

The rollout of a country's vaccination program is more divisive, compared to the act of providing vaccination against HPV. In more affluent countries, arguments have been made for publicly funded programs aimed at vaccinating all adolescents voluntarily. These arguments are supported by World Health Organization (WHO) surveys showing the effectiveness of cervical cancer prevention with HPV vaccination.[248]

In developing countries, cost of the vaccine, dosing schedule, and other factors have led to suboptimal levels of vaccination. Future research is focused on low-cost generics and single-dose vaccination in efforts to make the vaccine more accessible.[249]

Research

There are high-risk HPV types, that are not affected by available vaccines.[41] Ongoing research is focused on the development of HPV vaccines that will offer protection against a broader range of HPV types. One such method is a vaccine based on the minor capsid protein L2, which is highly conserved across HPV genotypes.[250] Efforts for this have included boosting the immunogenicity of L2 by linking together short amino acid sequences of L2 from different oncogenic HPV types or by displaying L2 peptides on a more immunogenic carrier.[251][252] There is also substantial research interest in the development of therapeutic vaccines, which seek to elicit immune responses against established HPV infections and HPV-induced cancers.[253]

Therapeutic vaccines

In addition to preventive vaccines, such as Gardasil and Cervarix, laboratory research and several human clinical trials are focused on the development of therapeutic HPV vaccines. In general, these vaccines focus on the main HPV oncogenes, E6 and E7. Since expression of E6 and E7 is required for promoting the growth of cervical cancer cells (and cells within warts), it is hoped that immune responses against the two oncogenes might eradicate established tumors.[254]

There is a working therapeutic HPV vaccine. It has gone through three clinical trials. The vaccine is officially called the MEL-1 vaccine but also known as the MVA-E2 vaccine. In a study it has been suggested that an immunogenic peptide pool containing epitopes that can be effective against all the high-risk HPV strains circulating globally and 14 conserved immunogenic peptide fragments from four early proteins (E1, E2, E6 and E7) of 16 high-risk HPV types providing CD8+ responses.[255][256][257][258]

Therapeutic DNA vaccine VGX-3100, which consists of plasmids pGX3001 and pGX3002, has been granted a waiver by the European Medicines Agency for pediatric treatment of squamous intraepithelial lesions of the cervix caused by HPV types 16 and 18.[259] According to an article published 16 September 2015 in The Lancet, which reviewed the safety, efficacy, and immunogenicity of VGX-3100 in a double-blind, randomized controlled trial (phase 2b) targeting HPV-16 and HPV-18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3, it is the first therapeutic vaccine to show efficacy against CIN 2/3 associated with HPV-16 and HPV-18.[260] In June 2017, VGX-3100 entered a phase III clinical trial called REVEAL-1 for the treatment of HPV-induced high-grade squamous intraepithelial lesions.[261] The estimated completion time for collecting primary clinical endpoint data is August 2019.[262]

As of October 2020, there are multiple therapeutic HPV vaccines in active development and in clinical trials, based on diverse vaccine platforms (protein-based, viral vector, bacterial vector, lipid encapsulated mRNA).[263]

Awards

In 2009, as part of the Q150 celebrations, the cervical cancer vaccine was announced as one of the Q150 Icons of Queensland for its role in "innovation and invention".[264]

In 2017, National Cancer Institute scientists Douglas R. Lowy and John T. Schiller received the Lasker-DeBakey Clinical Medical Research Award for their contributions leading to the development of HPV vaccines.[265]

References

  1. ^ "Human papillomavirus vaccine Use During Pregnancy". Drugs.com. 11 February 2019. from the original on 5 April 2020. Retrieved 3 April 2020.
  2. ^ "Gardasil HPV 6 L1 Protein / HPV 11 L1 Protein / HPV 16 L1 Protein / HPV 18 L1 Protein 20,40,40,20 micrograms/0.5mL sterile liquid syringe". Therapeutic Goods Administration (TGA). from the original on 8 July 2022. Retrieved 8 July 2022.
  3. ^ "Gardasil 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms/0.5mL, suspension for injection, syringe". Therapeutic Goods Administration (TGA). from the original on 8 July 2022. Retrieved 8 July 2022.
  4. ^ "Gardasil 9 Human Papillomavirus 9-valent Vaccine, Recombinant, 30, 40, 60, 40, 20, 20, 20, 20, 20 micrograms / 0.5mL, suspension for injection, vial". Therapeutic Goods Administration (TGA). from the original on 8 July 2022. Retrieved 8 July 2022.
  5. ^ "Gardasil (human papillomavirus vaccine)". Therapeutic Goods Administration (TGA). 24 June 2010. from the original on 23 March 2022. Retrieved 8 July 2022.
  6. ^ "AusPAR: Human papillomavirus quadrivalent vaccine". Therapeutic Goods Administration (TGA). 24 February 2011. from the original on 18 June 2022. Retrieved 8 July 2022.
  7. ^ "AusPAR: Human Papillomavirus 9 valent vaccine". Therapeutic Goods Administration (TGA). 16 January 2017. from the original on 4 April 2019. Retrieved 8 July 2022.
  8. ^ "AusPAR: Human papillomavirus (Types 6, 11, 16 & 18) quadrivalent recombinant vaccine". Therapeutic Goods Administration (TGA). 7 June 2012. from the original on 9 September 2017. Retrieved 8 July 2022.
  9. ^ "Gardasil Product information". Health Canada. 25 April 2012. from the original on 8 July 2022. Retrieved 8 July 2022.
  10. ^ "Gardasil 9 Product information". Health Canada. 25 April 2012. from the original on 6 May 2021. Retrieved 8 July 2022.
  11. ^ "Gardasil 9 suspension for injection - Summary of Product Characteristics (SmPC)". (emc). 24 January 2020. from the original on 6 April 2020. Retrieved 3 April 2020.
  12. ^ "Gardasil suspension for injection - Summary of Product Characteristics (SmPC)". (emc). 7 May 2019. from the original on 4 April 2020. Retrieved 3 April 2020.
  13. ^ a b "Gardasil- human papillomavirus quadrivalent- types 6, 11, 16, and 18 vaccine, recombinant injection, suspension". DailyMed. 2 December 2020. from the original on 21 April 2022. Retrieved 31 March 2022.
  14. ^ a b "Gardasil 9- human papillomavirus 9-valent vaccine, recombinant injection, suspension". DailyMed. 20 August 2021. from the original on 5 April 2020. Retrieved 31 March 2022.
  15. ^ "Cervarix". U.S. Food and Drug Administration (FDA). 4 October 2022. STN:BL 125259. from the original on 10 October 2022. Retrieved 9 October 2022.
  16. ^ "Silgard EPAR". European Medicines Agency (EMA). from the original on 6 April 2020. Retrieved 3 April 2020.
  17. ^ "Gardasil 9 EPAR". European Medicines Agency (EMA). from the original on 6 April 2020. Retrieved 3 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  18. ^ "Gardasil EPAR". European Medicines Agency. from the original on 11 June 2022. Retrieved 6 July 2022.
  19. ^ a b c d e f g h i j k l m n o p q r s "Human papillomavirus vaccines: WHO position paper, May 2017". Relevé Épidémiologique Hebdomadaire. 92 (19): 241–268. May 2017. hdl:10665/255354. PMID 28530369. Lay summary (PDF). {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
  20. ^ Kash N, Lee MA, Kollipara R, Downing C, Guidry J, Tyring SK (April 2015). "Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus". Journal of Clinical Medicine. 4 (4): 614–633. doi:10.3390/jcm4040614. PMC 4470159. PMID 26239350. S2CID 14149551.
  21. ^ De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S (April 2009). "Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis". International Journal of Cancer. 124 (7): 1626–1636. doi:10.1002/ijc.24116. PMID 19115209. S2CID 24197494.
  22. ^ Takes RP, Wierzbicka M, D'Souza G, Jackowska J, Silver CE, Rodrigo JP, et al. (December 2015). "HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?". Oral Oncology. 51 (12): 1057–1060. doi:10.1016/j.oraloncology.2015.10.011. PMID 26520047. S2CID 23356354.
  23. ^ Thaxton L, Waxman AG (May 2015). "Cervical cancer prevention: immunization and screening 2015". The Medical Clinics of North America. 99 (3): 469–477. doi:10.1016/j.mcna.2015.01.003. PMID 25841595. S2CID 2828633.
  24. ^ Anjum F, Zohaib J (4 December 2020). "Oropharyngeal Squamous Cell Carcinoma". Definitions. StatPearls (Updated ed.). Treasure Island (FL): StatPearls Publishing. doi:10.32388/G6TG1L. PMID 33085415. S2CID 229252540. Bookshelf ID: NBK563268. from the original on 11 June 2021. Retrieved 7 February 2021 – via NCBI.
  25. ^ Saville AM (April 2016). "Cervical cancer prevention in Australia: Planning for the future". Cancer Cytopathology. 124 (4): 235–240. doi:10.1002/cncy.21643. PMID 26619381.
  26. ^ World Health Organization (May 2011). The immunological basis for immunization series: module 19: human papillomavirus infection. World Health Organization. hdl:10665/44604. ISBN 9789241501590.
  27. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  28. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  29. ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
  30. ^ a b Fesenfeld M, Hutubessy R, Jit M (August 2013). "Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review". Vaccine. 31 (37): 3786–3804. doi:10.1016/j.vaccine.2013.06.060. PMID 23830973.
  31. ^ "What's New with VISs". Centers for Disease Control and Prevention (CDC). 5 April 2019. from the original on 15 October 2019. Retrieved 14 October 2019.
  32. ^ a b "The HPV Vaccine: Access and Use in the U.S." The Henry J. Kaiser Family Foundation. 9 October 2018. from the original on 15 October 2019. Retrieved 14 October 2019.
  33. ^ Drolet M, Bénard É, Pérez N, Brisson M (August 2019). "Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis". Lancet. 394 (10197): 497–509. doi:10.1016/S0140-6736(19)30298-3. PMC 7316527. PMID 31255301.
  34. ^ a b "FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old". U.S. Food and Drug Administration (FDA) (Press release). 5 October 2018. from the original on 14 October 2019. Retrieved 14 October 2018.
  35. ^ a b c d Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE (August 2019). "Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices" (PDF). MMWR. Morbidity and Mortality Weekly Report. 68 (32): 698–702. doi:10.15585/mmwr.mm6832a3. PMC 6818701. PMID 31415491. (PDF) from the original on 13 October 2019. Retrieved 15 October 2019.
  36. ^ a b "Human Papillomavirus (HPV) Vaccines: Q & A". Fact Sheets: Risk Factors and Possible Causes. National Cancer Institute (NCI). 22 October 2009. from the original on 21 June 2008. Retrieved 18 July 2008.
  37. ^ "Cervical Cancer: Screening". United States Preventive Services Task Force (USPSTF). August 2018. from the original on 7 November 2018. Retrieved 7 November 2018.
  38. ^ Cox B, Sneyd MJ (2018). "HPV screening, invasive cervical cancer and screening policy in Australia". Journal of the American Society of Cytopathology. 7 (6): 292–299. doi:10.1016/j.jasc.2018.07.003. PMID 31043298. S2CID 58548623.
  39. ^ Lew JB, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM, et al. (February 2017). "Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program". The Lancet. Public Health. 2 (2): e96–e107. doi:10.1016/S2468-2667(17)30007-5. PMID 29253402.
  40. ^ a b c d e Arbyn M, Xu L, Simoens C, Martin-Hirsch PP (May 2018). "Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors". The Cochrane Database of Systematic Reviews. 5 (3): CD009069. doi:10.1002/14651858.CD009069.pub3. PMC 4176676. PMID 29740819. CD009069.
  41. ^ a b c Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. (April 2006). "Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial". Lancet. 367 (9518): 1247–1255. doi:10.1016/S0140-6736(06)68439-0. PMID 16631880. S2CID 18685310.
  42. ^ a b De Vincenzo R, Conte C, Ricci C, Scambia G, Capelli G (3 December 2014). "Long-term efficacy and safety of human papillomavirus vaccination". International Journal of Women's Health. 6: 999–1010. doi:10.2147/IJWH.S50365. PMC 4262378. PMID 25587221.
  43. ^ "Committee opinion no. 467: human papillomavirus vaccination". Obstetrics and Gynecology. 116 (3): 800–803. September 2010. doi:10.1097/AOG.0b013e3181f680c8. PMID 20733476.
  44. ^ a b Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER (March 2007). "Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Recommendations and Reports. 56 (RR-2): 1–24. PMID 17380109. (PDF) from the original on 24 September 2015.
  45. ^ a b c d e f "HPV Vaccines". Centers for Disease Control and Prevention (CDC). 15 October 2010. from the original on 4 October 2015. Retrieved 27 February 2011.
  46. ^ a b c d e |Tay SK (February 2012). "Cervical cancer in the human papillomavirus vaccination era". Current Opinion in Obstetrics & Gynecology. 24 (1): 3–7. doi:10.1097/GCO.0b013e32834daed9. PMID 22123221. S2CID 23213383.
  47. ^ Jit M, Brisson M, Laprise JF, Choi YH (January 2015). "Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model". BMJ. 350: g7584. doi:10.1136/bmj.g7584. PMC 4285892. PMID 25567037.
  48. ^ "Meeting of the Advisory Committee on Immunization Practices (ACIP)" (PDF). Centers for Disease Control and Prevention (CDC). 14 October 2016. (PDF) from the original on 21 October 2016. Retrieved 21 October 2016.
  49. ^ Sonawane K, Nyitray AG, Nemutlu GS, Swartz MD, Chhatwal J, Deshmukh AA (December 2019). "Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women". JAMA Network Open. 2 (12): e1918571. doi:10.1001/jamanetworkopen.2019.18571. PMC 6986697. PMID 31880792.
  50. ^ Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. (February 2015). "A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women". The New England Journal of Medicine. 372 (8): 711–723. doi:10.1056/NEJMoa1405044. PMID 25693011.
  51. ^ Schuchat A (February 2015). "HPV "coverage"". The New England Journal of Medicine. 372 (8): 775–776. doi:10.1056/NEJMe1415742. PMC 6009818. PMID 25693018.
  52. ^ "FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old". U.S. Food and Drug Administration. from the original on 14 October 2019. Retrieved 9 November 2019.
  53. ^ "Human Papillomavirus (HPV) Prevention and HPV Vaccines: Questions and Answers". Public Health Agency of Canada. 18 June 2007. from the original on 26 September 2019. Retrieved 9 November 2019.
  54. ^ a b c (Press release). U.S. Food and Drug Administration (FDA). Archived from the original on 24 October 2009. Retrieved 30 October 2009.
  55. ^ a b Centers for Disease Control Prevention (CDC) (May 2010). "FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)" (PDF). MMWR. Morbidity and Mortality Weekly Report. 59 (20): 630–632. PMID 20508594. (PDF) from the original on 24 September 2015.
  56. ^ . Centers for Disease Control and Prevention (CDC). Archived from the original on 21 November 2015. Retrieved 20 November 2015.
  57. ^ Rosenthal E (19 August 2008). "Drug Makers' Push Leads to Cancer Vaccines' Fast Rise". The New York Times. from the original on 9 April 2009. Retrieved 20 August 2008. Said Dr. Raffle, the British cervical cancer specialist: 'Oh, dear. If we give it to boys, then all pretense of scientific worth and cost analysis goes out the window.'
  58. ^ . Cancer Research UK. 23 February 2007. Archived from the original on 24 March 2010. Retrieved 30 October 2009.
  59. ^ Karen Canfell: The road to cervical cancer elimination, from the original on 17 December 2021, retrieved 14 April 2022
  60. ^ Ní Aodha G (11 August 2019). "Explainer: The HPV vaccine is free for boys from next month - here's why that's important". thejournal.ie. from the original on 5 January 2021. Retrieved 6 January 2021.
  61. ^ Herbert T (2 September 2019). "What is the HPV vaccine for boys and are there any side effects?". Evening Standard. from the original on 7 November 2020. Retrieved 6 January 2021.
  62. ^ "Vacinas: Meningite B e HPV para rapazes passam a ser gratuitas em 2020 - DN". www.dn.pt (in Portuguese). from the original on 30 January 2020. Retrieved 30 January 2020.
  63. ^ Castle PE, Scarinci I (October 2009). "Should HPV vaccine be given to men?". BMJ. 339 (7726): b4127. doi:10.1136/bmj.b4127. PMID 19815585. S2CID 1922594.
  64. ^ (Press release). U.S. Food and Drug Administration (FDA). 2010. Archived from the original on 18 December 2014. Retrieved 15 January 2015.
  65. ^ "Gardasil". U.S. Food and Drug Administration (FDA). 25 April 2019. STN 125126. from the original on 15 October 2019. Retrieved 15 October 2019.
  66. ^ . U.S. Food and Drug Administration (FDA). 25 April 2019. STN 125508. Archived from the original on 15 October 2019. Retrieved 15 October 2019.
  67. ^ Rettner R (25 October 2011). "Boys Should Get HPV Vaccine Too, CDC Says". LiveScience. from the original on 3 July 2012. Retrieved 11 November 2011.
  68. ^ "CDC panel recommends HPV vaccine for boys, too". 26 October 2011. Archived from the original on 5 September 2012.
  69. ^ Moi H, Iversen OE (17 December 2011). "Gi guttene jentevaksine". Dagens Næringsliv (in Norwegian). p. 32. Zur Haussen, som fikk Nobelprisen i 2009 for sin HPV-forskning, har lenge argumentert for vaksinasjon av gutter, både som egen beskyttelse og beskyttelse av kvinner.
  70. ^ Montague L (5 October 2018). "Summary Basis for Regulatory Action" (PDF). U.S. Food and Drug Administration (FDA). from the original on 14 December 2019. Retrieved 7 August 2019.
  71. ^ a b c d e f Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al. (August 2004). "Against which human papillomavirus types shall we vaccinate and screen? The international perspective". International Journal of Cancer. 111 (2): 278–285. doi:10.1002/ijc.20244. PMID 15197783. S2CID 20679802.
  72. ^ Wittet S, Tsu V (June 2008). "Cervical cancer prevention and the Millennium Development Goals". Bulletin of the World Health Organization. 86 (6): 488–490. doi:10.2471/BLT.07.050450. PMC 2647477. PMID 18568279.
  73. ^ (PDF). ESGO. 2007. Archived from the original (PDF) on 26 July 2011.
  74. ^ a b . Medical News Today. Archived from the original on 3 January 2009. Retrieved 17 September 2010.
  75. ^ Attkisson S (19 August 2009). "Gardasil Researcher Speaks Out". CBS News. from the original on 3 March 2022. Retrieved 3 March 2022.
  76. ^ Yerman MG (28 December 2009). "An Interview with Dr. Diane M. Harper, HPV Expert". Huffington Post. from the original on 13 August 2013. Retrieved 28 August 2013.
  77. ^ Haelle T (23 February 2016). "HPV Infection Rates Plummet In Young Women Due To Vaccine". Forbes. from the original on 26 February 2016. Retrieved 23 February 2016.
  78. ^ (PDF). National Centre for Immunisation Research and Surveillance Factsheet. March 2013. Archived from the original (PDF) on 20 April 2013.
  79. ^ "GARDASIL®, Merck's HPV Vaccine, Available to Developing Countries through UNICEF Tender". BusinessWire. 9 May 2013. from the original on 18 December 2014. Retrieved 8 September 2013.
  80. ^ a b c d e f "Reports of Health Concerns Following HPV Vaccination". Centers for Disease Control and Prevention (CDC). 5 November 2009. from the original on 17 September 2013. Retrieved 8 September 2013.
  81. ^ "Review concludes evidence does not support that HPV vaccines cause CRPS or POTS" (PDF) (Press release). European Medicines Agency (EMA). 5 November 2015. (PDF) from the original on 14 February 2016. Retrieved 5 November 2015.
  82. ^ . Centers for Disease Control and Prevention (CDC). 22 July 2008. Archived from the original on 2 September 2013. Retrieved 8 September 2013.
  83. ^ Moghtaderi A, Dor A (April 2021). "Immunization and Moral Hazard: The HPV Vaccine and Uptake of Cancer Screening". Medical Care Research and Review. 78 (2): 125–137. doi:10.3386/w22523. PMID 31096862.
  84. ^ "Human Papillomavirus (HPV) Vaccines". 25 May 2018. from the original on 4 July 2014.
  85. ^ a b "HPV Vaccine Information for Clinicians – Fact Sheet". CDC. 11 January 2019. from the original on 1 May 2012.
  86. ^ a b (PDF). FDA. Archived from the original (PDF) on 7 March 2014.
  87. ^ a b . Merck & Co. 1 February 2012. Archived from the original on 1 March 2012. Retrieved 29 May 2007.
  88. ^ . Merck & Co. Archived from the original on 28 August 2018. Retrieved 21 October 2019.
  89. ^ "Who Should NOT Get Vaccinated with these Vaccines?". Centers for Disease Control and Prevention (CDC). 10 June 2010. from the original on 11 May 2011. Retrieved 27 February 2011.
  90. ^ Goss MA, Lievano F, Buchanan KM, Seminack MM, Cunningham ML, Dana A (June 2015). "Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine". Vaccine. 33 (29): 3422–3428. doi:10.1016/j.vaccine.2015.04.014. PMID 25869893.
  91. ^ "HPV Vaccine and Pregnancy". eMedTV. from the original on 24 July 2012.
  92. ^ . Ciitn.missouri.edu. 22 January 2007. Archived from the original on 2 October 2013. Retrieved 29 December 2013.
  93. ^ Lowy DR, Schiller JT (May 2006). "Prophylactic human papillomavirus vaccines". The Journal of Clinical Investigation. 116 (5): 1167–1173. doi:10.1172/JCI28607. PMC 1451224. PMID 16670757.
  94. ^ (Press release). U.S. Food and Drug Administration (FDA). 8 June 2006. Archived from the original on 19 October 2009. Retrieved 13 November 2009.
  95. ^ McNeil C (April 2006). "Who invented the VLP cervical cancer vaccines?". Journal of the National Cancer Institute. 98 (7): 433. doi:10.1093/jnci/djj144. PMID 16595773.
  96. ^ U.S. Patent 7,476,389, titled "Papilloma Virus Vaccines", was granted to co-inventors Ian Frazer and Jian Zhou (Zhou posthumously) on 13 January 2009. Its U.S. application was filed on 19 January 1994, but claimed priority under a 20 July 1992, PTC filing to the date of an initial [AU] Australian patent application filed on 19 July 1991.
  97. ^ (Press release). Archived from the original on 12 October 2007. Retrieved 16 October 2019.
  98. ^ "Glaxo prepares to launch Cervarix after EU okay". Reuters. 24 September 2007. from the original on 25 October 2008. Retrieved 18 July 2008.
  99. ^ . U.S. Food and Drug Administration (FDA). 16 October 2009. Archived from the original on 19 October 2009. Retrieved 13 November 2009.
  100. ^ a b c d "The Genital HPV Infection Fact Sheet". Centers for Disease Control and Prevention (CDC). 24 November 2009. from the original on 28 June 2013. Retrieved 13 February 2010.
  101. ^ a b (press release). U.S. Food and Drug Administration (FDA). 10 December 2014. Archived from the original on 10 January 2015. Retrieved 9 January 2015.
  102. ^ a b Kim JJ, Goldie SJ (October 2009). "Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States". BMJ. 339 (7726): b3884. doi:10.1136/bmj.b3884. PMC 2759438. PMID 19815582.
  103. ^ McNeil Jr DG (5 May 2013). "Cancer Vaccines Get a Price Cut in Poor Nations". The New York Times. from the original on 23 November 2013. Retrieved 23 November 2013.
  104. ^ Cutts FT, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al. (September 2007). "Human papillomavirus and HPV vaccines: a review". Bulletin of the World Health Organization. 85 (9): 719–726. doi:10.2471/BLT.06.038414. PMC 2636411. PMID 18026629.
  105. ^ Ko JS, Goldbeck CS, Baughan EB, Klausner JD (September 2020). "Association Between Human Papillomavirus Vaccination School-Entry Requirements and Vaccination Initiation". JAMA Pediatrics. 174 (9): 861–867. doi:10.1001/jamapediatrics.2020.1852. PMC 7325070. PMID 32597928. Lay summary. {{cite journal}}: Cite uses deprecated parameter |lay-url= (help)
  106. ^ a b c Thompson EL, Livingston MD, Daley EM, Saslow D, Zimet GD (August 2020). "Rhode Island Human Papillomavirus Vaccine School Entry Requirement Using Provider-Verified Report". American Journal of Preventive Medicine. 59 (2): 274–277. doi:10.1016/j.amepre.2020.02.022. hdl:1805/28509. PMID 32430223. S2CID 218758834.
  107. ^ Toh ZQ, Russell FM, Garland SM, Mulholland EK, Patton G, Licciardi PV (April 2021). "Human Papillomavirus Vaccination After COVID-19". JNCI Cancer Spectrum. Oxford University Press. 5 (2): pkab011. doi:10.1093/jncics/pkab011. eISSN 2515-5091. PMC 7962726. PMID 33748668. S2CID 232295180.
  108. ^ Daniels V, Saxena K, Roberts C, Kothari S, Corman S, Yao L, Niccolai L (May 2021). Poland G (ed.). "Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis". Vaccine. Elsevier. 39 (20): 2731–2735. doi:10.1016/j.vaccine.2021.04.003. PMC 8023201. PMID 33875269. S2CID 233034581.
  109. ^ a b Sheffield M, Hobgood K (30 August 2021). "St. Jude and leading cancer centers urge vaccination to protect against HPV and other diseases". www.stjude.org. Memphis, Tennessee: St. Jude Children's Research Hospital. from the original on 15 November 2021. Retrieved 8 September 2021.
  110. ^ a b Highleyman L (3 September 2021). "Get HPV Vaccination Back on Track, Experts Urge". POZ. New York City. ISSN 1075-5705. from the original on 8 September 2021. Retrieved 8 September 2021.
  111. ^ a b Frazer I. . GAVI Alliance. Archived from the original on 18 January 2014. Retrieved 29 December 2013.
  112. ^ a b c Tabrizi S. Brotherton J. Kaldor J et al. Fall in Human Papillomavirus Prevalence Following a National Vaccination Program. Journal of Infectious Diseases. 24 October 2012.
  113. ^ Immunise Australia: Information about the HPV immunisation program 4 May 2015 at the Wayback Machine
  114. ^ "Historical Human Papillomavirus (HPV) immunisation coverage rates". Australian Government Department of Health. 4 December 2019. from the original on 28 September 2021. Retrieved 28 September 2021.
  115. ^ 2011 Annual Surveillance Report of HIV, viral hepatitis, STIs 22 May 2013 at the Wayback Machine (page 28)
  116. ^ . Australian Government Department of Health. Archived from the original on 19 April 2013.
  117. ^ "Young men to be protected from cancers through HPV vaccine". Australian Cancer Research Foundation. 13 July 2012. from the original on 28 September 2021. Retrieved 28 September 2021.
  118. ^ Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. (October 2014). "Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study". The Lancet. Infectious Diseases. 14 (10): 958–966. doi:10.1016/S1473-3099(14)70841-2. PMID 25107680.
  119. ^ "Summary Safety Review - Gardasil (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases". Health Canada. 9 December 2015. from the original on 26 September 2019. Retrieved 21 October 2019.
  120. ^ Dawar DM, Harris MT, McNeil DS (January 2012). "Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) †". Canada Communicable Disease Report. 38 (ACS-1): 1–62. doi:10.14745/ccdr.v38i00a01. PMC 6802461. PMID 31701955. from the original on 21 October 2019. Retrieved 21 October 2019.
  121. ^ . Archived from the original on 18 July 2008. Retrieved 16 October 2019.
  122. ^ "Eligibility – Human Papillomavirus (HPV) Vaccination Program". www.quebec.ca. from the original on 28 September 2020. Retrieved 15 August 2020.
  123. ^ "HPV (Human Papillomavirus)". Immunize BC. 21 March 2011. from the original on 15 August 2020. Retrieved 15 August 2020.
  124. ^ "Human Papillomavirus (HPV-9) Vaccine". myhealth.alberta.ca. from the original on 29 September 2020. Retrieved 15 August 2020.
  125. ^ "Human Papillomavirus (HPV) Disease and Vaccines" (PDF). (PDF) from the original on 27 March 2020. Retrieved 15 August 2020.
  126. ^ "Manitoba's Immunization Program: Vaccines Offered Free-of-Charge (Eligibility Criteria for Publicly-Funded Vaccines)". Province of Manitoba - Health and Seniors Care. from the original on 20 July 2020. Retrieved 15 August 2020.
  127. ^ "Immunization Schedule Newfoundland and Labrador" (PDF). (PDF) from the original on 20 July 2020. Retrieved 15 August 2020.
  128. ^ Web Experience Toolkit (25 February 2016). "Childhood Immunizations". www.princeedwardisland.ca. from the original on 5 August 2020. Retrieved 15 August 2020.
  129. ^ . yukon.ca. 24 April 2017. Archived from the original on 26 April 2017.
  130. ^ "NWT Immunization Schedule" (PDF). (PDF) from the original on 27 October 2020. Retrieved 15 August 2020.
  131. ^ "Immunization Programs | Government of Nunavut". www.gov.nu.ca. from the original on 21 September 2020. Retrieved 15 August 2020.
  132. ^ "Getting the HPV vaccine". ontario.ca. from the original on 28 September 2021. Retrieved 28 September 2021.
  133. ^ "Routine Immunization Schedules for Children, Youth & Adults" (PDF). (PDF) from the original on 26 November 2020. Retrieved 15 August 2020.
  134. ^ "Immunization - Horizon Health Network". en.horizonnb.ca. from the original on 13 August 2020. Retrieved 15 August 2020.
  135. ^ "GSK announces Cervarix approved in China to help protect women from cervical cancer". GlaxoSmithKline (Press release). 18 July 2016. from the original on 24 July 2016. Retrieved 20 October 2019.
  136. ^ "Cervarix is approved for cervical cancer prevention in female population aged 9-45 years in mainland China". GlaxoSmithKline (Press release). 29 May 2018. from the original on 31 March 2019. Retrieved 20 October 2019.
  137. ^ "Cervarix, first vaccine for cervical cancer prevention in mainland China, has officially launched". GlaxoSmithKline (Press release). 31 July 2017. from the original on 4 September 2017. Retrieved 20 October 2019.
  138. ^ Carvajal Pineda L (4 September 2012). "Girón ya está vacunando contra el papiloma humano". Vanguardia (in Spanish). from the original on 4 March 2016. Retrieved 29 July 2015.
  139. ^ "Vacuna contra el Papiloma Humano será gratuita". Caracol Radio. No. Actualidad. Prisa Radio. 3 May 2013. Retrieved 29 July 2015.[permanent dead link]
  140. ^ . www.minsalud.gov.co. Archived from the original on 4 August 2015. Retrieved 29 July 2015.
  141. ^ "Costa Rica to begin administering HPV vaccine". The Tico Times Costa Rica. 25 April 2019. from the original on 15 June 2019. Retrieved 14 June 2019.
  142. ^ "Costa Rica begins nationwide HPV vaccination campaign". The Tico Times Costa Rica. 4 June 2019. from the original on 12 June 2019. Retrieved 14 June 2019.
  143. ^ "Impfkalender für Schulkinder". from the original on 24 September 2016. Retrieved 6 September 2016.
  144. ^ . en.ssi.dk. National Institute for Health Data and Disease Control. Archived from the original on 28 November 2019. Retrieved 28 November 2019.
  145. ^ . Ministry of Social Affairs and Health. 18 February 2010. Archived from the original on 26 April 2017. Retrieved 25 April 2017.
  146. ^ "HPV vaccine will now also be offered to boys". Lääketietokeskus. 20 May 2020. from the original on 9 August 2020. Retrieved 3 September 2020.
  147. ^ (in French). 17 July 2007. Archived from the original on 18 December 2014. Retrieved 10 August 2013.
  148. ^ a b Fagbire OJ (26 March 2007). . Vaccine Rx. Archived from the original on 28 September 2007. Retrieved 10 August 2013.
  149. ^ "HPV-Impfung jetzt auch für Jungen Kassenleistung" (in German). Kassenärztliche Vereinigung. 6 December 2018. from the original on 1 December 2020. Retrieved 18 November 2020.
  150. ^ Karakitsos P (7 March 2008). (in Greek). Archived from the original on 30 April 2013. Retrieved 10 August 2013.
  151. ^ "The vaccine against cervical cancer and Cervarix vs Gardasil" (in Greek). 12 February 2008. from the original on 13 June 2013. Retrieved 10 August 2013.
  152. ^ . www.antsz.hu. Archived from the original on 3 September 2014. Retrieved 16 October 2019.
  153. ^ a b c Cullen P. "HPV vaccine to be offered to boys from start of school year in 2019". The Irish Times. from the original on 4 September 2019. Retrieved 16 October 2019.
  154. ^ "Vaccination programmes". Folkhälsomyndigheten. The Public Health Agency of Sweden. 18 February 2022. from the original on 17 November 2022. Retrieved 26 November 2022.
  155. ^ "Statistik för HPV-vaccinationer — Folkhälsomyndigheten". Folkhälsomyndigheten (in Swedish). 14 May 2022. from the original on 2 June 2022. Retrieved 26 November 2022.
  156. ^ "Vaccin mot humant papillomvirus (HPV) — Folkhälsomyndigheten". Folkhälsomyndigheten (in Swedish). 21 February 2022. from the original on 26 October 2022. Retrieved 26 November 2022.
  157. ^ "Boys aged 12 and 13 years to be offered HPV vaccine from September 2019, PHE announces". Pharmaceutical Journal. 9 July 2019. Retrieved 25 August 2019.[permanent dead link]
  158. ^ a b "HPV vaccine overview". nhs.uk. 31 July 2019. from the original on 1 January 2019. Retrieved 5 February 2022.
  159. ^ "Centre for Health Protection, Department of Health - About human papillomavirus (HPV) vaccination". www.chp.gov.hk. from the original on 8 March 2021. Retrieved 15 August 2020.
  160. ^ Das M (February 2018). "Cervical cancer vaccine controversy in India". The Lancet. Oncology. 19 (2): e84. doi:10.1016/S1470-2045(18)30018-4. PMID 29413482.
  161. ^ (PDF). Archived from the original (PDF) on 11 January 2019. Retrieved 16 October 2019.
  162. ^ a b c d "HSE Guidelines for staff HPV second level school vaccination campaign" (PDF). (PDF) from the original on 11 January 2019. Retrieved 16 October 2019.
  163. ^ "HPV". HSE.ie. from the original on 12 January 2019. Retrieved 11 January 2019.
  164. ^ "Irish times- HPV vaccine to be offered to boys from start of school year in 2019". The Irish Times. from the original on 8 December 2018. Retrieved 11 January 2019.
  165. ^ health.gov.il 29 October 2013 at the Wayback Machine
  166. ^ Siegel J. "Health Ministry decides to offer free HPV vaccine to 13-year-old girls | JPost | Israel News". JPost. from the original on 2 December 2013. Retrieved 29 December 2013.
  167. ^ Gilmour S, Kanda M, Kusumi E, Tanimoto T, Kami M, Shibuya K (August 2013). "HPV vaccination programme in Japan". Lancet. 382 (9894): 768. doi:10.1016/S0140-6736(13)61831-0. PMID 23993189. S2CID 40619281.
  168. ^ Mulcahy N (25 June 2013). "Japan Withdraws HPV Vaccine Recommendation for Girls". Medscape. from the original on 23 April 2020. Retrieved 17 May 2020.
  169. ^ a b Ikeda S, Ueda Y, Yagi A, Matsuzaki S, Kobayashi E, Kimura T, et al. (April 2019). "HPV vaccination in Japan: what is happening in Japan?". Expert Review of Vaccines. 18 (4): 323–325. doi:10.1080/14760584.2019.1584040. PMID 30768373.
  170. ^ "Japan to Resume Active Promotion of HPV Vaccinations in April". Jiji Press News. 26 November 2021. from the original on 28 November 2021. Retrieved 28 November 2021.
  171. ^ "'Finally we can protect women': Japan's HPV vaccine battle". AFP News. 31 March 2022. from the original on 22 April 2022. Retrieved 2 April 2022.
  172. ^ "Japan to allow free HPV vaccines to women born FY1997-2005 after 8-year hiatus". Mainichi Shimbun. 24 December 2021. from the original on 28 December 2021. Retrieved 28 December 2021.
  173. ^ "Japan to Give Free HPV Vaccinations to Those Who Missed Them". nippon.com. 15 November 2021. from the original on 15 November 2021. Retrieved 4 February 2022.
  174. ^ a b "New technologies for cervical cancer prevention: from scientific evidence to program planning". Pan American Health Organization. from the original on 9 May 2012. Retrieved 18 April 2012.
  175. ^ a b "Progress Toward Implementation of Human Papillomavirus Vaccination—the Americas, 2006–2010". Center for Disease and Control Prevention. from the original on 9 May 2012. Retrieved 18 April 2012.
  176. ^ a b "Questions and answers about HPV immunisation". Ministry of Health NZ. 29 September 2021. from the original on 26 February 2018. Retrieved 24 November 2021.
  177. ^ a b Green A (7 June 2013). "Life saving cancer vaccine will be difficult to implement". Mail & Guardian. from the original on 17 July 2013. Retrieved 7 August 2013.
  178. ^ Botha MH, Dochez C (September 2012). "Introducing human papillomavirus vaccines into the health system in South Africa". Vaccine. 30 (Suppl 3): C28–C34. doi:10.1016/j.vaccine.2012.03.032. PMID 22939017.
  179. ^ a b SAPA (15 May 2013). "Schoolgirls to get cancer vaccine". ioL News. from the original on 12 August 2013. Retrieved 7 August 2013.
  180. ^ . 27 June 2007. Archived from the original on 29 September 2007. Retrieved 6 August 2007.
  181. ^ "[기획] 어린이 자궁경부암 예방접종 무료…가다실 Vs 서바릭스 어떤 백신 도입될까". 18 January 2016. from the original on 3 February 2016. Retrieved 27 January 2016.
  182. ^ "[자궁경부'앎'은 힘이다! - 가다실] "자궁경부암 백신 무료접종으로 공중보건 질적 향상 기대" - 라포르시안". rapportian.com. 5 April 2016. from the original on 28 August 2021. Retrieved 7 May 2018.
  183. ^ "HPV vaccine for first form students in Barbados while Trinidad suspends the same in schools". Caribbean Medical News. 1 December 2013. from the original on 27 October 2021. Retrieved 27 October 2021.
  184. ^ D'Souza C (24 April 2013). "Cervical cancer vaccination could be mandatory in UAE". Gulf News. from the original on 16 September 2018. Retrieved 16 September 2018.
  185. ^ Al Nowais S (21 May 2016). "Greater understanding of HPV in UAE may help reduce cervical cancer cases". The National. from the original on 17 September 2018. Retrieved 17 September 2018.
  186. ^ "UAE gets cervical cancer vaccine". Khaleej Times. 7 January 2007. from the original on 17 September 2018. Retrieved 17 September 2018.
  187. ^ "Prevention". from the original on 16 September 2018. Retrieved 16 September 2018.
  188. ^ Al Hassani Z (14 May 2013). "Free vaccination against cervical cancer for Abu Dhabi women". The National. from the original on 17 September 2018. Retrieved 17 September 2018.
  189. ^ السباعي, وجيه (15 September 2018). "قرار وزاري بإلزامية تطعيم سرطان عنق الرحم". Emarat Alyoum (in Arabic). from the original on 15 September 2018. Retrieved 16 September 2018.
  190. ^ Al Ali I (15 September 2018). . Gulf Today. Archived from the original on 15 September 2018. Retrieved 16 September 2018.
  191. ^ Roberts M (23 February 2007). "Gay men seek 'female cancer' jab". BBC. from the original on 30 January 2009.
  192. ^ "NHS Cervical Screening Program". from the original on 14 September 2008. Retrieved 26 June 2008.
  193. ^ a b c "HPV vaccine". nhs.uk. 9 May 2018. from the original on 1 January 2019. Retrieved 3 January 2019.
  194. ^ Nadarzynski T, Frost M, Miller D, Wheldon CW, Wiernik BM, Zou H, et al. (June 2021). "Vaccine acceptability, uptake and completion amongst men who have sex with men: A systematic review, meta-analysis and theoretical framework" (PDF). Vaccine. 39 (27): 3565–3581. doi:10.1016/j.vaccine.2021.05.013. PMID 34034949. S2CID 235203871. (PDF) from the original on 19 June 2022. Retrieved 8 June 2022.
  195. ^ "JCVI statement: extending the HPV vaccination programme – conclusions". GOV.UK. from the original on 4 January 2019. Retrieved 4 January 2019.
  196. ^ "Boots launches HPV vaccination for boys and men". Pharmaceutical Journal. 13 April 2017. Retrieved 23 May 2017.[permanent dead link]
  197. ^ "Human papillomavirus (HPV): the green book, chapter 18a". Public Health England. 20 March 2013. from the original on 15 October 2019. Retrieved 3 January 2019.
  198. ^ "HPV vaccination programme switching to Gardasil from September 2012". immunisation.dh.gov.uk. Department of Health. 28 November 2011. Archived from the original on 4 January 2013. Retrieved 3 January 2019.
  199. ^ "1 in 4 US teen girls got cervical cancer shot". USA Today. Associated Press. 9 October 2008. from the original on 14 October 2013. Retrieved 10 August 2013.
  200. ^ a b "More US Girls Now Getting Cervical Cancer Vaccine". Discovery and Development. Associated Press. 25 July 2014. from the original on 26 July 2014.
  201. ^ a b "HPV Vaccine Information For Young Women". Centers for Disease Control and Prevention (CDC). from the original on 28 June 2009. Retrieved 14 June 2009.
  202. ^ Niccolai LM, Hansen CE (July 2015). "Practice- and Community-Based Interventions to Increase Human Papillomavirus Vaccine Coverage: A Systematic Review". JAMA Pediatrics. 169 (7): 686–692. doi:10.1001/jamapediatrics.2015.0310. PMC 4862306. PMID 26010507.
  203. ^ Caskey R, Lindau ST, Alexander GC (November 2009). "Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey". The Journal of Adolescent Health. 45 (5): 453–462. doi:10.1016/j.jadohealth.2009.04.021. PMID 19837351. from the original on 17 October 2014.
  204. ^ Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M (June 2013). "Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis". International Journal of Epidemiology. 42 (3): 896–908. doi:10.1093/ije/dyt049. PMC 3733698. PMID 23620381.
  205. ^ Stobbe M (19 June 2013). "Study: Vaccine against sexually transmitted HPV cut infections in teen girls by half". Star Tribune. from the original on 23 June 2013. Retrieved 7 August 2013.
  206. ^ Knox R (19 June 2013). "Vaccine Against HPV Has Cut Infections In Teenage Girls". NPR. from the original on 20 June 2013. Retrieved 21 June 2013.
  207. ^ a b c Schwartz JL (October 2010). "HPV vaccination's second act: promotion, competition, and compulsion". American Journal of Public Health. 100 (10): 1841–1844. doi:10.2105/AJPH.2010.193060. PMC 2936995. PMID 20724671.
  208. ^ Moghtaderi A, Adams S (June 2016). "The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations". Applied Health Economics and Health Policy. 14 (3): 349–359. doi:10.1007/s40258-016-0225-6. PMID 26873090. S2CID 25655517.
  209. ^ a b c d "HPV Vaccine: State Legislation and Statutes". National Conference of State Legislatures. from the original on 18 November 2015. Retrieved 2 January 2023.
  210. ^ "States With Religious and Philosophical Exemptions From School Immunization Requirements". National Conference of State Legislatures. 25 May 2022. Retrieved 2 January 2023.
  211. ^ "HPV Vaccine: State Legislation and Statutes". www.ncsl.org. from the original on 18 November 2015. Retrieved 20 November 2015.
  212. ^ "Immunization Information for Schools & Childcare Providers: Department of Health". www.health.ri.gov. from the original on 21 November 2015. Retrieved 20 November 2015.
  213. ^ 216 R.I. Code R. § 216-RICR-30-05-3.5
  214. ^ "HPV Mandates for Children in Secondary Schools". from the original on 28 May 2017. Retrieved 27 May 2017.
  215. ^ "2020-2021 School Health Requirements". Hawaii State Department of Health. from the original on 1 July 2020. Retrieved 30 June 2020.
  216. ^ Virginia Administrative Code §32.1-46
  217. ^ Jordan M (1 October 2008). "Gardasil Requirement for Immigrants Stirs Backlash". The Wall Street Journal. from the original on 18 December 2014. Retrieved 15 January 2009.
  218. ^ . 16 November 2009. Archived from the original on 27 September 2011. Retrieved 31 January 2011.
  219. ^ Budhwani H, De P (December 2017). "Human papillomavirus vaccine initiation in Asian Indians and Asian subpopulations: a case for examining disaggregated data in public health research". Public Health. 153: 111–117. doi:10.1016/j.puhe.2017.07.036. PMID 29028565.
  220. ^ De P, Budhwani H (March 2017). "Human papillomavirus (HPV) vaccine initiation in minority Americans". Public Health. 144: 86–91. doi:10.1016/j.puhe.2016.11.005. PMID 28274389.
  221. ^ "Vaccines for Children Program (VFC)". Centers for Disease Control and Prevention. from the original on 28 September 2013. Retrieved 10 August 2013.
  222. ^ . Immunization for Women. Archived from the original on 9 September 2013. Retrieved 10 August 2013.
  223. ^ "Human Papillomavirus Vaccination Coverage Among Female Adolescents in Managed Care Plans — United States, 2013". Center of Disease Control and Prevention. 30 October 2015. from the original on 18 October 2020. Retrieved 10 September 2020.
  224. ^ a b "About VFC". Centers for Disease Control and Prevention (CDC). 25 May 2018. from the original on 7 November 2018. Retrieved 7 November 2018.
  225. ^ VAP Patient Eligibility – GlaxoSmithKline 9 April 2016 at the Wayback Machine
  226. ^ . www.gskforyou.com. Archived from the original on 15 July 2016. Retrieved 16 October 2019.
  227. ^ (877-822-2911)
  228. ^ . Archived from the original on 21 August 2016. Retrieved 16 October 2019.
  229. ^ 1-800-727-5400
  230. ^ . www.merckhelps.com. Archived from the original on 5 June 2016. Retrieved 16 October 2019.
  231. ^ a b Smith MJ (December 2015). "Promoting Vaccine Confidence". Infectious Disease Clinics of North America (Review). 29 (4): 759–769. doi:10.1016/j.idc.2015.07.004. PMID 26337737.
  232. ^ HPV Vaccine—Why Your Doctor Doesn't Offer the HPV Vaccine—Gardasil 31 December 2007 at the Wayback Machine
  233. ^ . Kaiser Family Foundation. 29 March 2007. Archived from the original on 15 October 2007.
  234. ^ . Archived from the original on 15 October 2007. Retrieved 16 October 2019.
  235. ^ Gabriel T, Grady D (13 September 2011). "Rick Perry Under Fire by Republican Rivals for Requiring HPV Vaccine for Girls". The New York Times. from the original on 14 September 2011. Retrieved 22 February 2017.
  236. ^ Sprigg P (15 July 2006). "Pro-Family, Pro-Vaccine—But Keep It Voluntary". The Washington Post. from the original on 5 November 2012. Retrieved 4 February 2007.
  237. ^ Coyne B (2 November 2005). "Cervical Cancer Vaccine Raises 'Promiscuity' Controversy". The New Standard. from the original on 7 August 2006. Retrieved 28 August 2006.
  238. ^ "IF07B01". Family Research Council. 7 February 2008. from the original on 4 August 2007.
  239. ^ . Focus on the Family. Archived from the original on 30 August 2008. Retrieved 4 January 2008.
  240. ^ a b c d "Opposition To HPV Vaccine Stirs Passion, Bewilderment". ripr.org. from the original on 21 November 2015. Retrieved 20 November 2015.
  241. ^ "HPV Vaccination Does Not Lead to Increased Sexual Activity" (press release). AAP. from the original on 25 February 2014. Retrieved 3 February 2014.
  242. ^ . Ms. Spring 2007. pp. 12–13. Archived from the original on 1 June 2007.
  243. ^ Artega A. . Zimbio. Archived from the original on 17 May 2013. Retrieved 7 March 2012.
  244. ^ Brouwer AF, Delinger RL, Eisenberg MC, Campredon LP, Walline HM, Carey TE, Meza R (June 2019). "HPV vaccination has not increased sexual activity or accelerated sexual debut in a college-aged cohort of men and women". BMC Public Health. 19 (1): 821. doi:10.1186/s12889-019-7134-1. PMC 6593582. PMID 31238911.
  245. ^ Gilkey MB, Moss JL, Coyne-Beasley T, Hall ME, Shah PD, Brewer NT (August 2015). "Physician communication about adolescent vaccination: How is human papillomavirus vaccine different?". Preventive Medicine. 77: 181–185. doi:10.1016/j.ypmed.2015.05.024. PMC 4490050. PMID 26051197.
  246. ^ Gostin LO (June 2018). "HPV Vaccination: A Public Good and a Health Imperative". The Journal of Law, Medicine & Ethics. 46 (2): 511–513. doi:10.1177/1073110518782958. PMID 30147001. S2CID 52092917.
  247. ^ Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (February 2007). "Prevalence of HPV infection among females in the United States". JAMA. 297 (8): 813–819. doi:10.1001/jama.297.8.813. PMID 17327523.
  248. ^ a b Malmqvist E, Helgesson G, Lehtinen J, Natunen K, Lehtinen M (February 2011). "The ethics of implementing human papillomavirus vaccination in developed countries". Medicine, Health Care and Philosophy. 14 (1): 19–27. doi:10.1007/s11019-010-9285-9. PMID 20853152. S2CID 27444545.
  249. ^ Oberlin AM, Rahangdale L, Chinula L, Fuseini NM, Chibwesha CJ (December 2018). "Making HPV vaccination available to girls everywhere". International Journal of Gynaecology and Obstetrics. 143 (3): 267–276. doi:10.1002/ijgo.12656. PMC 6221992. PMID 30144050.
  250. ^ Ma B, Roden R, Wu TC (July 2010). "Current status of human papillomavirus vaccines". Journal of the Formosan Medical Association = Taiwan Yi Zhi. 109 (7): 481–483. doi:10.1016/S0929-6646(10)60081-2. PMC 2917202. PMID 20677402.
  251. ^ Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, et al. (June 2009). "Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines". Journal of the National Cancer Institute. 101 (11): 782–792. doi:10.1093/jnci/djp106. PMC 2689872. PMID 19470949.
  252. ^ Tumban E, Peabody J, Tyler M, Peabody DS, Chackerian B (2012). "VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus". PLOS ONE. 7 (11): e49751. Bibcode:2012PLoSO...749751T. doi:10.1371/journal.pone.0049751. PMC 3501453. PMID 23185426.
  253. ^ van Driel WJ, Ressing ME, Brandt RM, Toes RE, Fleuren GJ, Trimbos JB, et al. (December 1996). "The current status of therapeutic HPV vaccine". Annals of Medicine. 28 (6): 471–477. doi:10.3109/07853899608999110. PMID 9017105.
  254. ^ Roden RB, Ling M, Wu TC (August 2004). "Vaccination to prevent and treat cervical cancer". Human Pathology. 35 (8): 971–982. doi:10.1016/j.humpath.2004.04.007. PMID 15297964.
  255. ^ Albarran Y, Carvajal A, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Díaz Estrada I, et al. (2007). "MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study". BioDrugs. 21 (1): 47–59. doi:10.2165/00063030-200721010-00006. PMID 17263589. S2CID 26415621.
  256. ^ Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, et al. (May 2004). "Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus". Human Gene Therapy. 15 (5): 421–431. doi:10.1089/10430340460745757. PMID 15144573.
  257. ^ "Virolab, Inc. – FORM 8-K/A". Getfilings.com. 24 June 2011. from the original on 3 December 2013. Retrieved 29 December 2013.
  258. ^ Singh KP, Verma N, Akhoon BA, Bhatt V, Gupta SK, Gupta SK, Smita S (June 2016). "Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains". 3 Biotech. 6 (1): 39. doi:10.1007/s13205-015-0352-z. PMC 4729761. PMID 28330110.
  259. ^ (PDF). www.ema.europa.eu. European Medicines Agency. Archived from the original (PDF) on 2 November 2017. Retrieved 2 November 2017.
  260. ^ Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, et al. (November 2015). "Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial". Lancet. 386 (10008): 2078–2088. doi:10.1016/S0140-6736(15)00239-1. PMC 4888059. PMID 26386540.
  261. ^ . www.inovio.com. Inovio Pharmaceuticals. Archived from the original on 2 November 2017. Retrieved 2 November 2017.
  262. ^ . clinicaltrials.gov. The National Library of Medicine. Archived from the original on 2 November 2017. Retrieved 2 November 2017.
  263. ^ Smalley Rumfield C, Roller N, Pellom ST, Schlom J, Jochems C (7 October 2020). "Therapeutic Vaccines for HPV-Associated Malignancies". ImmunoTargets and Therapy. 9: 167–200. doi:10.2147/ITT.S273327. PMC 7549137. PMID 33117742.
  264. ^ Bligh A (10 June 2009). "Premier Unveils Queensland's 150 Icons" (Press release). Queensland Government. from the original on 24 May 2017. Retrieved 24 May 2017.
  265. ^ "NCI's Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award" (Press release). National Institutes of Health (NIH). 6 September 2017. from the original on 7 November 2017.

Further reading

  • World Health Organization (2011). The immunological basis for immunization series: module 19: human papillomavirus infection. World Health Organization (WHO). hdl:10665/44604. ISBN 9789241501590.
  • World Health Organization (2016). Scaling-up HPV vaccine introduction. World Health Organization (WHO). hdl:10665/251909. ISBN 9789241511544.
  • Phillips A, Hickie M, Totterdell J, Brotherton J, Dey A, Hill R, et al. (August 2020). "Adverse events following HPV vaccination: 11 years of surveillance in Australia". Vaccine. 38 (38): 6038–6046. doi:10.1016/j.vaccine.2020.06.039. PMID 32709432.
  • Ramsay M, ed. (2019). "Chapter 18a: Human papillomavirus (HPV)". Immunisation against infectious disease. Public Health England.

External links

January 07, 2023
vaccine, human, papillomavirus, vaccines, vaccines, that, prevent, infection, certain, types, human, papillomavirus, available, protect, against, either, four, nine, types, protect, against, least, types, which, cause, greatest, risk, cervical, cancer, estimat. Human papillomavirus HPV vaccines are vaccines that prevent infection by certain types of human papillomavirus HPV 19 Available HPV vaccines protect against either two four or nine types of HPV 19 20 All HPV vaccines protect against at least HPV types 16 and 18 which cause the greatest risk of cervical cancer 19 It is estimated that HPV vaccines may prevent 70 of cervical cancer 80 of anal cancer 60 of vaginal cancer 40 of vulvar cancer and show more than 90 efficacy in preventing HPV positive oropharyngeal cancers 21 22 23 24 They additionally prevent some genital warts with the quadrivalent and nonavalent vaccines that protect against HPV types HPV 6 and HPV 11 providing greater protection 19 HPV vaccineVaccine descriptionTargetHuman papillomavirus HPV Vaccine typeProtein subunitClinical dataTrade namesGardasil Cervarix othersAHFS Drugs comMonographMedlinePlusa615028License dataUS DailyMed Human papillomavirus vaccinePregnancycategoryAU B2 1 Routes ofadministrationIntramuscular injectionATC codeJ07BM01 WHO J07BM02 WHO J07BM03 WHO Legal statusLegal statusAU S4 Prescription only 2 3 4 5 6 7 8 CA Rx only Schedule D 9 10 UK POM Prescription only 11 12 US only 13 14 15 EU Rx only 16 17 18 IdentifiersCAS Number910046 32 1ChemSpidernone N Y what is this verify The World Health Organization WHO recommends HPV vaccines as part of routine vaccinations in all countries along with other prevention measures 19 The vaccines require two or three doses depending on a person s age and immune status 19 Vaccinating girls around the ages of nine to thirteen is typically recommended 19 The vaccines provide protection for at least 5 to 10 years 19 Cervical cancer screening is still required following vaccination 19 Vaccinating a large portion of the population may also benefit the unvaccinated 25 HPV vaccines are very safe 19 Pain at the site of injection occurs in about 80 of people 19 Redness and swelling at the site and fever may also occur 19 No link to Guillain Barre syndrome has been found 19 The first HPV vaccine became available in 2006 19 26 As of 2017 71 countries include it in their routine vaccinations at least for girls 19 It is on the World Health Organization s List of Essential Medicines 27 28 and prequalified vaccines 29 Vaccination may be cost effective in the low and middle income countries 30 As of 2017 Gardasil 9 is the only version available in the United States as the older version Gardasil has been discontinued as the Gardasil 9 offers protection against same four HPV types as Gardasil as well as an additional five HPV types 31 32 Contents 1 Medical uses 1 1 Efficacy 1 2 Males 1 2 1 Recommendations by national bodies 1 3 Older age 1 4 Public health 2 Side effects 2 1 Contraindications 2 2 Pregnancy 3 Mechanism of action 4 History 5 Society and culture 5 1 Cost 5 2 Vaccine implementation 5 2 1 Africa 5 2 2 Australia 5 2 3 Canada 5 2 4 China 5 2 5 Colombia 5 2 6 Costa Rica 5 2 7 Europe 5 2 8 Hong Kong 5 2 9 India 5 2 10 Ireland 5 2 11 Israel 5 2 12 Japan 5 2 13 Kenya 5 2 14 Laos 5 2 15 Mexico 5 2 16 New Zealand 5 2 17 Panama 5 2 18 South Africa 5 2 19 South Korea 5 2 20 Trinidad and Tobago 5 2 21 United Arab Emirates 5 2 22 United Kingdom 5 2 23 United States 5 2 23 1 Adoption 5 2 23 2 Legislation 5 2 23 2 1 State by state 5 2 23 3 Immigrants 5 2 23 4 Coverage 5 2 23 5 Opposition in the United States 5 2 23 5 1 Insurance companies 5 2 23 5 2 Religious and conservative groups 5 2 23 5 3 Parental opposition 5 2 23 5 4 Physician impact 5 3 Ethics 6 Research 6 1 Therapeutic vaccines 6 2 Awards 7 References 8 Further reading 9 External linksMedical uses Edit Gardasil Syringe HPV vaccines are used to prevent HPV infection and therefore cervical cancer 19 Good evidence supports that vaccination of large percentage of people within a population decreases rates of HPV infections with part of the benefit from herd immunity 33 Some types are recommended in the United States for women and men who are 9 26 years of age and are approved for those who are 27 45 years of age 34 35 Since the vaccines only cover some high risk types of HPV cervical cancer screening is recommended even after vaccination 19 36 In the U S the recommendation is for women to receive routine Pap smears beginning at age 21 37 In Australia the national screening program has changed from the two yearly cytology pap smears to being based on tests for HPV DNA 38 based on work by Karen Canfell and others 39 Efficacy Edit The HPV vaccine has been shown to prevent cervical dysplasia from the high risk HPV types 16 and 18 and provide some protection against a few closely related high risk HPV types 19 40 However there are other high risk HPV types that are not affected by the vaccine 41 The protection against HPV 16 and 18 has lasted at least eight years after vaccination for Gardasil 42 and more than nine years for Cervarix 42 It is thought that booster vaccines will not be necessary 43 Gardasil and Gardasil 9 protect against HPV types 6 and 11 which can cause genital warts 13 14 19 Cervarix is just as effective at protecting women against persistent HPV 16 and 18 infection in the anus as it is at protecting them from these infections in the cervix Overall about 30 percent of cervical cancers will not be prevented by these vaccines Also in the case of Gardasil ten percent of genital warts will not be prevented by the vaccine Neither vaccine prevents other sexually transmitted diseases nor do they treat existing HPV infection or cervical cancer 44 45 HPV types 16 18 and 45 contribute to 94 of cervical adenocarcinoma cancers originating in the glandular cells of the cervix 46 While most cervical cancer arises in the squamous cells adenocarcinomas make up a sizable minority of cancers 46 Further Pap smears are not as effective at detecting adenocarcinomas so where Pap screening programs are in place a larger proportion of the remaining cancers are adenocarcinomas 46 Trials suggest that HPV vaccines may also reduce the incidence of adenocarcinoma 46 Two doses of the vaccine may work as well as three doses 47 The Centers for Disease Control and Prevention CDC recommends two doses in those less than 15 years and three doses in those over 15 years 48 A single dose might be effective 49 A study with 9vHPV a 9 valent HPV vaccine that protects against HPV types 6 11 16 18 31 33 45 52 and 58 came to the result that the rate of high grade cervical vulvar or vaginal disease was the same as when using a quadrivalent HPV vaccine 50 A lack of a difference may have been caused by the study design of including women 16 to 26 years of age who may largely already have been infected with the five additional HPV types that are additionally covered by the 9 valent vaccine 51 Males Edit HPV vaccines are approved for males in several countries and regions including Switzerland Portugal Canada Australia Ireland South Korea Hong Kong the United Kingdom New Zealand and the United States 52 53 In males Gardasil may reduce their risk of genital warts and precancerous lesions caused by HPV This reduction in precancerous lesions might be predicted to reduce the rates of penile and anal cancer in men Gardasil has been shown to also be effective in preventing genital warts in males 54 55 While Gardasil and the Gardasil 9 vaccines have been approved for males a third HPV vaccine Cervarix has not Unlike the Gardasil based vaccines Cervarix does not protect against genital warts 56 Since penile and anal cancers are much less common than cervical cancer HPV vaccination of young men is likely to be much less cost effective than for young women 57 Gardasil is also used among men who have sex with men who are at higher risk for genital warts penile cancer and anal cancer 58 Recommendations by national bodies Edit Australia introduced HPV vaccination for boys over 12 from 2013 onwards 59 while UK and Ireland introduced HPV vaccination for boys aged 12 and 13 as part of their National Immunization Plan in 2019 60 61 Portugal introduced universal HPV vaccination for boys aged 10 years and above as part of its National Immunization Plan in 2020 62 On 9 September 2009 an advisory panel recommended that the Food and Drug Administration FDA of the USA license Gardasil in the United States for boys and men ages 9 26 for the prevention of genital warts 63 Soon after that the vaccine was approved by the FDA for use in males aged 9 to 26 for prevention of genital warts 54 55 and anal cancer 64 65 66 In 2011 an advisory panel for the Centers for Disease Control and Prevention CDC recommended the vaccine for boys ages 11 12 35 This was intended to prevent genital warts and anal cancers in males and possibly prevent head and neck cancer though the vaccine s effectiveness against head and neck cancers has not yet been proven 67 The committee also made the vaccination recommendation for males 13 to 21 years who have not been vaccinated previously or who have not completed the three dose series 54 68 For those under the age of 27 who have not been fully vaccinated the CDC recommends vaccination 35 Harald zur Hausen s support for vaccinating boys so that they will be protected and thereby so will women was joined by professors Harald Moi and Ole Erik Iversen in 2011 69 Older age Edit When Gardasil was first introduced it was recommended as a prevention for cervical cancer for women that were 25 years old or younger 35 Evidence suggests that HPV vaccines are effective in preventing cervical cancer for women up to 45 years of age 34 In 2018 the Food and Drug Administration released a summary basis for regulatory action and approval for expansion of usage and indication for the 9 valent HPV vaccine to include men and women 27 to 45 years of age 70 Public health Edit The National Cancer Institute states Widespread vaccination has the potential to reduce cervical cancer deaths around the world by as much as two thirds if all women were to take the vaccine and if protection turns out to be long term In addition the vaccines can reduce the need for medical care biopsies and invasive procedures associated with the follow up from abnormal Pap tests thus helping to reduce health care costs and anxieties related to abnormal Pap tests and follow up procedures 36 As of 2004 update preventive vaccines protect against the two HPV types 16 and 18 that cause about 70 of cervical cancers worldwide 71 Because of the distribution of HPV types associated with cervical cancer the vaccines are likely to be most effective in Asia Europe and North America 71 Some other high risk types cause a larger percentage of cancers in other parts of the world 71 Vaccines that protect against more of the types common in cancers would prevent more cancers and be less subject to regional variation 71 For instance a vaccine against the seven types most common in cervical cancers 16 18 45 31 33 52 58 would prevent an estimated 87 of cervical cancers worldwide 71 Only 41 of women with cervical cancer in the developing world get medical treatment 72 Therefore prevention of HPV by vaccination may be a more effective way of lowering the disease burden in developing countries than cervical screening The European Society of Gynecological Oncology sees the developing world as most likely to benefit from HPV vaccination 73 However individuals in many resource limited nations Kenya for example are unable to afford the vaccine 74 In more developed countries populations that do not receive adequate medical care such as poor or minorities in the United States or parts of Europe also have less access to cervical screening and appropriate treatment and are similarly more likely to benefit 46 In 2009 Dr Diane Harper a researcher for the HPV vaccines questioned whether the benefits of the vaccine outweigh its risks in countries where Pap smear screening is common 75 She has also encouraged women to continue pap screening after they are vaccinated and to be aware of potential adverse effects 76 According to the CDC in 2012 use of the HPV vaccine had cut rates of infection with HPV 6 11 16 and 18 in half in American teenagers from 11 5 to 4 3 and by one third in American women in their early twenties from 18 5 to 12 1 77 Side effects EditThe HPV vaccine is generally safe with no increased risk of serious adverse effects 40 HPV vaccines are approved for use in over 100 countries with more than 100 million doses distributed worldwide Extensive clinical trial and post marketing safety surveillance data indicate that both Gardasil and Cervarix are well tolerated and safe 40 78 When comparing the HPV vaccine to a placebo control vaccine taken by women there is no difference in the risk of severe adverse events 40 Gardasil is a three dose injection vaccine As of 8 September 2013 update there were more than 57 million doses distributed in the United States though it is unknown how many were administered 79 There have been 22 000 Vaccine Adverse Event Reporting System VAERS reports following the vaccination 80 92 were reports of events considered to be non serious e g fainting pain and swelling at the injection site arm headache nausea and fever and the rest were considered to be serious death permanent disability life threatening illness and hospitalization However VAERS reports include any reported effects whether coincidental or causal In response to concerns regarding the rates of adverse events associated with the vaccine the CDC stated When evaluating data from VAERS it is important to note that for any reported event no cause and effect relationship has been established VAERS receives reports on all potential associations between vaccines and adverse events 80 As of 1 September 2009 update in the US there were 44 reports of death in females after receiving the vaccine 80 None of the 27 confirmed deaths of women and girls who had taken the vaccine were linked to the vaccine 80 There is no evidence suggesting that Gardasil causes or raises the risk of Guillain Barre syndrome Additionally there have been rare reports of blood clots forming in the heart lungs and legs 80 A 2015 review conducted by the European Medicines Agency s Pharmacovigilance Risk Assessment Committee concluded that evidence does not support the idea that HPV vaccination causes complex regional pain syndrome or postural orthostatic tachycardia syndrome 81 As of 8 September 2013 update the CDC continued to recommend Gardasil vaccination for the prevention of four types of HPV 80 The manufacturer of Gardasil has committed to ongoing research assessing the vaccine s safety 82 According to the Centers for Disease Control and Prevention CDC and the FDA the rate of adverse side effects related to Gardasil immunization in the safety review was consistent with what has been seen in the safety studies carried out before the vaccine was approved and were similar to those seen with other vaccines However a higher proportion of syncope fainting was seen with Gardasil than is usually seen with other vaccines The FDA and CDC have reminded health care providers that to prevent falls and injuries all vaccine recipients should remain seated or lying down and be closely observed for 15 minutes after vaccination 45 The HPV vaccination does not appear to reduce the willingness of women to undergo pap tests 83 Contraindications Edit While the use of HPV vaccines can help reduce cervical cancer deaths by two thirds around the world 84 not everyone is eligible for vaccination There are some factors that exclude people from receiving HPV vaccines These factors include 85 People with history of immediate hypersensitivity to vaccine components Patients with a hypersensitivity to yeast should not receive Gardasil since yeast is used in its production People with moderate or severe acute illnesses This does not completely exclude patients from vaccination but postpones the time of vaccination until the illness has improved 86 Pregnancy Edit In the Gardasil clinical trials 1 115 pregnant women received the HPV vaccine Overall the proportions of pregnancies with an adverse outcome were comparable in subjects who received Gardasil and subjects who received placebo 87 88 However the clinical trials had a relatively small sample size As of 2018 update the vaccine is not recommended for pregnant women 40 87 89 90 The FDA has classified the HPV vaccine as a pregnancy Category B meaning there is no apparent harm to the fetus in animal studies HPV vaccines have not been causally related with adverse pregnancy outcomes or adverse effects on the fetus However data on vaccination during pregnancy is very limited and vaccination during the pregnancy term should be delayed until more information is available If a woman is found to be pregnant during the three dose series of vaccination the series should be postponed until pregnancy has been completed While there is no indication for intervention for vaccine dosages administered during pregnancy patients and healthcare providers are encouraged to report exposure to vaccines to the appropriate HPV vaccine pregnancy registry 85 86 91 Mechanism of action EditThe HPV vaccines are based on hollow virus like particles VLPs assembled from recombinant HPV coat proteins The natural virus capsid is composed of two proteins L1 and L2 but vaccines only contain L1 Gardasil contains inactive L1 proteins from four different HPV strains 6 11 16 and 18 synthesized in the yeast Saccharomyces cerevisiae Each vaccine dose contains 225 µg of aluminum 9 56 mg of sodium chloride 0 78 mg of L histidine 50 µg of polysorbate 80 35 µg of sodium borate and water The combination of ingredients totals 0 5 mL 92 HPV types 16 and 18 cause about 70 of all cervical cancer 71 Gardasil also targets HPV types 6 and 11 which together cause about 90 percent of all cases of genital warts 93 Gardasil and Cervarix are designed to elicit virus neutralizing antibody responses that prevent initial infection with the HPV types represented in the vaccine The vaccines have been shown to offer 100 percent protection against the development of cervical pre cancers and genital warts caused by the HPV types in the vaccine with few or no side effects The protective effects of the vaccine are expected to last a minimum of 4 5 years after the initial vaccination 41 While the study period was not long enough for cervical cancer to develop the prevention of these cervical precancerous lesions or dysplasias is believed highly likely to result in the prevention of those cancers 94 History EditThe vaccine was first developed by the University of Queensland in Australia and the final form was made by researchers at the University of Queensland Georgetown University Medical Center University of Rochester and the U S National Cancer Institute 95 Researchers Ian Frazer and Jian Zhou at the University of Queensland have been accorded priority under U S patent law for the invention of the HPV vaccine s basis the VLPs 96 In 2006 the FDA approved the first preventive HPV vaccine marketed by Merck amp Co under the trade name Gardasil According to a Merck press release 97 by the second quarter of 2007 it had been approved in 80 countries many under fast track or expedited review Early in 2007 GlaxoSmithKline filed for approval in the United States for a similar preventive HPV vaccine known as Cervarix In June 2007 this vaccine was licensed in Australia and it was approved in the European Union in September 2007 98 Cervarix was approved for use in the U S in October 2009 99 Harald zur Hausen a German researcher who suspected and later helped to prove that genital HPV infection can lead to cervical cancer was awarded half of the 1 4 million Nobel Prize in Medicine in 2008 for his work Verification that cervical cancer is caused by an infectious agent led several other groups to develop vaccines against HPV strains that cause most cases of cervical cancer The other half of the award went to Francoise Barre Sinoussi and Luc Montagnier two French virologists for their part in the discovery of HIV 100 Harald zur Hausen was skeptical of the prevailing dogma and postulated that oncogenic human papilloma virus HPV caused cervical cancer 45 He realized that HPV DNA could exist in an inactive state in the tumours and should be detectable by specific searches for viral DNA 100 He and workers at the Pasteur Institute found HPV to be a heterogeneous family of viruses Only some HPV types cause cancer 45 Harald zur Hausen pursued his research for over ten years searching for different HPV types 100 This research was difficult because only parts of the viral DNA were integrated into the host genome He found novel HPV DNA in cervix cancer biopsies and thus discovered the new tumourigenic HPV16 type in 1983 In 1984 he cloned HPV16 and 18 from patients with cervical cancer 100 The HPV types 16 and 18 were consistently found in about 70 of cervical cancer biopsies throughout the world 45 His observation of HPV oncogenic potential in human malignancy provided impetus within the research community to characterize the natural history of HPV infection and to develop a better understanding of mechanisms of HPV induced carcinogenesis 45 In December 2014 the US Food and Drug Administration FDA approved a vaccine called Gardasil 9 to protect females between the ages of 9 and 26 and males between the ages of 9 and 15 against nine strains of HPV 101 Gardasil 9 protects against infection from the strains covered by the first generation of Gardasil HPV 6 HPV 11 HPV 16 and HPV 18 and protects against five other HPV strains responsible for 20 of cervical cancers HPV 31 HPV 33 HPV 45 HPV 52 and HPV 58 101 Society and culture EditCost Edit As of 2013 update vaccinating girls and young women was estimated to be cost effective in the low and middle income countries especially in places without organized programs for screening cervical cancer 30 When the cost of the vaccine itself or the cost of administering it to individuals were higher or if cervical cancer screening were readily available then vaccination was less likely to be cost effective From a public health point of view vaccinating men as well as women decreases the virus pool within the population but is only cost effective to vaccinate men when the uptake in the female population is extremely low 102 In the United States the cost per quality adjusted life year is greater than US 100 000 for vaccinating the male population compared to the less than US 50 000 for vaccinating the female population 102 This assumes a 75 vaccination rate In 2013 the two companies who sell the most common vaccines announced a price cut to less than US 5 per dose to poor countries as opposed to US 130 per dose in the U S 103 Vaccine implementation Edit Main article Vaccination policy In developed countries the widespread use of cervical Pap smear screening programs has reduced the incidence of invasive cervical cancer by 50 or more Preventive vaccines reduce but do not eliminate the chance of getting cervical cancer Therefore experts recommend that women combine the benefits of both programs by seeking regular Pap smear screening even after vaccination 104 School entry vaccination requirements were found to increase the use of the HPV vaccine 105 106 Due to the COVID 19 pandemic 2019 2021 HPV vaccination programs have been significantly affected in the United States low income and lower middle income countries 107 108 109 110 On 30 August 2021 fifteen leading academic and freestanding cancer centers with membership in the Association of American Cancer Institutes AACI all National Cancer Institute NCI designated cancer centers the American Cancer Society the American Society of Clinical Oncology the American Association for Cancer Research and the St Jude Children s Research Hospital have issued a joint statement urging the U S health care systems physicians parents children and young adults to get HPV vaccination and other recommended vaccinations back on track during the National Immunization Awareness Month 109 110 Africa Edit With support from the GAVI Alliance a number of low income African countries have begun rollout of the HPV vaccine with others to follow In 2013 Ghana Kenya Madagascar Malawi Niger Sierra Leone and the United Republic of Tanzania begin implementation of the vaccine In 2014 Rwanda will begin nationwide rollout and demonstration programs will take place in Mozambique and Zimbabwe 111 Australia Edit In April 2007 Australia became the second country after Austria to introduce a government funded National Human Papillomavirus HPV Vaccination Program to protect young women against HPV infections that can lead to cancers and disease 112 The National HPV Vaccination Program is listed on the National Immunisation Program NIP Schedule and funded under the Immunise Australia Program 113 The Immunise Australia Program is a joint Federal State and Territory Government initiative to increase immunisation rates for vaccine preventable diseases The National HPV Vaccination Program for females was made up of two components an ongoing school based program for 12 and 13 year old girls and a time limited catch up program females aged 14 26 years delivered through schools general practices and community immunization services which ceased on 31 December 2009 During 2007 2009 an estimated 83 of females aged 12 17 years received at least one dose of HPV vaccine and 70 completed the 3 dose HPV vaccination course 112 By 2017 HPV coverage data on the Immunise Australia website show that by 15 years of age over 82 of Australian females had received all three doses 114 Since the National HPV Vaccination Program commenced in 2007 there has been a reduction in HPV related infections in young women A study published in The Journal of Infectious Diseases in October 2012 found the prevalence of vaccine preventable HPV types 6 11 16 and 18 in Papanicolaou test results of women aged 18 24 years has significantly decreased from 28 7 to 6 7 four years after the introduction of the National HPV Vaccination Program 112 A 2011 report published found the diagnosis of genital warts caused by HPV types 6 and 11 had also decreased in young women and men 115 In October 2010 the Australian regulatory agency the Therapeutic Goods Administration extended the registration of the quadrivalent vaccine Gardasil to include use in males aged 9 through 26 years of age for the prevention of external genital lesions and infection with HPV types 6 11 16 and 18 In November 2011 the Pharmaceutical Benefits Advisory Committee PBAC recommended the extension of the National HPV Vaccination Program to include males The PBAC made its recommendation on the preventive health benefits that can be achieved such as a reduction in the incidence of anal and penile cancers and other HPV related diseases In addition to the direct benefit to males it was estimated that routine HPV vaccination of adolescent males would contribute to the reduction of vaccine HPV type infection and associated disease in women through herd immunity 116 In 2012 the Australian Government announced it would be extending the National HPV Vaccination Program to include males through the National Immunisation Program Schedule 117 Updated results were reported in 2014 118 From February 2013 free HPV vaccine is being provided through school based programs for males and females aged 12 13 years ongoing program and males aged between 14 and 15 years until the end of the school year in 2014 catch up program Canada Edit In July 2006 human papillomavirus vaccine against four types of HPV was authorized in Canada for females 9 to 26 years 119 In February 2010 use in males 9 to 26 years of age for prevention of genital warts was authorized 120 Canada has approved use of Gardasil 121 Initiating and funding free vaccination programs has been left to individual Province Territory Governments All Provincial Territorial governments offer free vaccination for school aged children irrespective of gender at grade 4 Quebec 122 grade 6 British Columbia 123 Alberta 124 Saskatchewan 125 Manitoba 126 Newfoundland and Labrador 127 Prince Edward Island 128 Yukon 129 Northwest Territories 130 and Nunavut 131 or grade 7 Ontario 132 Nova Scotia 133 and New Brunswick 134 level China Edit GlaxoSmithKline China announced in 2016 that Cervarix HPV vaccine 16 and 18 had been approved by the China Food and Drug Administration CFDA 135 Cervarix is registered in China for girls aged 9 to 45 adopting 3 dose program within 6 months 136 Cervarix was launched in China in 2017 and it was the first approved HPV vaccine in China 137 Colombia Edit The vaccine was introduced in 2012 approved for girls aged 9 138 139 The HPV vaccine was initially offered to girls aged 9 and older and attending the fourth grade of school Since 2013 the age of coverage was extended to girls in school from grade four who have reached the age of 9 to grade eleven independent of age and no schooling from age 9 17 years 11 months and 29 days old 140 Costa Rica Edit Since June 2019 the vaccine is administered compulsorily by the state free of charge to girls at ten years of age 141 142 Europe Edit Country Date of introduction Gender s Target age group Financed by PolicyAustria 2006 M F 10 12 Fully financed by national health authorities 143 Belgium 2007 F 10 13 Fully financed by national health authorities Mandatory part of the national immunization scheduleCroatia 20 May 2016 M F 12 Fully financed by national health authorities Voluntary immunization for women not yet sexually activeDenmark 144 1 January 2009 M F 12 Fully financed by national health authorities Part of the Danish Childhood Vaccination programFinland 145 21 November 2013 for female 20 May 2020 for male 146 M F 11 12 Fully financed by national health authorities Part of the Finnish National Vaccination programFrance 147 11 July 2007 F 14 23 Financed 65 by national health authorities Voluntary immunization for women not yet sexually activeGermany 148 149 26 March 2007 M F 9 14 Fully financed by mandatory health insurance Voluntary immunizationGreece 150 151 12 February 2007 F 12 26 Fully financed by national health authorities Mandatory for all girls entering 7th gradeHungary 152 2014 F 12 Fully financed by national health authorities In addition subsidised by local councils for 13 and 14 year olds Iceland 2011 12 Fully financed by national health authoritiesIreland 153 2009 M F 12 13 Fully financed by national health authorities Offered to males and female in first year of secondary school Non mandatory HPV vaccination introduced to national immunisation scheme for males in 2019 Italy 148 26 March 2007 M F 12 Fully financed by national health authorities initially for girls only Offered to boys from 2017 Latvia 2009 12 Fully financed by national health authoritiesLuxembourg 2008 12 Fully financed by national health authoritiesNetherlands 2009 F 12 13 Fully financed by national health authoritiesNorth Macedonia 2009 F 12 Fully financed by national health authorities Mandatory part of the national immunization scheduleNorway 2009 F 12 13 Part of the national immunization programPortugal 2007 F 13 Fully financed by national health authorities Part of the national immunization program for both boys and girlsRomania November 2008 F 10 18 Fully financed by national health authorities Part of the national immunization program but not mandatory for 10 14 years old girls until August 2021 up to 18 years old as of 3 September 2021Slovenia 2009 11 12 Fully financed by national health authoritiesSpain 2007 11 14 Fully financed by national health authoritiesSweden 154 2012 155 M F 10 11 The school based vaccination program is fully financed by national health authorities initially for girls only Offered to all children in fifth grade from August 2020 boys born 2009 are included 156 All vaccinations within the national vaccination programme for children are voluntary Switzerland 2008 11 14 Fully financed by national health authoritiesUK September 2008 M F M 9 45 F 9 45 Fully financed by national health authorities initially for girls only Offered to boys aged 12 and 13 years from September 2019 157 The HPV vaccine is available for free on the NHS up until a person s 25th birthday if they were eligible and missed the HPV vaccine offered in Year 8 at school 158 girls born after 1 September 1991 boys born after 1 September 2006Also fully financed by national health authorities since 2018 for men aged up to and including 45 years of age who have sex with other men MSM when they visit sexual health clinics and HIV clinics in England Trans women people who were assigned male at birth are eligible in the same way as MSM if their risk of getting HPV is similar to the risk of MSM who are eligible for the HPV vaccine Trans men people who were assigned female at birth are eligible if they have sex with other men and are aged 45 or under 158 Offered to males and female in second year of secondary school as well as at sexual health and HIV clinics in England Non mandatory Hong Kong Edit HPV vaccines are approved for use in Hong Kong As part of the Hong Kong Childhood Immunisation Programme HPV vaccines became mandatory for students in the 2019 2020 school year exclusively for females at primary 5 and 6 levels 159 India Edit HPV vaccination has been recommended by the National Technical Advisory Group on Immunization but has not been implemented in India as of 2018 160 Ireland Edit The HPV vaccination programme in Ireland is part of the national strategy to protect females from cervical cancer Since 2009 the Health Service Executive has offered the HPV vaccine free of charge to all girls from first year onwards ages 12 13 Secondary schools began implementing the vaccine program on an annual basis from September 2010 onwards 161 The programme was expanded to include males in 2019 162 Two HPV vaccines are licensed for use in Ireland Cervarix and Gardasil To ensure high uptake the vaccine is administered to teenagers aged 12 13 in their first year of secondary school with the first dose administered between September October and the final dose in April of the following year 162 163 Males and females aged 12 13 who are outside of the traditional school setting home school etc are invited to Health service Executive clinics for their vaccines HPV vaccination in Ireland in not mandatory and consent is obtained prior to vaccination 153 162 For males and females aged 16 and under consent is granted by a parent or guardian unless it is explicitly refused by the child Any male or female aged 16 and over may provide their own consent if they want to be vaccinated 162 HIQA has stated the vaccine will provide further protection particularly to men who have sex with men The vaccine has been extended following evidence that 25 of HPV cancers occur in men 164 Additionally HIQA is aiming to replace the current vaccination which covers 4 major HPV strains with an updated vaccine providing protection from 9 strains The over cost with the gender neutral nine talent vaccine is estimated to be nearly 11 66 million over the next five years 153 Israel Edit Introduced in 2012 Target age group 13 14 Fully financed by national health authorities only for this age group For the year 2013 2014 girls in the eighth grade may get the vaccine free of charge only in school and not in Ministry of Health offices or clinics Girls in the ninth grade may receive the vaccine free of charge only at Ministry of Health offices and not in schools or clinics 165 Religious and conservative groups are expected to refuse the vaccination 166 Japan Edit Introduced in 2010 widely available only since April 2013 Fully financed by national health authorities to females aged 11 to 16 years In June 2013 however Japan s Vaccine Adverse Reactions Review Committee VARRC suspended recommendation of the vaccine due to fears of adverse events This directive has been criticized by researchers at the University of Tokyo as a failure of governance since the decision was taken without presentation of adequate scientific evidence 167 At the time Ministry spokespeople emphasized that The decision does not mean that the vaccine itself is problematic from the viewpoint of safety but that they wanted time to conduct analyses on possible adverse effects to offer information that can make the people feel more at ease 168 However the suspension of the Ministry s endorsement was still in place as of February 2019 by which time the HPV vaccination rate among younger women fell from approximately 70 in 2013 to 1 or less 169 Over an overlapping time period 2009 2019 the age adjusted mortality rate from cervical cancer increased by 9 6 169 Japan to Resume Active Promotion of HPV Vaccinations in April 2022 170 171 In December 2021 the Ministry of Health Labour and Welfare has decided to allow free vaccines to women born between fiscal year 1997 and 2005 after eight year hiatus 172 A panel of Japan s Ministry of Health Labour and Welfare agreed to give women born between fiscal 1997 and fiscal 2005 free vaccinations if they missed the country s free vaccination program 173 Kenya Edit Both Cervarix and Gardasil are approved for use within Kenya by the Pharmacy and Poisons Board However at a cost of 20 000 Kenyan shillings which is more than the average annual income for a family the director of health promotion in the Ministry of Health Nicholas Muraguri states that many Kenyans are unable to afford the vaccine 74 Laos Edit In 2013 Laos began implementation of the HPV vaccine with the assistance of the Gavi Alliance 111 Mexico Edit The vaccine was introduced in 2008 to 5 of the population This percentage of the population had the lowest development index which correlates with the highest incidence of cervical cancer 174 The HPV vaccine is delivered to girls 12 16 years old following the 0 2 6 dosing schedule By 2009 Mexico had expanded the vaccine use to girls 9 12 years of age the dosing schedule in this group was different the time elapsed between the first and second dose was six months and the third dose 60 months later 175 In 2011 Mexico approved a nationwide use of HPV vaccination program to include vaccination of all 9 year old girls 175 New Zealand Edit Immunization as of 2017 is free for males and females aged 9 to 26 years 176 The public funding began on 1 September 2008 The vaccine was initially offered only to girls usually through a school based program in Year 8 approximately age 12 but also through general practices and some family planning clinics Over 200 000 New Zealand girls and young women have received HPV immunization 176 Panama Edit The vaccine was added to the national immunization program in 2008 to target 10 year old girls 174 South Africa Edit Cervical cancer represents the most common cause of cancer related deaths more than 3 000 deaths per year among women in South Africa because of high HIV prevalence making introduction of the vaccine highly desirable 177 A Papanicolaou test program was established in 2000 to help screen for cervical cancer but since this program has not been implemented widely vaccination would offer more efficient form of prevention 178 In May 2013 the Minister of Health of South Africa Aaron Motsoaledi announced the government would provide free HPV vaccines for girls aged 9 and 10 in the poorest 80 of schools starting in February 2014 and the fifth quintile later on 179 South Africa will be the first African country with an immunisation schedule that includes vaccines to protect people from HPV infection but because the effectiveness of the vaccines in women who later become infected with HIV is not yet fully understood it is difficult to assess how cost effective the vaccine will be Negotiations are currently when underway for more affordable HPV vaccines since they are up to 10 times more expensive than others already included in the immunization schedule 177 179 South Korea Edit On 27 July 2007 South Korean government approved Gardasil for use in girls and women aged 9 to 26 and boys aged 9 to 15 180 Approval for use in boys was based on safety and immunogenicity but not efficacy Since 2016 HPV vaccination has been part of the National Immunization Program offered free of charge to all children under 12 in South Korea with costs fully covered by the Korean government 181 For 2016 only Korean girls born between 1 January 2003 and 31 December 2004 were also eligible to receive the free vaccinations as a limited time offer From 2017 the free vaccines are available to those under 12 only 182 Trinidad and Tobago Edit Introduced in 2013 Target Group 9 26 Fully financed by national health authorities But was suspended later on that year owing to objections and concerns raised by the Catholic Board but fully available in local health centers 183 United Arab Emirates Edit The World Health Organization ranks cervical cancer as the fourth most frequent cancer among women in UAE at 7 4 per 100 000 women 184 and according to Abu Dhabi Health Authority the cancer is also the seventh highest cause of death of women in the U A E 185 In 2007 the HPV vaccine was approved for girls and young women 15 to 26 years of age and offered optionally at hospitals and clinics 186 187 Moreover starting 1 June 2013 the vaccine was offered free of charge for women between the ages of 18 and 26 in Abu Dhabi 188 However on 14 September 2018 the U A E s Ministry of Health and Community Protection announced that HPV vaccine became a mandatory part of the routine vaccinations for all girls in the U A E 189 The vaccine is to be administers to all school girls in the 8th grade girls aged 13 190 United Kingdom Edit In the UK the vaccine is licensed for females aged 9 26 for males aged 9 15 and for men who have sex with men aged 18 45 191 HPV vaccination was introduced into the national immunisation programme in September 2008 for girls aged 12 13 across the UK A two year catch up campaign started in Autumn 2009 to vaccinate all girls up to 18 years of age Catch up vaccination was offered to girls aged between 16 and 18 from autumn 2009 and girls aged between 15 and 17 from autumn 2010 It will be many years before the vaccination programme has an effect on cervical cancer incidence so women are advised to continue accepting their invitations for cervical screening 192 Men who have sex with men up to and including the age of 45 became eligible for free HPV vaccination on the NHS in April 2018 They get the vaccine by visiting sexual health clinics and HIV clinics in England 193 A meta analysis of vaccinations for men who have sex with men showed that this strategy is most effective when combined with gender neutral vaccination of all boys regardeless of their sexual orientation 194 From the 2019 2020 school year it is expected that 12 to 13 year old boys will also become eligible for the HPV vaccine as part of the national immunisation programme This follows a statement by the Joint Committee on Vaccination and Immunisation 195 The first dose of the HPV vaccine will be offered routinely to boys aged 12 and 13 in school year 8 in the same way that it is currently May 2018 offered to girls 193 Boots UK had opened a private HPV vaccination service to boys and men aged 12 44 years in April 2017 at a cost of 150 per vaccination In children aged 12 14 years two doses are recommended while those aged 15 44 years a course of three is recommended 196 Cervarix was the HPV vaccine offered from introduction in September 2008 to August 2012 with Gardasil being offered from September 2012 193 197 The change was motivated by Gardasil s added protection against genital warts 198 United States Edit Adoption Edit As of late 2007 update about one quarter of U S females age 13 17 years had received at least one of the three HPV shots 199 By 2014 update the proportion of such females receiving an HPV vaccination had risen to 38 200 The government began recommending vaccination for boys in 2011 by 2014 update the vaccination rate among boys at least one dose had reached 35 200 According to the U S Centers for Disease Control and Prevention CDC getting as many girls vaccinated as early and as quickly as possible will reduce the cases of cervical cancer among middle aged women in 30 to 40 years and reduce the transmission of this highly communicable infection Barriers include the limited understanding by many people that HPV causes cervical cancer the difficulty of getting pre teens and teens into the doctor s office to get a shot and the high cost of the vaccine 120 dose 360 total for the three required doses plus the cost of doctor visits 44 201 Community based interventions can increase the uptake of HPV vaccination among adolescents 202 A survey was conducted in 2009 to gather information about knowledge and adoption of the HPV vaccine Thirty percent of 13 to 17 year olds and 9 of 18 to 26 year olds out of the total 1 011 young women surveyed reported receipt of at least one HPV injection Knowledge about HPV varied however 5 or fewer subjects believed that the HPV vaccine precluded the need for regular cervical cancer screening or safe sex practices Few girls and young women overestimate the protection provided by the vaccine Despite moderate uptake many females at risk of acquiring HPV have not yet received the vaccine 203 For example young black women are less likely to receive HPV vaccines compared to young white women Additionally young women of all races and ethnicities without health insurance are less likely to get vaccinated 204 Since the approval of Gardasil in 2006 and despite low vaccine uptake prevalence of HPV among teenagers aged 14 19 has been cut in half with an 88 reduction among vaccinated women No decline in prevalence was observed in other age groups indicating the vaccine to have been responsible for the sharp decline in cases The drop in number of infections is expected to in turn lead to a decline in cervical and other HPV related cancers in the future 205 206 Legislation Edit Shortly after the first HPV vaccine was approved bills to make the vaccine mandatory for school attendance were introduced in many states 207 Only two such bills passed in Virginia and Washington DC during the first four years after vaccine introduction 207 Mandates have been effective at increasing uptake of other vaccines such as mumps measles rubella and hepatitis B which is also sexually transmitted 201 However most such efforts developed for five or more years after vaccine release while financing and supply were arranged further safety data was gathered and education efforts increased understanding before mandates were considered 207 Most public policies including school mandates have not been effective in promoting HPV vaccination while receiving a recommendation from a physician increased the probability of vaccination 208 The FDA approved Gardasil 9 for women and men ages 27 to 45 in October 2018 32 State by state Edit The National Conference of State Legislatures periodically issues summaries of HPV vaccine related legislation 209 All school immunization laws grant exemptions to children for medical reasons with other opt out policies varying by state 210 In July 2015 Rhode Island added an HPV vaccine requirement for admittance into public school This mandate requires all students entering the seventh grade to receive at least one dose of the HPV vaccine starting in August 2015 all students entering the eighth grade to receive at least two doses of the HPV vaccine starting in August 2016 and all students entering the ninth grade to receive at least three doses of the HPV vaccine starting in August 2017 211 212 213 No legislative action is required for the Rhode Island Department of Health to add new vaccine mandates Rhode Island is the only state that requires the vaccine for both male and female 7th graders 106 209 214 Other states are also preparing bills regarding the HPV vaccine 209 State Proposal StatusAlabama HB 42 would allow parents the option of immunizing female students entering the sixth grade and requires the Department of Health and Senior Services to directly mail age appropriate information to parents or guardians to those students regarding the connection between HPV and cervical cancer and the availability of the immunization PassedAlaska Voluntary vaccination program PassedDistrict of Columbia Required vaccination program starting with 2014 2015 school year for sixth grade Passed D C Municipal Regulations 22 B 146Florida SB 1116 Would require the Department of Health to adopt a rule adding HPV cervical cancer to the list of communicable diseases for which immunizations are recommended requires that schools provide the parents or guardians of certain public school students information regarding the disease and the availability of a vaccine requires the department to prescribe the required information Not passedGeorgia HB 736 Would require public Schools to provide parents or guardians of sixth grade female students information concerning the infection and the immunization against the human papillomavirus Hawaii Mandatory vaccination program starting with 2020 2021 school year for seventh grade Passed 215 Hawaii Administrative Rule 11 157 Iowa SSB 3097 Would create a study bill for a HPV public awareness program and make appropriations for the public awareness program provision of vaccinations and cervical cancer screenings In committeeKansas HR 6019 Resolution would urge the FDA to use caution in approving new vaccines such as Gardasil which has had a number of health problems including some deaths associated with the use of this vaccine In committeeKentucky HR 80 Would urge females ages 9 to 26 and males ages 11 to 26 to obtain the Human papillomavirus HPV vaccination and all citizens to become more knowledgeable about the benefits of HPV vaccination PassedMaryland HB 411 Would require the Statewide Advisory Commission on Immunizations to study the safety of the human papillomavirus HPV vaccine requires the commission to include specified components in the study make recommendations and report the results of its study PassedMinnesota HF 1758 Would require the commissioner of health to prepare informational materials on vaccines including the HPV vaccines and encourages public and private schools with students in grades 6 12 to provide this information to parents in a cost effective and programmatically effective manner Introduced 3 16 09 Michigan SB 1062 and SB 1063 Each would require health insurers to provide coverage for human papillomavirus screenings for cervical cancer In committeeMississippi HB 1512 Would require health benefit plans to cover HPV screenings Not PassedMissouri HB 1935 Would require health insurers to provide coverage for human papillomavirus screenings for cervical cancer In committeeNew Jersey S 1163 Would require health insurers and State Health Benefits Program and SEHBP to provide coverage for screening for cervical cancer including testing for HPV Sent to Committee 1 23 12 A 2185 Would require insurers and State health care coverage programs to cover cost of HPV vaccine In committeeNew York SB 98 same as AB 2360 Would encourage voluntary informed vaccination against human papillomavirus HPV Amended in Senate Committee on Health 1 5 12 AB 699 Would require immunization against HPV for children born after 1 January 1996 Sent to Assembly Committee on Health 1 5 11 AB 1946 Would require insurance companies to provide coverage for the vaccine against human papilloma virus Sent to committee 1 12 11 AB 2360 Would encourage voluntary informed vaccination against human papillomavirus HPV for school aged children and their parents or guardians Sent to committee 1 18 11 SB 4708 Would require insurance companies to cover HPV vaccine In committeeOregon HB 2794 Would require health benefit plans to provide coverage of human papillomavirus vaccine for female beneficiaries who are 11 years of age or older PassedPennsylvania HB 524 Would require health insurance policies to provide coverage for vaccinations for human papilloma virus In committeePuerto Rico Required starting with 2018 2019 school year Passed Law 25South Carolina HB 4497 Would enact the Cervical Cancer Prevention Act and allow the Department of Health and Environmental Control to offer the option of an HPV vaccine series to female students entering the seventh grade at the request of their parent or guardian pending state and federal funding In committeeTexas HB 2220 Would allow the Executive Commissioner of the Health and Human Services Commission to require immunization against human papillomavirus or other immunizations for a person s admission to elementary or secondary school In committeeVirginia Three doses of properly spaced HPV vaccines are required for females before entering the sixth grade 216 HB 1419 would repeal the HPV vaccination requirement for female children Passed House 1 21 11 Indefinitely passed by the Senate Committee 2 17 11 HB 65 would repeal the requirement for children to receive the HPV vaccination for school attendance Left in committee 2 14 12 HB 824 would require that the Commonwealth shall assume liability for any injury resulting from administration of the human papillomavirus vaccine HB 1112 would eliminate the requirement for vaccination against human papillomavirus for female children Passed House and sent to SenateSource National Conference of State Legislatures 209 Immigrants Edit Between July 2008 and December 2009 proof of the first of three doses of HPV Gardasil vaccine was required for women ages 11 26 intending to legally enter the United States This requirement stirred controversy because of the cost of the vaccine and because all the other vaccines so required prevent diseases which are spread by respiratory route and considered highly contagious 217 The Centers for Disease Control and Prevention repealed all HPV vaccination directives for immigrants effective 14 December 2009 218 Uptake in the United States appears to vary by ethnicity and whether someone was born outside the United States 219 220 Coverage Edit Measures have been considered including requiring insurers to cover HPV vaccination and funding HPV vaccines for those without insurance The cost of the HPV vaccines for females under 18 who are uninsured is covered under the federal Vaccines for Children Program 221 As of 23 September 2010 vaccines are required to be covered by insurers under the Patient Protection and Affordable Care Act HPV vaccines specifically are to be covered at no charge for women including those who are pregnant or nursing 222 Medicaid covers HPV vaccination in accordance with the ACIP recommendations and immunizations are a mandatory service under Medicaid for eligible individuals under age 21 223 In addition Medicaid includes the Vaccines for Children Program 224 This program provides immunization services for children 18 and under who are Medicaid eligible uninsured underinsured receiving immunizations through a Federally Qualified Health Center or Rural Health Clinic or are Native American or Alaska Native 224 The vaccine manufacturers also offer help for people who cannot afford HPV vaccination GlaxoSmithKline s Vaccines Access Program 225 provides Cervarix 226 free of charge 1 877 VACC 911 227 to low income women ages 19 to 25 who do not have insurance 228 Merck s Vaccine Patient Assistance Program 1 800 293 3881 229 provides Gardasil free to low income women and men ages 19 to 26 who do not have insurance including immigrants who are legal residents 230 Opposition in the United States Edit See also Vaccine controversy The idea that the HPV vaccine is linked to increased sexual behavior is not supported by scientific evidence A review of nearly 1 400 adolescent girls found no difference in teen pregnancy incidence of sexually transmitted infection or contraceptive counseling regardless of whether they received the HPV vaccine 231 Thousands of Americans die each year from cancers preventable by the vaccine 231 Insurance companies Edit There has been significant opposition from health insurance companies to covering the cost of the vaccine 360 232 233 234 Religious and conservative groups Edit Opposition due to the safety of the vaccine has been addressed through studies leaving opposition focused on the sexual implications of the vaccine to remain Conservative 235 who groups in the U S have opposed the concept of making HPV vaccination mandatory for pre adolescent girls claiming that making the vaccine mandatory is a violation of parental rights and that it will give a false sense of immunity to sexually transmitted disease leading to early sexual activity See Peltzman effect Both the Family Research Council and the group Focus on the Family support widespread universal availability of HPV vaccines but oppose mandatory HPV vaccinations for entry to public school 236 237 238 239 Parents also express confusion over recent mandates for entry to public school pointing out that HPV is transmitted through sexual contact not through attending school with other children 240 Conservative groups are concerned children will see the vaccine as a safeguard against STDs and will have sex sooner than they would without the vaccine while failing to use contraceptives 240 However the American Academy of Pediatrics disagreed with the argument that the vaccine increases sexual activity among teens 241 Christine Peterson director of the University of Virginia s Gynecology Clinic said The presence of seat belts in cars doesn t cause people to drive less safely The presence of a vaccine in a person s body doesn t cause them to engage in risk taking behavior they would not otherwise engage in 242 243 A 2018 study of college aged students found that HPV vaccination did not increase sexual activity 244 unreliable medical source Parental opposition Edit Many parents opposed to providing the HPV vaccine to their pre teens agree the vaccine is safe and effective but find talking to their children about sex uncomfortable Elizabeth Lange of Waterman Pediatrics in Providence RI addresses this concern by emphasizing what the vaccine is doing for the child Lange suggests parents should focus on the cancer prevention aspect without being distracted by words like sexually transmitted Everyone wants cancer prevention yet here parents are denying their children a form of protection due to the nature of the cancer Lange suggests that this much controversy would not surround a breast cancer or colon cancer vaccine The HPV vaccine is suggested for 11 year olds because it should be administered before possible exposure to HPV but also because the immune system has the highest response for creating antibodies around this age Lange also emphasized the studies showing that the HPV vaccine does not cause children to be more promiscuous than they would be without the vaccine 240 Controversy over the HPV vaccine remains present in the media Parents in Rhode Island have created a Facebook group called Rhode Islanders Against Mandated HPV Vaccinations in response to Rhode Island s mandate that males and females entering the 7th grade as of September 2015 be vaccinated for HPV before attending public school 106 240 Physician impact Edit The effectiveness of a physician s recommendation for the HPV vaccine also contributes to low vaccination rates and controversy surrounding the vaccine A 2015 study of national physician communication and support for the HPV vaccine found physicians routinely recommend HPV vaccines less strongly than they recommend Tdap or meningitis vaccines find the discussion about HPV to be long and burdensome and discuss the HPV vaccine last after all other vaccines Researchers suggest these factors discourage patients and parents from setting up timely HPV vaccines In order to increase vaccination rates this issue must be addressed and physicians should be better trained to handle discussing the importance of the HPV vaccine with patients and their families 245 Ethics Edit Some researchers have compared the need for adolescent HPV vaccination to that of other childhood diseases such as chicken pox measles and mumps This is because vaccination before infection decreases the risk of a number of forms of cancer 246 247 There has been some controversy around the HPV vaccine s rollout and distribution Countries have taken different routes based on economics and social climate leading to issues of forced vaccination and marginalization of segments of the population in some cases 248 The rollout of a country s vaccination program is more divisive compared to the act of providing vaccination against HPV In more affluent countries arguments have been made for publicly funded programs aimed at vaccinating all adolescents voluntarily These arguments are supported by World Health Organization WHO surveys showing the effectiveness of cervical cancer prevention with HPV vaccination 248 In developing countries cost of the vaccine dosing schedule and other factors have led to suboptimal levels of vaccination Future research is focused on low cost generics and single dose vaccination in efforts to make the vaccine more accessible 249 Research EditThere are high risk HPV types that are not affected by available vaccines 41 Ongoing research is focused on the development of HPV vaccines that will offer protection against a broader range of HPV types One such method is a vaccine based on the minor capsid protein L2 which is highly conserved across HPV genotypes 250 Efforts for this have included boosting the immunogenicity of L2 by linking together short amino acid sequences of L2 from different oncogenic HPV types or by displaying L2 peptides on a more immunogenic carrier 251 252 There is also substantial research interest in the development of therapeutic vaccines which seek to elicit immune responses against established HPV infections and HPV induced cancers 253 Therapeutic vaccines Edit In addition to preventive vaccines such as Gardasil and Cervarix laboratory research and several human clinical trials are focused on the development of therapeutic HPV vaccines In general these vaccines focus on the main HPV oncogenes E6 and E7 Since expression of E6 and E7 is required for promoting the growth of cervical cancer cells and cells within warts it is hoped that immune responses against the two oncogenes might eradicate established tumors 254 There is a working therapeutic HPV vaccine It has gone through three clinical trials The vaccine is officially called the MEL 1 vaccine but also known as the MVA E2 vaccine In a study it has been suggested that an immunogenic peptide pool containing epitopes that can be effective against all the high risk HPV strains circulating globally and 14 conserved immunogenic peptide fragments from four early proteins E1 E2 E6 and E7 of 16 high risk HPV types providing CD8 responses 255 256 257 258 Therapeutic DNA vaccine VGX 3100 which consists of plasmids pGX3001 and pGX3002 has been granted a waiver by the European Medicines Agency for pediatric treatment of squamous intraepithelial lesions of the cervix caused by HPV types 16 and 18 259 According to an article published 16 September 2015 in The Lancet which reviewed the safety efficacy and immunogenicity of VGX 3100 in a double blind randomized controlled trial phase 2b targeting HPV 16 and HPV 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2 3 it is the first therapeutic vaccine to show efficacy against CIN 2 3 associated with HPV 16 and HPV 18 260 In June 2017 VGX 3100 entered a phase III clinical trial called REVEAL 1 for the treatment of HPV induced high grade squamous intraepithelial lesions 261 The estimated completion time for collecting primary clinical endpoint data is August 2019 262 As of October 2020 there are multiple therapeutic HPV vaccines in active development and in clinical trials based on diverse vaccine platforms protein based viral vector bacterial vector lipid encapsulated mRNA 263 Awards Edit In 2009 as part of the Q150 celebrations the cervical cancer vaccine was announced as one of the Q150 Icons of Queensland for its role in innovation and invention 264 In 2017 National Cancer Institute scientists Douglas R Lowy and John T Schiller received the Lasker DeBakey Clinical Medical Research Award for their contributions leading to the development of HPV vaccines 265 References Edit Human papillomavirus vaccine Use During Pregnancy Drugs com 11 February 2019 Archived from the original on 5 April 2020 Retrieved 3 April 2020 Gardasil HPV 6 L1 Protein HPV 11 L1 Protein HPV 16 L1 Protein HPV 18 L1 Protein 20 40 40 20 micrograms 0 5mL sterile liquid syringe Therapeutic Goods Administration TGA Archived from the original on 8 July 2022 Retrieved 8 July 2022 Gardasil 9 Human Papillomavirus 9 valent Vaccine Recombinant 30 40 60 40 20 20 20 20 20 micrograms 0 5mL suspension for injection syringe Therapeutic Goods Administration TGA Archived from the original on 8 July 2022 Retrieved 8 July 2022 Gardasil 9 Human Papillomavirus 9 valent Vaccine Recombinant 30 40 60 40 20 20 20 20 20 micrograms 0 5mL suspension for injection vial Therapeutic Goods Administration TGA Archived from the original on 8 July 2022 Retrieved 8 July 2022 Gardasil human papillomavirus vaccine Therapeutic Goods Administration TGA 24 June 2010 Archived from the original on 23 March 2022 Retrieved 8 July 2022 AusPAR Human papillomavirus quadrivalent vaccine Therapeutic Goods Administration TGA 24 February 2011 Archived from the original on 18 June 2022 Retrieved 8 July 2022 AusPAR Human Papillomavirus 9 valent vaccine Therapeutic Goods Administration TGA 16 January 2017 Archived from the original on 4 April 2019 Retrieved 8 July 2022 AusPAR Human papillomavirus Types 6 11 16 amp 18 quadrivalent recombinant vaccine Therapeutic Goods Administration TGA 7 June 2012 Archived from the original on 9 September 2017 Retrieved 8 July 2022 Gardasil Product information Health Canada 25 April 2012 Archived from the original on 8 July 2022 Retrieved 8 July 2022 Gardasil 9 Product information Health Canada 25 April 2012 Archived from the original on 6 May 2021 Retrieved 8 July 2022 Gardasil 9 suspension for injection Summary of Product Characteristics SmPC emc 24 January 2020 Archived from the original on 6 April 2020 Retrieved 3 April 2020 Gardasil suspension for injection Summary of Product Characteristics SmPC emc 7 May 2019 Archived from the original on 4 April 2020 Retrieved 3 April 2020 a b Gardasil human papillomavirus quadrivalent types 6 11 16 and 18 vaccine recombinant injection suspension DailyMed 2 December 2020 Archived from the original on 21 April 2022 Retrieved 31 March 2022 a b Gardasil 9 human papillomavirus 9 valent vaccine recombinant injection suspension DailyMed 20 August 2021 Archived from the original on 5 April 2020 Retrieved 31 March 2022 Cervarix U S Food and Drug Administration FDA 4 October 2022 STN BL 125259 Archived from the original on 10 October 2022 Retrieved 9 October 2022 Silgard EPAR European Medicines Agency EMA Archived from the original on 6 April 2020 Retrieved 3 April 2020 Gardasil 9 EPAR European Medicines Agency EMA Archived from the original on 6 April 2020 Retrieved 3 April 2020 Text was copied from this source which is copyright European Medicines Agency Reproduction is authorized provided the source is acknowledged Gardasil EPAR European Medicines Agency Archived from the original on 11 June 2022 Retrieved 6 July 2022 a b c d e f g h i j k l m n o p q r s Human papillomavirus vaccines WHO position paper May 2017 Releve Epidemiologique Hebdomadaire 92 19 241 268 May 2017 hdl 10665 255354 PMID 28530369 Lay summary PDF a href Template Cite journal html title Template Cite journal cite journal a Cite uses deprecated parameter lay url help Kash N Lee MA Kollipara R Downing C Guidry J Tyring SK April 2015 Safety and Efficacy Data on Vaccines and Immunization to Human Papillomavirus Journal of Clinical Medicine 4 4 614 633 doi 10 3390 jcm4040614 PMC 4470159 PMID 26239350 S2CID 14149551 De Vuyst H Clifford GM Nascimento MC Madeleine MM Franceschi S April 2009 Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva vagina and anus a meta analysis International Journal of Cancer 124 7 1626 1636 doi 10 1002 ijc 24116 PMID 19115209 S2CID 24197494 Takes RP Wierzbicka M D Souza G Jackowska J Silver CE Rodrigo JP et al December 2015 HPV vaccination to prevent oropharyngeal carcinoma What can be learned from anogenital vaccination programs Oral Oncology 51 12 1057 1060 doi 10 1016 j oraloncology 2015 10 011 PMID 26520047 S2CID 23356354 Thaxton L Waxman AG May 2015 Cervical cancer prevention immunization and screening 2015 The Medical Clinics of North America 99 3 469 477 doi 10 1016 j mcna 2015 01 003 PMID 25841595 S2CID 2828633 Anjum F Zohaib J 4 December 2020 Oropharyngeal Squamous Cell Carcinoma Definitions StatPearls Updated ed Treasure Island FL StatPearls Publishing doi 10 32388 G6TG1L PMID 33085415 S2CID 229252540 Bookshelf ID NBK563268 Archived from the original on 11 June 2021 Retrieved 7 February 2021 via NCBI Saville AM April 2016 Cervical cancer prevention in Australia Planning for the future Cancer Cytopathology 124 4 235 240 doi 10 1002 cncy 21643 PMID 26619381 World Health Organization May 2011 The immunological basis for immunization series module 19 human papillomavirus infection World Health Organization hdl 10665 44604 ISBN 9789241501590 World Health Organization 2019 World Health Organization model list of essential medicines 21st list 2019 Geneva World Health Organization hdl 10665 325771 WHO MVP EMP IAU 2019 06 License CC BY NC SA 3 0 IGO World Health Organization 2021 World Health Organization model list of essential medicines 22nd list 2021 Geneva World Health Organization hdl 10665 345533 WHO MHP HPS EML 2021 02 Hotez PJ Bottazzi ME January 2022 Whole Inactivated Virus and Protein Based COVID 19 Vaccines Annual Review of Medicine 73 1 55 64 doi 10 1146 annurev med 042420 113212 PMID 34637324 S2CID 238747462 a b Fesenfeld M Hutubessy R Jit M August 2013 Cost effectiveness of human papillomavirus vaccination in low and middle income countries a systematic review Vaccine 31 37 3786 3804 doi 10 1016 j vaccine 2013 06 060 PMID 23830973 What s New with VISs Centers for Disease Control and Prevention CDC 5 April 2019 Archived from the original on 15 October 2019 Retrieved 14 October 2019 a b The HPV Vaccine Access and Use in the U S The Henry J Kaiser Family Foundation 9 October 2018 Archived from the original on 15 October 2019 Retrieved 14 October 2019 Drolet M Benard E Perez N Brisson M August 2019 Population level impact and herd effects following the introduction of human papillomavirus vaccination programmes updated systematic review and meta analysis Lancet 394 10197 497 509 doi 10 1016 S0140 6736 19 30298 3 PMC 7316527 PMID 31255301 a b FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old U S Food and Drug Administration FDA Press release 5 October 2018 Archived from the original on 14 October 2019 Retrieved 14 October 2018 a b c d Meites E Szilagyi PG Chesson HW Unger ER Romero JR Markowitz LE August 2019 Human Papillomavirus Vaccination for Adults Updated Recommendations of the Advisory Committee on Immunization Practices PDF MMWR Morbidity and Mortality Weekly Report 68 32 698 702 doi 10 15585 mmwr mm6832a3 PMC 6818701 PMID 31415491 Archived PDF from the original on 13 October 2019 Retrieved 15 October 2019 a b Human Papillomavirus HPV Vaccines Q amp A Fact Sheets Risk Factors and Possible Causes National Cancer Institute NCI 22 October 2009 Archived from the original on 21 June 2008 Retrieved 18 July 2008 Cervical Cancer Screening United States Preventive Services Task Force USPSTF August 2018 Archived from the original on 7 November 2018 Retrieved 7 November 2018 Cox B Sneyd MJ 2018 HPV screening invasive cervical cancer and screening policy in Australia Journal of the American Society of Cytopathology 7 6 292 299 doi 10 1016 j jasc 2018 07 003 PMID 31043298 S2CID 58548623 Lew JB Simms KT Smith MA Hall M Kang YJ Xu XM et al February 2017 Primary HPV testing versus cytology based cervical screening in women in Australia vaccinated for HPV and unvaccinated effectiveness and economic assessment for the National Cervical Screening Program The Lancet Public Health 2 2 e96 e107 doi 10 1016 S2468 2667 17 30007 5 PMID 29253402 a b c d e Arbyn M Xu L Simoens C Martin Hirsch PP May 2018 Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors The Cochrane Database of Systematic Reviews 5 3 CD009069 doi 10 1002 14651858 CD009069 pub3 PMC 4176676 PMID 29740819 CD009069 a b c Harper DM Franco EL Wheeler CM Moscicki AB Romanowski B Roteli Martins CM et al April 2006 Sustained efficacy up to 4 5 years of a bivalent L1 virus like particle vaccine against human papillomavirus types 16 and 18 follow up from a randomised control trial Lancet 367 9518 1247 1255 doi 10 1016 S0140 6736 06 68439 0 PMID 16631880 S2CID 18685310 a b De Vincenzo R Conte C Ricci C Scambia G Capelli G 3 December 2014 Long term efficacy and safety of human papillomavirus vaccination International Journal of Women s Health 6 999 1010 doi 10 2147 IJWH S50365 PMC 4262378 PMID 25587221 Committee opinion no 467 human papillomavirus vaccination Obstetrics and Gynecology 116 3 800 803 September 2010 doi 10 1097 AOG 0b013e3181f680c8 PMID 20733476 a b Markowitz LE Dunne EF Saraiya M Lawson HW Chesson H Unger ER March 2007 Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices ACIP PDF MMWR Recommendations and Reports 56 RR 2 1 24 PMID 17380109 Archived PDF from the original on 24 September 2015 a b c d e f HPV Vaccines Centers for Disease Control and Prevention CDC 15 October 2010 Archived from the original on 4 October 2015 Retrieved 27 February 2011 a b c d e Tay SK February 2012 Cervical cancer in the human papillomavirus vaccination era Current Opinion in Obstetrics amp Gynecology 24 1 3 7 doi 10 1097 GCO 0b013e32834daed9 PMID 22123221 S2CID 23213383 Jit M Brisson M Laprise JF Choi YH January 2015 Comparison of two dose and three dose human papillomavirus vaccine schedules cost effectiveness analysis based on transmission model BMJ 350 g7584 doi 10 1136 bmj g7584 PMC 4285892 PMID 25567037 Meeting of the Advisory Committee on Immunization Practices ACIP PDF Centers for Disease Control and Prevention CDC 14 October 2016 Archived PDF from the original on 21 October 2016 Retrieved 21 October 2016 Sonawane K Nyitray AG Nemutlu GS Swartz MD Chhatwal J Deshmukh AA December 2019 Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women JAMA Network Open 2 12 e1918571 doi 10 1001 jamanetworkopen 2019 18571 PMC 6986697 PMID 31880792 Joura EA Giuliano AR Iversen OE Bouchard C Mao C Mehlsen J et al February 2015 A 9 valent HPV vaccine against infection and intraepithelial neoplasia in women The New England Journal of Medicine 372 8 711 723 doi 10 1056 NEJMoa1405044 PMID 25693011 Schuchat A February 2015 HPV coverage The New England Journal of Medicine 372 8 775 776 doi 10 1056 NEJMe1415742 PMC 6009818 PMID 25693018 FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old U S Food and Drug Administration Archived from the original on 14 October 2019 Retrieved 9 November 2019 Human Papillomavirus HPV Prevention and HPV Vaccines Questions and Answers Public Health Agency of Canada 18 June 2007 Archived from the original on 26 September 2019 Retrieved 9 November 2019 a b c FDA Approves New Indication for Gardasil to Prevent Genital Warts in Men and Boys Press release U S Food and Drug Administration FDA Archived from the original on 24 October 2009 Retrieved 30 October 2009 a b Centers for Disease Control Prevention CDC May 2010 FDA licensure of quadrivalent human papillomavirus vaccine HPV4 Gardasil for use in males and guidance from the Advisory Committee on Immunization Practices ACIP PDF MMWR Morbidity and Mortality Weekly Report 59 20 630 632 PMID 20508594 Archived PDF from the original on 24 September 2015 Vaccine Information Statement Centers for Disease Control and Prevention CDC Archived from the original on 21 November 2015 Retrieved 20 November 2015 Rosenthal E 19 August 2008 Drug Makers Push Leads to Cancer Vaccines Fast Rise The New York Times Archived from the original on 9 April 2009 Retrieved 20 August 2008 Said Dr Raffle the British cervical cancer specialist Oh dear If we give it to boys then all pretense of scientific worth and cost analysis goes out the window Gay men seeking HPV vaccine Cancer Research UK 23 February 2007 Archived from the original on 24 March 2010 Retrieved 30 October 2009 Karen Canfell The road to cervical cancer elimination archived from the original on 17 December 2021 retrieved 14 April 2022 Ni Aodha G 11 August 2019 Explainer The HPV vaccine is free for boys from next month here s why that s important thejournal ie Archived from the original on 5 January 2021 Retrieved 6 January 2021 Herbert T 2 September 2019 What is the HPV vaccine for boys and are there any side effects Evening Standard Archived from the original on 7 November 2020 Retrieved 6 January 2021 Vacinas Meningite B e HPV para rapazes passam a ser gratuitas em 2020 DN www dn pt in Portuguese Archived from the original on 30 January 2020 Retrieved 30 January 2020 Castle PE Scarinci I October 2009 Should HPV vaccine be given to men BMJ 339 7726 b4127 doi 10 1136 bmj b4127 PMID 19815585 S2CID 1922594 FDA Gardasil approved to prevent anal cancer Press release U S Food and Drug Administration FDA 2010 Archived from the original on 18 December 2014 Retrieved 15 January 2015 Gardasil U S Food and Drug Administration FDA 25 April 2019 STN 125126 Archived from the original on 15 October 2019 Retrieved 15 October 2019 Gardasil 9 U S Food and Drug Administration FDA 25 April 2019 STN 125508 Archived from the original on 15 October 2019 Retrieved 15 October 2019 Rettner R 25 October 2011 Boys Should Get HPV Vaccine Too CDC Says LiveScience Archived from the original on 3 July 2012 Retrieved 11 November 2011 CDC panel recommends HPV vaccine for boys too 26 October 2011 Archived from the original on 5 September 2012 Moi H Iversen OE 17 December 2011 Gi guttene jentevaksine Dagens Naeringsliv in Norwegian p 32 Zur Haussen som fikk Nobelprisen i 2009 for sin HPV forskning har lenge argumentert for vaksinasjon av gutter bade som egen beskyttelse og beskyttelse av kvinner Montague L 5 October 2018 Summary Basis for Regulatory Action PDF U S Food and Drug Administration FDA Archived from the original on 14 December 2019 Retrieved 7 August 2019 a b c d e f Munoz N Bosch FX Castellsague X Diaz M de Sanjose S Hammouda D et al August 2004 Against which human papillomavirus types shall we vaccinate and screen The international perspective International Journal of Cancer 111 2 278 285 doi 10 1002 ijc 20244 PMID 15197783 S2CID 20679802 Wittet S Tsu V June 2008 Cervical cancer prevention and the Millennium Development Goals Bulletin of the World Health Organization 86 6 488 490 doi 10 2471 BLT 07 050450 PMC 2647477 PMID 18568279 ESGO Statement on Cervical Cancer Vaccination PDF ESGO 2007 Archived from the original PDF on 26 July 2011 a b Cervarix Marketing in Kenya Medical News Today Archived from the original on 3 January 2009 Retrieved 17 September 2010 Attkisson S 19 August 2009 Gardasil Researcher Speaks Out CBS News Archived from the original on 3 March 2022 Retrieved 3 March 2022 Yerman MG 28 December 2009 An Interview with Dr Diane M Harper HPV Expert Huffington Post Archived from the original on 13 August 2013 Retrieved 28 August 2013 Haelle T 23 February 2016 HPV Infection Rates Plummet In Young Women Due To Vaccine Forbes Archived from the original on 26 February 2016 Retrieved 23 February 2016 Human papillomavirus HPV vaccines for Australians PDF National Centre for Immunisation Research and Surveillance Factsheet March 2013 Archived from the original PDF on 20 April 2013 GARDASIL Merck s HPV Vaccine Available to Developing Countries through UNICEF Tender BusinessWire 9 May 2013 Archived from the original on 18 December 2014 Retrieved 8 September 2013 a b c d e f Reports of Health Concerns Following HPV Vaccination Centers for Disease Control and Prevention CDC 5 November 2009 Archived from the original on 17 September 2013 Retrieved 8 September 2013 Review concludes evidence does not support that HPV vaccines cause CRPS or POTS PDF Press release European Medicines Agency EMA 5 November 2015 Archived PDF from the original on 14 February 2016 Retrieved 5 November 2015 Information from FDA and CDC on Gardasil and its Safety Centers for Disease Control and Prevention CDC 22 July 2008 Archived from the original on 2 September 2013 Retrieved 8 September 2013 Moghtaderi A Dor A April 2021 Immunization and Moral Hazard The HPV Vaccine and Uptake of Cancer Screening Medical Care Research and Review 78 2 125 137 doi 10 3386 w22523 PMID 31096862 Human Papillomavirus HPV Vaccines 25 May 2018 Archived from the original on 4 July 2014 a b HPV Vaccine Information for Clinicians Fact Sheet CDC 11 January 2019 Archived from the original on 1 May 2012 a b Human Papillomavirus HPV Vaccine Recommendations PDF FDA Archived from the original PDF on 7 March 2014 a b Gardasil Pregnancy Registry Merck amp Co 1 February 2012 Archived from the original on 1 March 2012 Retrieved 29 May 2007 Gardasil 9 Pregnancy Registry Merck amp Co Archived from the original on 28 August 2018 Retrieved 21 October 2019 Who Should NOT Get Vaccinated with these Vaccines Centers for Disease Control and Prevention CDC 10 June 2010 Archived from the original on 11 May 2011 Retrieved 27 February 2011 Goss MA Lievano F Buchanan KM Seminack MM Cunningham ML Dana A June 2015 Final report on exposure during pregnancy from a pregnancy registry for quadrivalent human papillomavirus vaccine Vaccine 33 29 3422 3428 doi 10 1016 j vaccine 2015 04 014 PMID 25869893 HPV Vaccine and Pregnancy eMedTV Archived from the original on 24 July 2012 leftside Ciitn missouri edu 22 January 2007 Archived from the original on 2 October 2013 Retrieved 29 December 2013 Lowy DR Schiller JT May 2006 Prophylactic human papillomavirus vaccines The Journal of Clinical Investigation 116 5 1167 1173 doi 10 1172 JCI28607 PMC 1451224 PMID 16670757 FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus Press release U S Food and Drug Administration FDA 8 June 2006 Archived from the original on 19 October 2009 Retrieved 13 November 2009 McNeil C April 2006 Who invented the VLP cervical cancer vaccines Journal of the National Cancer Institute 98 7 433 doi 10 1093 jnci djj144 PMID 16595773 U S Patent 7 476 389 titled Papilloma Virus Vaccines was granted to co inventors Ian Frazer and Jian Zhou Zhou posthumously on 13 January 2009 Its U S application was filed on 19 January 1994 but claimed priority under a 20 July 1992 PTC filing to the date of an initial AU Australian patent application filed on 19 July 1991 Merck Reports Double Digit Earnings Per Share Growth for Second Quarter 2007 Press release Archived from the original on 12 October 2007 Retrieved 16 October 2019 Glaxo prepares to launch Cervarix after EU okay Reuters 24 September 2007 Archived from the original on 25 October 2008 Retrieved 18 July 2008 16 October 2009 Approval Letter Cervarix U S Food and Drug Administration FDA 16 October 2009 Archived from the original on 19 October 2009 Retrieved 13 November 2009 a b c d The Genital HPV Infection Fact Sheet Centers for Disease Control and Prevention CDC 24 November 2009 Archived from the original on 28 June 2013 Retrieved 13 February 2010 a b FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV press release U S Food and Drug Administration FDA 10 December 2014 Archived from the original on 10 January 2015 Retrieved 9 January 2015 a b Kim JJ Goldie SJ October 2009 Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States BMJ 339 7726 b3884 doi 10 1136 bmj b3884 PMC 2759438 PMID 19815582 McNeil Jr DG 5 May 2013 Cancer Vaccines Get a Price Cut in Poor Nations The New York Times Archived from the original on 23 November 2013 Retrieved 23 November 2013 Cutts FT Franceschi S Goldie S Castellsague X de Sanjose S Garnett G et al September 2007 Human papillomavirus and HPV vaccines a review Bulletin of the World Health Organization 85 9 719 726 doi 10 2471 BLT 06 038414 PMC 2636411 PMID 18026629 Ko JS Goldbeck CS Baughan EB Klausner JD September 2020 Association Between Human Papillomavirus Vaccination School Entry Requirements and Vaccination Initiation JAMA Pediatrics 174 9 861 867 doi 10 1001 jamapediatrics 2020 1852 PMC 7325070 PMID 32597928 Lay summary a href Template Cite journal html title Template Cite journal cite journal a Cite uses deprecated parameter lay url help a b c Thompson EL Livingston MD Daley EM Saslow D Zimet GD August 2020 Rhode Island Human Papillomavirus Vaccine School Entry Requirement Using Provider Verified Report American Journal of Preventive Medicine 59 2 274 277 doi 10 1016 j amepre 2020 02 022 hdl 1805 28509 PMID 32430223 S2CID 218758834 Toh ZQ Russell FM Garland SM Mulholland EK Patton G Licciardi PV April 2021 Human Papillomavirus Vaccination After COVID 19 JNCI Cancer Spectrum Oxford University Press 5 2 pkab011 doi 10 1093 jncics pkab011 eISSN 2515 5091 PMC 7962726 PMID 33748668 S2CID 232295180 Daniels V Saxena K Roberts C Kothari S Corman S Yao L Niccolai L May 2021 Poland G ed Impact of reduced human papillomavirus vaccination coverage rates due to COVID 19 in the United States A model based analysis Vaccine Elsevier 39 20 2731 2735 doi 10 1016 j vaccine 2021 04 003 PMC 8023201 PMID 33875269 S2CID 233034581 a b Sheffield M Hobgood K 30 August 2021 St Jude and leading cancer centers urge vaccination to protect against HPV and other diseases www stjude org Memphis Tennessee St Jude Children s Research Hospital Archived from the original on 15 November 2021 Retrieved 8 September 2021 a b Highleyman L 3 September 2021 Get HPV Vaccination Back on Track Experts Urge POZ New York City ISSN 1075 5705 Archived from the original on 8 September 2021 Retrieved 8 September 2021 a b Frazer I Human papillomavirus vaccine New and underused vaccines support Types of support GAVI Alliance Archived from the original on 18 January 2014 Retrieved 29 December 2013 a b c Tabrizi S Brotherton J Kaldor J et al Fall in Human Papillomavirus Prevalence Following a National Vaccination Program Journal of Infectious Diseases 24 October 2012 Immunise Australia Information about the HPV immunisation program Archived 4 May 2015 at the Wayback Machine Historical Human Papillomavirus HPV immunisation coverage rates Australian Government Department of Health 4 December 2019 Archived from the original on 28 September 2021 Retrieved 28 September 2021 2011 Annual Surveillance Report of HIV viral hepatitis STIs Archived 22 May 2013 at the Wayback Machine page 28 Pharmaceutical Benefits Scheme PBS Recommendations made by the PBAC November 2011 Australian Government Department of Health Archived from the original on 19 April 2013 Young men to be protected from cancers through HPV vaccine Australian Cancer Research Foundation 13 July 2012 Archived from the original on 28 September 2021 Retrieved 28 September 2021 Tabrizi SN Brotherton JM Kaldor JM Skinner SR Liu B Bateson D et al October 2014 Assessment of herd immunity and cross protection after a human papillomavirus vaccination programme in Australia a repeat cross sectional study The Lancet Infectious Diseases 14 10 958 966 doi 10 1016 S1473 3099 14 70841 2 PMID 25107680 Summary Safety Review Gardasil Quadrivalent Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases Health Canada 9 December 2015 Archived from the original on 26 September 2019 Retrieved 21 October 2019 Dawar DM Harris MT McNeil DS January 2012 Update on Human Papillomavirus HPV Vaccines An Advisory Committee Statement ACS National Advisory Committee on Immunization NACI Canada Communicable Disease Report 38 ACS 1 1 62 doi 10 14745 ccdr v38i00a01 PMC 6802461 PMID 31701955 Archived from the original on 21 October 2019 Retrieved 21 October 2019 Human Papillomavirus HPV Prevention and HPV Vaccine Questions and Answers Archived from the original on 18 July 2008 Retrieved 16 October 2019 Eligibility Human Papillomavirus HPV Vaccination Program www quebec ca Archived from the original on 28 September 2020 Retrieved 15 August 2020 HPV Human Papillomavirus Immunize BC 21 March 2011 Archived from the original on 15 August 2020 Retrieved 15 August 2020 Human Papillomavirus HPV 9 Vaccine myhealth alberta ca Archived from the original on 29 September 2020 Retrieved 15 August 2020 Human Papillomavirus HPV Disease and Vaccines PDF Archived PDF from the original on 27 March 2020 Retrieved 15 August 2020 Manitoba s Immunization Program Vaccines Offered Free of Charge Eligibility Criteria for Publicly Funded Vaccines Province of Manitoba Health and Seniors Care Archived from the original on 20 July 2020 Retrieved 15 August 2020 Immunization Schedule Newfoundland and Labrador PDF Archived PDF from the original on 20 July 2020 Retrieved 15 August 2020 Web Experience Toolkit 25 February 2016 Childhood Immunizations www princeedwardisland ca Archived from the original on 5 August 2020 Retrieved 15 August 2020 Yukon to offer free HPV immunization to boys yukon ca 24 April 2017 Archived from the original on 26 April 2017 NWT Immunization Schedule PDF Archived PDF from the original on 27 October 2020 Retrieved 15 August 2020 Immunization Programs Government of Nunavut www gov nu ca Archived from the original on 21 September 2020 Retrieved 15 August 2020 Getting the HPV vaccine ontario ca Archived from the original on 28 September 2021 Retrieved 28 September 2021 Routine Immunization Schedules for Children Youth amp Adults PDF Archived PDF from the original on 26 November 2020 Retrieved 15 August 2020 Immunization Horizon Health Network en horizonnb ca Archived from the original on 13 August 2020 Retrieved 15 August 2020 GSK announces Cervarix approved in China to help protect women from cervical cancer GlaxoSmithKline Press release 18 July 2016 Archived from the original on 24 July 2016 Retrieved 20 October 2019 Cervarix is approved for cervical cancer prevention in female population aged 9 45 years in mainland China GlaxoSmithKline Press release 29 May 2018 Archived from the original on 31 March 2019 Retrieved 20 October 2019 Cervarix first vaccine for cervical cancer prevention in mainland China has officially launched GlaxoSmithKline Press release 31 July 2017 Archived from the original on 4 September 2017 Retrieved 20 October 2019 Carvajal Pineda L 4 September 2012 Giron ya esta vacunando contra el papiloma humano Vanguardia in Spanish Archived from the original on 4 March 2016 Retrieved 29 July 2015 Vacuna contra el Papiloma Humano sera gratuita Caracol Radio No Actualidad Prisa Radio 3 May 2013 Retrieved 29 July 2015 permanent dead link ABC VPH vaccine www minsalud gov co Archived from the original on 4 August 2015 Retrieved 29 July 2015 Costa Rica to begin administering HPV vaccine The Tico Times Costa Rica 25 April 2019 Archived from the original on 15 June 2019 Retrieved 14 June 2019 Costa Rica begins nationwide HPV vaccination campaign The Tico Times Costa Rica 4 June 2019 Archived from the original on 12 June 2019 Retrieved 14 June 2019 Impfkalender fur Schulkinder Archived from the original on 24 September 2016 Retrieved 6 September 2016 Childhood vaccination programme en ssi dk National Institute for Health Data and Disease Control Archived from the original on 28 November 2019 Retrieved 28 November 2019 HPV vaccination Coverage Ministry of Social Affairs and Health 18 February 2010 Archived from the original on 26 April 2017 Retrieved 25 April 2017 HPV vaccine will now also be offered to boys Laaketietokeskus 20 May 2020 Archived from the original on 9 August 2020 Retrieved 3 September 2020 Cancer of the cervix reimbursement of Gardasil in French 17 July 2007 Archived from the original on 18 December 2014 Retrieved 10 August 2013 a b Fagbire OJ 26 March 2007 Gardasil Merck HPV Vaccine Gets German And Italian Approval For Girls Vaccine Rx Archived from the original on 28 September 2007 Retrieved 10 August 2013 HPV Impfung jetzt auch fur Jungen Kassenleistung in German Kassenarztliche Vereinigung 6 December 2018 Archived from the original on 1 December 2020 Retrieved 18 November 2020 Karakitsos P 7 March 2008 Vaccination against HPV in Greece in Greek Archived from the original on 30 April 2013 Retrieved 10 August 2013 The vaccine against cervical cancer and Cervarix vs Gardasil in Greek 12 February 2008 Archived from the original on 13 June 2013 Retrieved 10 August 2013 Mehnyakrak megelozese HPV www antsz hu Archived from the original on 3 September 2014 Retrieved 16 October 2019 a b c Cullen P HPV vaccine to be offered to boys from start of school year in 2019 The Irish Times Archived from the original on 4 September 2019 Retrieved 16 October 2019 Vaccination programmes Folkhalsomyndigheten The Public Health Agency of Sweden 18 February 2022 Archived from the original on 17 November 2022 Retrieved 26 November 2022 Statistik for HPV vaccinationer Folkhalsomyndigheten Folkhalsomyndigheten in Swedish 14 May 2022 Archived from the original on 2 June 2022 Retrieved 26 November 2022 Vaccin mot humant papillomvirus HPV Folkhalsomyndigheten Folkhalsomyndigheten in Swedish 21 February 2022 Archived from the original on 26 October 2022 Retrieved 26 November 2022 Boys aged 12 and 13 years to be offered HPV vaccine from September 2019 PHE announces Pharmaceutical Journal 9 July 2019 Retrieved 25 August 2019 permanent dead link a b HPV vaccine overview nhs uk 31 July 2019 Archived from the original on 1 January 2019 Retrieved 5 February 2022 Centre for Health Protection Department of Health About human papillomavirus HPV vaccination www chp gov hk Archived from the original on 8 March 2021 Retrieved 15 August 2020 Das M February 2018 Cervical cancer vaccine controversy in India The Lancet Oncology 19 2 e84 doi 10 1016 S1470 2045 18 30018 4 PMID 29413482 HSPC HPV vaccine uptake in Ireland PDF Archived from the original PDF on 11 January 2019 Retrieved 16 October 2019 a b c d HSE Guidelines for staff HPV second level school vaccination campaign PDF Archived PDF from the original on 11 January 2019 Retrieved 16 October 2019 HPV HSE ie Archived from the original on 12 January 2019 Retrieved 11 January 2019 Irish times HPV vaccine to be offered to boys from start of school year in 2019 The Irish Times Archived from the original on 8 December 2018 Retrieved 11 January 2019 health gov il Archived 29 October 2013 at the Wayback Machine Siegel J Health Ministry decides to offer free HPV vaccine to 13 year old girls JPost Israel News JPost Archived from the original on 2 December 2013 Retrieved 29 December 2013 Gilmour S Kanda M Kusumi E Tanimoto T Kami M Shibuya K August 2013 HPV vaccination programme in Japan Lancet 382 9894 768 doi 10 1016 S0140 6736 13 61831 0 PMID 23993189 S2CID 40619281 Mulcahy N 25 June 2013 Japan Withdraws HPV Vaccine Recommendation for Girls Medscape Archived from the original on 23 April 2020 Retrieved 17 May 2020 a b Ikeda S Ueda Y Yagi A Matsuzaki S Kobayashi E Kimura T et al April 2019 HPV vaccination in Japan what is happening in Japan Expert Review of Vaccines 18 4 323 325 doi 10 1080 14760584 2019 1584040 PMID 30768373 Japan to Resume Active Promotion of HPV Vaccinations in April Jiji Press News 26 November 2021 Archived from the original on 28 November 2021 Retrieved 28 November 2021 Finally we can protect women Japan s HPV vaccine battle AFP News 31 March 2022 Archived from the original on 22 April 2022 Retrieved 2 April 2022 Japan to allow free HPV vaccines to women born FY1997 2005 after 8 year hiatus Mainichi Shimbun 24 December 2021 Archived from the original on 28 December 2021 Retrieved 28 December 2021 Japan to Give Free HPV Vaccinations to Those Who Missed Them nippon com 15 November 2021 Archived from the original on 15 November 2021 Retrieved 4 February 2022 a b New technologies for cervical cancer prevention from scientific evidence to program planning Pan American Health Organization Archived from the original on 9 May 2012 Retrieved 18 April 2012 a b Progress Toward Implementation of Human Papillomavirus Vaccination the Americas 2006 2010 Center for Disease and Control Prevention Archived from the original on 9 May 2012 Retrieved 18 April 2012 a b Questions and answers about HPV immunisation Ministry of Health NZ 29 September 2021 Archived from the original on 26 February 2018 Retrieved 24 November 2021 a b Green A 7 June 2013 Life saving cancer vaccine will be difficult to implement Mail amp Guardian Archived from the original on 17 July 2013 Retrieved 7 August 2013 Botha MH Dochez C September 2012 Introducing human papillomavirus vaccines into the health system in South Africa Vaccine 30 Suppl 3 C28 C34 doi 10 1016 j vaccine 2012 03 032 PMID 22939017 a b SAPA 15 May 2013 Schoolgirls to get cancer vaccine ioL News Archived from the original on 12 August 2013 Retrieved 7 August 2013 가다실 제품 허가 공지 27 June 2007 Archived from the original on 29 September 2007 Retrieved 6 August 2007 기획 어린이 자궁경부암 예방접종 무료 가다실 Vs 서바릭스 어떤 백신 도입될까 18 January 2016 Archived from the original on 3 February 2016 Retrieved 27 January 2016 자궁경부 앎 은 힘이다 가다실 자궁경부암 백신 무료접종으로 공중보건 질적 향상 기대 라포르시안 rapportian com 5 April 2016 Archived from the original on 28 August 2021 Retrieved 7 May 2018 HPV vaccine for first form students in Barbados while Trinidad suspends the same in schools Caribbean Medical News 1 December 2013 Archived from the original on 27 October 2021 Retrieved 27 October 2021 D Souza C 24 April 2013 Cervical cancer vaccination could be mandatory in UAE Gulf News Archived from the original on 16 September 2018 Retrieved 16 September 2018 Al Nowais S 21 May 2016 Greater understanding of HPV in UAE may help reduce cervical cancer cases The National Archived from the original on 17 September 2018 Retrieved 17 September 2018 UAE gets cervical cancer vaccine Khaleej Times 7 January 2007 Archived from the original on 17 September 2018 Retrieved 17 September 2018 Prevention Archived from the original on 16 September 2018 Retrieved 16 September 2018 Al Hassani Z 14 May 2013 Free vaccination against cervical cancer for Abu Dhabi women The National Archived from the original on 17 September 2018 Retrieved 17 September 2018 السباعي وجيه 15 September 2018 قرار وزاري بإلزامية تطعيم سرطان عنق الرحم Emarat Alyoum in Arabic Archived from the original on 15 September 2018 Retrieved 16 September 2018 Al Ali I 15 September 2018 Cervical cancer vaccination for Dubai schools Gulf Today Archived from the original on 15 September 2018 Retrieved 16 September 2018 Roberts M 23 February 2007 Gay men seek female cancer jab BBC Archived from the original on 30 January 2009 NHS Cervical Screening Program Archived from the original on 14 September 2008 Retrieved 26 June 2008 a b c HPV vaccine nhs uk 9 May 2018 Archived from the original on 1 January 2019 Retrieved 3 January 2019 Nadarzynski T Frost M Miller D Wheldon CW Wiernik BM Zou H et al June 2021 Vaccine acceptability uptake and completion amongst men who have sex with men A systematic review meta analysis and theoretical framework PDF Vaccine 39 27 3565 3581 doi 10 1016 j vaccine 2021 05 013 PMID 34034949 S2CID 235203871 Archived PDF from the original on 19 June 2022 Retrieved 8 June 2022 JCVI statement extending the HPV vaccination programme conclusions GOV UK Archived from the original on 4 January 2019 Retrieved 4 January 2019 Boots launches HPV vaccination for boys and men Pharmaceutical Journal 13 April 2017 Retrieved 23 May 2017 permanent dead link Human papillomavirus HPV the green book chapter 18a Public Health England 20 March 2013 Archived from the original on 15 October 2019 Retrieved 3 January 2019 HPV vaccination programme switching to Gardasil from September 2012 immunisation dh gov uk Department of Health 28 November 2011 Archived from the original on 4 January 2013 Retrieved 3 January 2019 1 in 4 US teen girls got cervical cancer shot USA Today Associated Press 9 October 2008 Archived from the original on 14 October 2013 Retrieved 10 August 2013 a b More US Girls Now Getting Cervical Cancer Vaccine Discovery and Development Associated Press 25 July 2014 Archived from the original on 26 July 2014 a b HPV Vaccine Information For Young Women Centers for Disease Control and Prevention CDC Archived from the original on 28 June 2009 Retrieved 14 June 2009 Niccolai LM Hansen CE July 2015 Practice and Community Based Interventions to Increase Human Papillomavirus Vaccine Coverage A Systematic Review JAMA Pediatrics 169 7 686 692 doi 10 1001 jamapediatrics 2015 0310 PMC 4862306 PMID 26010507 Caskey R Lindau ST Alexander GC November 2009 Knowledge and early adoption of the HPV vaccine among girls and young women results of a national survey The Journal of Adolescent Health 45 5 453 462 doi 10 1016 j jadohealth 2009 04 021 PMID 19837351 Archived from the original on 17 October 2014 Fisher H Trotter CL Audrey S MacDonald Wallis K Hickman M June 2013 Inequalities in the uptake of human papillomavirus vaccination a systematic review and meta analysis International Journal of Epidemiology 42 3 896 908 doi 10 1093 ije dyt049 PMC 3733698 PMID 23620381 Stobbe M 19 June 2013 Study Vaccine against sexually transmitted HPV cut infections in teen girls by half Star Tribune Archived from the original on 23 June 2013 Retrieved 7 August 2013 Knox R 19 June 2013 Vaccine Against HPV Has Cut Infections In Teenage Girls NPR Archived from the original on 20 June 2013 Retrieved 21 June 2013 a b c Schwartz JL October 2010 HPV vaccination s second act promotion competition and compulsion American Journal of Public Health 100 10 1841 1844 doi 10 2105 AJPH 2010 193060 PMC 2936995 PMID 20724671 Moghtaderi A Adams S June 2016 The Role of Physician Recommendations and Public Policy in Human Papillomavirus Vaccinations Applied Health Economics and Health Policy 14 3 349 359 doi 10 1007 s40258 016 0225 6 PMID 26873090 S2CID 25655517 a b c d HPV Vaccine State Legislation and Statutes National Conference of State Legislatures Archived from the original on 18 November 2015 Retrieved 2 January 2023 States With Religious and Philosophical Exemptions From School Immunization Requirements National Conference of State Legislatures 25 May 2022 Retrieved 2 January 2023 HPV Vaccine State Legislation and Statutes www ncsl org Archived from the original on 18 November 2015 Retrieved 20 November 2015 Immunization Information for Schools amp Childcare Providers Department of Health www health ri gov Archived from the original on 21 November 2015 Retrieved 20 November 2015 216 R I Code R 216 RICR 30 05 3 5 HPV Mandates for Children in Secondary Schools Archived from the original on 28 May 2017 Retrieved 27 May 2017 2020 2021 School Health Requirements Hawaii State Department of Health Archived from the original on 1 July 2020 Retrieved 30 June 2020 Virginia Administrative Code 32 1 46 Jordan M 1 October 2008 Gardasil Requirement for Immigrants Stirs Backlash The Wall Street Journal Archived from the original on 18 December 2014 Retrieved 15 January 2009 Green card seekers won t have to get HPV vaccine 16 November 2009 Archived from the original on 27 September 2011 Retrieved 31 January 2011 Budhwani H De P December 2017 Human papillomavirus vaccine initiation in Asian Indians and Asian subpopulations a case for examining disaggregated data in public health research Public Health 153 111 117 doi 10 1016 j puhe 2017 07 036 PMID 29028565 De P Budhwani H March 2017 Human papillomavirus HPV vaccine initiation in minority Americans Public Health 144 86 91 doi 10 1016 j puhe 2016 11 005 PMID 28274389 Vaccines for Children Program VFC Centers for Disease Control and Prevention Archived from the original on 28 September 2013 Retrieved 10 August 2013 ACA Preventative Services Benefits for Women and Pregnant Women Immunization for Women Archived from the original on 9 September 2013 Retrieved 10 August 2013 Human Papillomavirus Vaccination Coverage Among Female Adolescents in Managed Care Plans United States 2013 Center of Disease Control and Prevention 30 October 2015 Archived from the original on 18 October 2020 Retrieved 10 September 2020 a b About VFC Centers for Disease Control and Prevention CDC 25 May 2018 Archived from the original on 7 November 2018 Retrieved 7 November 2018 VAP Patient Eligibility GlaxoSmithKline Archived 9 April 2016 at the Wayback Machine Patient Assistance for Vaccines GSKForYou www gskforyou com Archived from the original on 15 July 2016 Retrieved 16 October 2019 877 822 2911 GSK Vaccines Access Program Archived from the original on 21 August 2016 Retrieved 16 October 2019 1 800 727 5400 Merck Programs to Help Those in Need Programs www merckhelps com Archived from the original on 5 June 2016 Retrieved 16 October 2019 a b Smith MJ December 2015 Promoting Vaccine Confidence Infectious Disease Clinics of North America Review 29 4 759 769 doi 10 1016 j idc 2015 07 004 PMID 26337737 HPV Vaccine Why Your Doctor Doesn t Offer the HPV Vaccine Gardasil Archived 31 December 2007 at the Wayback Machine Detroit News Examines Cost of HPV Vaccine Gardasil Kaiser Family Foundation 29 March 2007 Archived from the original on 15 October 2007 A question of protection Archived from the original on 15 October 2007 Retrieved 16 October 2019 Gabriel T Grady D 13 September 2011 Rick Perry Under Fire by Republican Rivals for Requiring HPV Vaccine for Girls The New York Times Archived from the original on 14 September 2011 Retrieved 22 February 2017 Sprigg P 15 July 2006 Pro Family Pro Vaccine But Keep It Voluntary The Washington Post Archived from the original on 5 November 2012 Retrieved 4 February 2007 Coyne B 2 November 2005 Cervical Cancer Vaccine Raises Promiscuity Controversy The New Standard Archived from the original on 7 August 2006 Retrieved 28 August 2006 IF07B01 Family Research Council 7 February 2008 Archived from the original on 4 August 2007 Position Statement Human Papillomavirus Vaccines Focus on the Family Archived from the original on 30 August 2008 Retrieved 4 January 2008 a b c d Opposition To HPV Vaccine Stirs Passion Bewilderment ripr org Archived from the original on 21 November 2015 Retrieved 20 November 2015 HPV Vaccination Does Not Lead to Increased Sexual Activity press release AAP Archived from the original on 25 February 2014 Retrieved 3 February 2014 Lifesaving Politics Ms Spring 2007 pp 12 13 Archived from the original on 1 June 2007 Artega A The Shape and Structure of HPV Zimbio Archived from the original on 17 May 2013 Retrieved 7 March 2012 Brouwer AF Delinger RL Eisenberg MC Campredon LP Walline HM Carey TE Meza R June 2019 HPV vaccination has not increased sexual activity or accelerated sexual debut in a college aged cohort of men and women BMC Public Health 19 1 821 doi 10 1186 s12889 019 7134 1 PMC 6593582 PMID 31238911 Gilkey MB Moss JL Coyne Beasley T Hall ME Shah PD Brewer NT August 2015 Physician communication about adolescent vaccination How is human papillomavirus vaccine different Preventive Medicine 77 181 185 doi 10 1016 j ypmed 2015 05 024 PMC 4490050 PMID 26051197 Gostin LO June 2018 HPV Vaccination A Public Good and a Health Imperative The Journal of Law Medicine amp Ethics 46 2 511 513 doi 10 1177 1073110518782958 PMID 30147001 S2CID 52092917 Dunne EF Unger ER Sternberg M McQuillan G Swan DC Patel SS Markowitz LE February 2007 Prevalence of HPV infection among females in the United States JAMA 297 8 813 819 doi 10 1001 jama 297 8 813 PMID 17327523 a b Malmqvist E Helgesson G Lehtinen J Natunen K Lehtinen M February 2011 The ethics of implementing human papillomavirus vaccination in developed countries Medicine Health Care and Philosophy 14 1 19 27 doi 10 1007 s11019 010 9285 9 PMID 20853152 S2CID 27444545 Oberlin AM Rahangdale L Chinula L Fuseini NM Chibwesha CJ December 2018 Making HPV vaccination available to girls everywhere International Journal of Gynaecology and Obstetrics 143 3 267 276 doi 10 1002 ijgo 12656 PMC 6221992 PMID 30144050 Ma B Roden R Wu TC July 2010 Current status of human papillomavirus vaccines Journal of the Formosan Medical Association Taiwan Yi Zhi 109 7 481 483 doi 10 1016 S0929 6646 10 60081 2 PMC 2917202 PMID 20677402 Jagu S Karanam B Gambhira R Chivukula SV Chaganti RJ Lowy DR et al June 2009 Concatenated multitype L2 fusion proteins as candidate prophylactic pan human papillomavirus vaccines Journal of the National Cancer Institute 101 11 782 792 doi 10 1093 jnci djp106 PMC 2689872 PMID 19470949 Tumban E Peabody J Tyler M Peabody DS Chackerian B 2012 VLPs displaying a single L2 epitope induce broadly cross neutralizing antibodies against human papillomavirus PLOS ONE 7 11 e49751 Bibcode 2012PLoSO 749751T doi 10 1371 journal pone 0049751 PMC 3501453 PMID 23185426 van Driel WJ Ressing ME Brandt RM Toes RE Fleuren GJ Trimbos JB et al December 1996 The current status of therapeutic HPV vaccine Annals of Medicine 28 6 471 477 doi 10 3109 07853899608999110 PMID 9017105 Roden RB Ling M Wu TC August 2004 Vaccination to prevent and treat cervical cancer Human Pathology 35 8 971 982 doi 10 1016 j humpath 2004 04 007 PMID 15297964 Albarran Y Carvajal A de la Garza A Cruz Quiroz BJ Vazquez Zea E Diaz Estrada I et al 2007 MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma a phase I II study BioDrugs 21 1 47 59 doi 10 2165 00063030 200721010 00006 PMID 17263589 S2CID 26415621 Corona Gutierrez CM Tinoco A Navarro T Contreras ML Cortes RR Calzado P et al May 2004 Therapeutic vaccination with MVA E2 can eliminate precancerous lesions CIN 1 CIN 2 and CIN 3 associated with infection by oncogenic human papillomavirus Human Gene Therapy 15 5 421 431 doi 10 1089 10430340460745757 PMID 15144573 Virolab Inc FORM 8 K A Getfilings com 24 June 2011 Archived from the original on 3 December 2013 Retrieved 29 December 2013 Singh KP Verma N Akhoon BA Bhatt V Gupta SK Gupta SK Smita S June 2016 Sequence based approach for rapid identification of cross clade CD8 T cell vaccine candidates from all high risk HPV strains 3 Biotech 6 1 39 doi 10 1007 s13205 015 0352 z PMC 4729761 PMID 28330110 European Medicines Agency decision P 0367 2016 PDF www ema europa eu European Medicines Agency Archived from the original PDF on 2 November 2017 Retrieved 2 November 2017 Trimble CL Morrow MP Kraynyak KA Shen X Dallas M Yan J et al November 2015 Safety efficacy and immunogenicity of VGX 3100 a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2 3 a randomised double blind placebo controlled phase 2b trial Lancet 386 10008 2078 2088 doi 10 1016 S0140 6736 15 00239 1 PMC 4888059 PMID 26386540 Inovio Begins Phase 3 Clinical Trial of VGX 3100 for the Treatment of HPV Related Cervical Pre Cancer www inovio com Inovio Pharmaceuticals Archived from the original on 2 November 2017 Retrieved 2 November 2017 REVEAL 1 Evaluation of VGX 3100 and Electroporation for the Treatment of Cervical HSIL clinicaltrials gov The National Library of Medicine Archived from the original on 2 November 2017 Retrieved 2 November 2017 Smalley Rumfield C Roller N Pellom ST Schlom J Jochems C 7 October 2020 Therapeutic Vaccines for HPV Associated Malignancies ImmunoTargets and Therapy 9 167 200 doi 10 2147 ITT S273327 PMC 7549137 PMID 33117742 Bligh A 10 June 2009 Premier Unveils Queensland s 150 Icons Press release Queensland Government Archived from the original on 24 May 2017 Retrieved 24 May 2017 NCI s Douglas R Lowy and John T Schiller to receive 2017 Lasker Award Press release National Institutes of Health NIH 6 September 2017 Archived from the original on 7 November 2017 Further reading EditWorld Health Organization 2011 The immunological basis for immunization series module 19 human papillomavirus infection World Health Organization WHO hdl 10665 44604 ISBN 9789241501590 World Health Organization 2016 Scaling up HPV vaccine introduction World Health Organization WHO hdl 10665 251909 ISBN 9789241511544 Phillips A Hickie M Totterdell J Brotherton J Dey A Hill R et al August 2020 Adverse events following HPV vaccination 11 years of surveillance in Australia Vaccine 38 38 6038 6046 doi 10 1016 j vaccine 2020 06 039 PMID 32709432 Ramsay M ed 2019 Chapter 18a Human papillomavirus HPV Immunisation against infectious disease Public Health England External links Edit HPV Human Papillomavirus Vaccine Information Statement Centers for Disease Control and Prevention CDC 17 August 2021 Human Papillomavirus HPV Vaccines National Institutes of Health NIH 18 June 2021 Papillomavirus Vaccines at the US National Library of Medicine Medical Subject Headings MeSH Portals Medicine Viruses Retrieved from https en wikipedia org w index php title HPV vaccine amp oldid 1131050119, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.